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ABSTRACT
Cancer-induced cachexia is a debilitating disease that diminishes quality of life
due to severe loss of skeletal muscle mass and function. Skeletal muscle proteostasis
fluctuates diurnally depending on different fasting and feeding durations as well as in
response to activity and exercise stimuli. Nutrient availability is key in the net loss and
gain of skeletal muscle protein. The adenosine monophosphate protein kinase (AMPK) is
a nutrient sensitive kinase that has long been established as a critical regulator of both
protein synthesis and protein degradation. AMPK is capable of being activated by many
different stimuli as well as diseases such as cancer cachexia. During severe cancer
cachexia, skeletal muscle AMPK is dysregulated which could have dire consequences
regarding muscle proteostasis. When activated, AMPK will phosphorylate tuberous
sclerosis protein 2 (TSC2) and Raptor which inhibit mTORC1 activity. In addition to
suppressing protein synthesis, AMPK controls degradation through the activation of its
direct downstream targets ULK-1 and FOXO3a. While the chronic activation of AMPK
and its potential role in anabolic suppression has been examined in detail, the role of this
signaling axis in the regulation of protein turnover (synthesis and degradation through
UPS and autophagy) is poorly understood in the skeletal muscle of cachectic mice.
Moreover, given the sensitivity of this pathway to nutrient availability, further
investigation is warranted to elucidate if the physiological fasting and feeding regulation
of AMPK signaling is disrupted in the cancer environment. The purpose of this study
was to determine if cachexia associated aberrant AMPK signaling is responsive to
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fasting, feeding, and increased wheel running activity to regulate skeletal muscle
proteostasis. We hypothesized that cancer cachexia induces the disruption mitochondrial
quality control which disrupts the regulation of AMPK by fasting and feeding leading to
muscle mass loss. We also hypothesized that increased physical activity will improve
mitochondrial quality control and thus improve the regulation of AMPK to fasting and
feeding thus improving protein turnover and attenuating wasting. Our results suggest that
skeletal muscle AMPK is necessary for the regulation of protein turnover during cancer
cachexia. Furthermore, cachectic mice exhibit an accelerated AMPK signaling response
to fasting, which may serve to exacerbate muscle wasting. We also report that cachectic
Min mice exhibit an increased sensitivity to nutrients or feeding following a short term
fast, suggesting that fasting increases skeletal muscle sensitivity to feeding. Finally, we
demonstrate that increased physical activity via wheel running is capable of attenuating
or improving the cachectic skeletal muscle AMPK response to fasting.
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CHAPTER 1
REVIEW OF LITERATURE
1.1 Cancer Cachexia
Cachexia is defined as a complex metabolic syndrome associated with underlying
illness and characterized by loss of muscle with or without loss of fat mass(Baracos,
Martin, Korc, Guttridge, & Fearon, 2018; Evans et al., 2008). Cancer cachexia is a
debilitating wasting syndrome that occurs in approximately 80% of all cancer patients
and is responsible for approximately 30% of all cancer related deaths (Argiles et al.,
2010; Baracos, 2006a, 2006b, 2011; Evans et al., 2008; K. Fearon et al., 2011; K. C.
Fearon & Baracos, 2010). Cachexia is infrequently identified or diagnosed and rarely
treated(Baracos, 2011, 2013; Blum et al., 2010; Bruggeman et al., 2016). Cachexia
development is not associated with all cancers, but the progression of cachexia is directly
associated with cancer patient morbidity and mortality(Baracos, 2006a; Sadeghi et al.,
2018; Solheim et al., 2011; Solheim et al., 2018). While cachexia has been reported to
account for a significant number of cancer deaths successful treatment of the cachectic
cancer patient remains elusive (Sadeghi et al., 2018; Solheim et al., 2018). There are
currently no approved therapeutic treatments for cachexia, and while it has been a widely
investigated syndrome the mechanisms that underlie cancer cachexia have yet to be fully
elucidated.
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Paradoxically, in some cases muscle protein synthesis has also been reported to be
elevated due to an abundance of amino acids from accelerated muscle protein
degradation(Dworzak, Ferrari, Gavazzi, Maiorana, & Bozzetti, 1998; Emery et al., 1984;
Whitehouse, Smith, Drake, & Tisdale, 2001).

Muscle wasting is an important

pathophysiological characteristic of cachexia and a major cause of fatigue and decreased
quality of life in cancer patients (Baracos, 2001; Dodson et al., 2011; K. Fearon et al.,
2011). Skeletal muscle quality has also become a current method of classifying muscle,
and is directly related to a muscle’s metabolic capacity and ability to utilize substrates
(Chomentowski, Coen, Radikova, Goodpaster, & Toledo, 2011; B. N. VanderVeen,
Hardee, Fix, & Carson, 2017; White, Baltgalvis, et al., 2011). Disruption of these
processes by cancer cachexia could impact health and survival and also regulate the
muscles microenvironment.

Muscle quality can also be expanded to include the

regulation of muscle anabolic and catabolic processes which can also regulate the muscle
proteostasis or balance between synthesis and degradation (Emery et al., 1984;
Romanello & Sandri, 2015; Suliman & Piantadosi, 2016; Whitehouse et al., 2001).
Our laboratory as well as others have demonstrated a suppression of anabolic
signaling mechanistic target of rapamycin complex 1 (mTORC1) and the induction of
muscle protein degradation in pre-clinical animal models of cancer cachexia (White,
Baynes, et al., 2011a; White, Puppa, Gao, et al., 2013). Interestingly coinciding with the
suppression of the mTORC1 signaling pathway is the potent induction of adenosine
monophosphate protein kinase signaling (AMPK)(White, Puppa, Gao, et al., 2013).
AMPK has been deemed a critical regulator of skeletal muscle protein degradation
through the regulation of multiple signaling pathways such as forkhead box O (FOXO)
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and the autophagy lysosomal proteasome system (Koh, Brandauer, & Goodyear, 2008;
Long & Zierath, 2006; Sanchez, Csibi, et al., 2012; White, Puppa, Gao, et al., 2013).
AMPK has been deemed a target of multiple stimuli ranging from inflammatory
cytokines

such

as

IL-6,

to

acute

exercise,

and

nutrient

deprivation

or

fasting/starvation(Narsale & Carson, 2014; Sanchez, Csibi, et al., 2012; White, Puppa,
Gao, et al., 2013). AMPK has also been deemed as a master regulatory switch that
contributes the regulation of muscle mitochondria through the stimulation of
mitochondrial biogenesis and its negative regulation of energy consuming pathways such
as mTORC1(Carson, Hardee, & VanderVeen, 2016). Numerous pre-clinical models of
cancer cachexia have demonstrated elevated AMPK in skeletal muscle that is
concomitant with elevations in skeletal muscle protein degradation and decreased
anabolic signaling (Mangum et al., 2016; Puppa, Gao, Narsale, & Carson, 2014; Puppa et
al., 2012). The following review of literature will discuss cancer cachexia in detail,
potential mechanisms, and regulators of skeletal muscle mass.

Additionally, the

mTORC1 anabolic signaling pathway and protein synthesis will be discussed and how
cancer cachexia affects this signaling axis. The AMPK signaling pathway will also be
discussed in detail and will encompass its regulatory roles in protein synthesis and
degradation of skeletal muscle while highlighting current gaps in our understanding of
this signaling pathway during cancer cachexia.
Weight Loss
Cachexia is a common modality that affects numerous cancer patients and
patients with chronic diseases such as HIV, cancer, and chronic kidney disease (Argiles
et al., 2010). While not all types of cancer are susceptible to cachexia many that do
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present with the disease are often un-diagnosed or diagnosed far too late to have any
chance of an intervention (Baracos, 2013; Baracos et al., 2018). Much of this initial
problem was due to a lack of a consensus definition among clinicians and researchers as
to what cachexia is (Blum et al., 2011; Bruggeman et al., 2016; Hemming & Maher,
2005). Further exacerbating this lack of consensus is the poorly understood mechanisms
that underlie this disease (Baracos, 2006a, 2013, 2018; K. C. Fearon, Voss, Hustead, &
Cancer Cachexia Study, 2006; Hemming & Maher, 2005; N. MacDonald, Easson,
Mazurak, Dunn, & Baracos, 2003). Weight loss is a common and powerful variable that
predicts mortality and morbidity in cancer patients (Balstad, Solheim, Strasser, Kaasa, &
Bye, 2014; Bruggeman et al., 2016; Hemming & Maher, 2005; Roeland et al., 2017). In
HIV patients, body weight loss as little as 3% increased morbidity and mortality, and the
risk of death increases with the magnitude of weight loss (Evans et al., 2008; Sadeghi et
al., 2018). However, therapies that slow or prevent weight loss are not always beneficial
and have proven difficult to interpret in a clinical setting (K. Fearon et al., 2015; K. C.
Fearon & Baracos, 2010; Johns et al., 2017; Khan et al., 2003; Martin et al., 2013). Some
researchers argue that weight loss alone does not always encompass the full effect of
cachexia on physical function and should not be used as the sole prognostic
variable(Bruggeman et al., 2016; K. Fearon, Arends, & Baracos, 2013; Johns et al.,
2017). However, it is clear that body weight changers can be accurately assessed, and the
evidence demonstrates that it is highly predictive of morbidity and mortality in cachectic
patients (Baracos, 2006a; Blum et al., 2014; Carson et al., 2016; Evans et al., 2008;
Solheim et al., 2011; Solheim et al., 2018).
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The Importance of Skeletal Muscle Mass and Cancer Cachexia
The loss of skeletal muscle mass is often used as a key feature of cancer cachexia
and is often a major cause of fatigue in cancer patients (Baracos, 2001; Blum et al., 2011;
Dodson et al., 2011). Regardless of body mass index (BMI), skeletal muscle depletion is
often considered an important prognostic factor during cancer(Burckart, Beca, Urban, &
Sheffield-Moore, 2010).

The accelerated loss of muscle mass also has the ability to

diminish quality of life and negatively effects the responsiveness to chemotherapy and
survival (Aoyagi, Terracina, Raza, Matsubara, & Takabe, 2015; Martin, 2016; Sandri,
2016; Yoshida & Delafontaine, 2015). Additionally, shorter time to tumor progression
and poorer surgical outcome are also reported in cachectic cancer patients(Penet &
Bhujwalla, 2015).

The molecular mechanisms that underlie cancer related muscle

wasting have not been fully elucidated (Penna, Bonelli, Baccino, & Costelli, 2013;
Petruzzelli & Wagner, 2016; Sakuma, Aoi, & Yamaguchi, 2017; Tan et al., 2014;
Whitehouse et al., 2001; Yoshida & Delafontaine, 2015). Evidence suggests that skeletal
muscle mass loss during cachexia is thought to be due to an acceleration of protein
degradation or muscle breakdown(Baracos, 2000; Johns, Stephens, & Preston, 2012;
Sandri, 2016; Whitehouse et al., 2001). Although it is important to state that impaired
muscle protein synthesis and defective myogenesis may also be major contributors as
well. The prevalence of muscle mass loss in cancer patients has been reported between
20% and 70% depending on the tumor type and criteria that were used for the assessment
(Aversa, Costelli, & Muscaritoli, 2017). In lymphoma patients not receiving any type of
exercise or preventative measure for muscle mass loss, a decrease of up to 14% in muscle
strength was reported (Aversa et al., 2017). The loss of muscle mass and strength can
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result in increased fatigue and lead to a decrease in physical activity which can
potentially further exacerbate muscle mass loss (Drescher, Konishi, Ebner, & Springer,
2016). A more recent study of patients with cancer of the gastrointestinal tract also
demonstrated a substantial loss of mass and strength regardless of daily nutritional intake
(Drescher et al., 2016). Even though the mechanism of skeletal muscle mass loss during
cancer cachexia have been intensely studied over recent years, the identification of key
processes and therapeutic targets have proven to be challenging due to the large numbers
of mediators and signaling pathways that are involved in this multi-modal syndrome.
However, there is evidence of potential complex tissue interactions in this systemic
syndrome mediated through inflammatory cytokines, tumor-derived factors, and even
some hormones (Ali & Garcia, 2014; Argiles, Busquets, Stemmler, & Lopez-Soriano,
2015; Baracos, 2006a; Ebner, Elsner, Springer, & von Haehling, 2014; K. Fearon et al.,
2013; Grabiec, Burchert, Milewska, Blaszczyk, & Grzelkowska-Kowalczyk, 2013;
Mendes, Pimentel, Costa, & Carvalheira, 2015; "Molecular mechanisms of cancer
cachexia," 2016; Petruzzelli & Wagner, 2016; Tan et al., 2014).
1.2 Pre-Clinical Models of Cancer Cachexia
Tumor Implants
Despite the gravity of cachexia as a disease, few large scale human trials have
been conducted to evaluate compounds and establish potential treatments. Due to the
heterogeneity of these trials and the underlying diseases, well characterized and
established animal models have become the norm for studying cancer cachexia. Preclinical rodent models of cancer cachexia have become the standard for basic science

6

research to elucidate and study molecular mechanisms(Ballaro, Costelli, & Penna, 2016;
Bennani-Baiti & Walsh, 2011; Cannon et al., 2007). Models can vary depending on
tumor type and disease progression much like what is seen in the clinic by physicians.
Initial models utilized implantable tumor cell lines such as the Lewis Lung Carcinoma
(LLC), colorectal tumors (C26), and syngeneic sarcomas (Ballaro et al., 2016; Baracos,
2018; Bennani-Baiti & Walsh, 2011; Romanick, Thompson, & Brown-Borg, 2013;
Stewart Coats, 2018). These cell lines are implanted subcutaneously and allowed to
proliferate and grow to a particular burden that causes the symptoms of cachexia
(Bonetto, Rupert, Barreto, & Zimmers, 2016). Many of these implanted tumor cell lines
have been very useful in establishing inflammations role in the process of muscle wasting
during cachexia as they often secret multiple inflammatory cytokines. These models are
extremely beneficial in studying cancer cachexia however, they do have some drawbacks
as they are often viewed as quick models, with death occurring anywhere from 14 to 35
days (Blackwell et al., 2018; Bonetto et al., 2016).

This small window can make

studying compounds or interventions difficult as the disease progresses extremely fast.
Additionally, a non-clinical tumor burden can often result in these models as well with
some LLC tumors accounting for nearly 10-30% of total bodyweight of the mouse
(Bennani-Baiti & Walsh, 2011). This presents a problem when translating the findings to
the human condition as cancer patients very rarely ever have a tumor of such magnitude.
A newer trend in cancer cachexia genetic mouse models are exploiting the
potency of pancreatic cancer. A recently developed model known as the pancreatic
ductal adenocarcinoma (PDAC), among all forms of malignancy, PDAC is among the
most highly associated with cachexia (Michaelis et al., 2017).
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It is estimated that

approximately 83% of patients suffering from the condition present with cachexia
clinically (Michaelis et al., 2017). This particular allograft model utilizes cells isolated
from the PDAC lesion of a C57BL/6 mouse which is then genetically modified to
produce oncogenic KRAS (KPC) mutation generating a highly malignant tumor cell line
(K. C. Fearon et al., 1999; Henderson, Makhijani, & Mace, 2018). These cells are then
cultured and injected into mice either intraperitoneally or sub-cutaneous. KPC injected
mice exhibit gastrocnemius muscle mass loss at 7 days with death occurring at
approximately 12-14 days post inoculation (Gopinathan, Morton, Jodrell, & Sansom,
2015). This model also exhibits a pronounced pro-inflammatory response with elevations
in IL-6 gene expression in skeletal muscle as well as in white adipose tissue(Gopinathan
et al., 2015; Martignoni et al., 2009; Martignoni et al., 2005). This model also produces
significant fat loss as well as loss of cardiac muscle mass (Holecek, 2012).

Most

importantly, in line with other cachexia models, this model induces a pronounced effect
in catabolism particularly in the mixed fiber type skeletal muscles of the hind-limb
(gastrocnemius, quadriceps, and tibialis anterior)(Holecek, 2012). Overall, this model is
an effective an efficient method to study regulatory mechanism of cancer cachexia.
Genetic Mouse Models
Genetic mouse models of cancer cachexia are also common and useful in
establishing mechanisms and therapeutic targets. The adenomatous polyposis coli (Apc)
gene is mutated in a large percentage of human colon cancer cases, this is a common
model for studying environmental factors that influence the genetic predisposition for
colorectal cancer (Baltgalvis, Berger, Pena, Davis, & Carson, 2008; Baltgalvis et al.,
2010; Blum et al., 2011; White, Puppa, Narsale, & Carson, 2013). The ApcMin/+ (Min)
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mouse is heterozygous for a mutation in the APC gene and will spontaneously develop
intestinal adenomas (Baltgalvis et al., 2010). Invasive cancers are reported in older mice
but without metastases.

Most Min mice will not live past 4-5 months due to the

development of severe cachexia and anemia (Baltgalvis et al., 2008; Baltgalvis et al.,
2010). However, this time-span allows for the study of cachexia as a progression and not
simply just an endpoint measurement. Final tumor burden for these mice is typically set
around 12 weeks of age, and by 15 weeks of age the mice will begin to loss body weight
and initiate cachexia with severe cachexia occurring around 18-20 weeks of age
(Baltgalvis et al., 2008). The advantage to using the Min mouse model is that these mice
have little to no anorexia, are chronically inflamed, and have a slow rate of wasting
which makes them ideal for interventions and closely mimics the human progression of
cancer cachexia (Baltgalvis et al., 2008; Baltgalvis et al., 2010; Narsale et al., 2016b;
White, Baynes, et al., 2011a; White, Puppa, Narsale, et al., 2013). Our laboratory has
characterized the Min mice as having muscle weakness and fatigue that worsens as the
disease progresses and will decrease volitional activity and pronounced elevated
interleukin 6 (IL-6) levels (B. N. VanderVeen, Hardee, et al., 2017). Min mice respond
to exercise in a normal manner pre-cachexia but do have decreased running performance
as cachexia sets in (Baltgalvis et al., 2008; Baltgalvis et al., 2010). Additionally, our
laboratory has demonstrated that the elevated circulating IL-6 found in cachectic Min
mice suppresses muscle protein synthesis and can inhibit the response to muscle
contraction. Furthermore, previous work from our laboratory has also demonstrated that
cachectic Min mice also exhibit elevated adenosine monophosphate protein kinase
(AMPK) signaling following a standard 5 hour fasting paradigm that is used to measure
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protein synthesis (White, Puppa, Gao, et al., 2013). AMPK is a known and established
target of inflammatory cytokines such as interleukin 6 (IL-6) and directly inhibits
mechanistic target of rapamycin (mTORC1) signaling (White, Puppa, Gao, et al., 2013).
Additionally, accelerated degradation is also a hallmark of the Min mouse model which
AMPK also plays a role in (White, Baynes, et al., 2011a). Given the slow progression of
cachexia the Min model is ideal for use with interventions such as exercise or therapeutic
drug treatments. Our laboratory has utilized exercise, IL-6 receptor antibody treatments,
and anti-oxidants in the Min mouse model (Puppa et al., 2012; White et al., 2012). All of
these interventions have demonstrated promising benefits and have led to potential
mechanisms of regulation and therapeutic targets for cancer cachexia.
Keeping in line with the previously mentioned newer trend in cachexia modeling
is the Kras genetic mouse model of pancreatic cancer.

Recent advances in genetic

editing techniques and have provided new and exciting mouse models of PDAC
(Gopinathan et al., 2015; Michaelis et al., 2017). In particular is the KPC genetically
modified mouse model of cancer cachexia. This model is highly metastatic and
aggressive and mimics the human condition often found in PDAC patients(Gopinathan et
al., 2015; Holecek, 2012; Michaelis et al., 2017). The KPC mouse contains a conditional
point mutation in the transformation related protein 53 and a point mutation in the KRAS
gene (Wyart et al., 2018). Various iterations of this model have been genetically created
and tested with varying degrees of tumor burden and progression (Wyart et al., 2018).
Consistently across all genetic models of PDAC are the development of severe cachexia
(Gopinathan et al., 2015). While the injectable or allograft model discussed previously
leads to death in very rapid time frame, the genetic variation of PDAC cancer cachexia is
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much slower with the mean survival occurring at 5 months of age which closely mimics
the Min model (Gopinathan et al., 2015). While this model is still being characterized
mechanistically, it is apparent that the skeletal muscle of these mice exhibits extreme
muscle mass loss. The acceleration of degradation through the activation of muscle E3
ligases has been reported and characterized (Jones-Bolin & Ruggeri, 2007). Early studies
of PDAC genetic mouse models suggest that much like the Min model there is an
imbalance

in

protein

turnover,

with

accelerated

degradation

and

high

inflammation(Jones-Bolin & Ruggeri, 2007). However, the question of protein synthesis
signaling still remains to be fully elucidated in this model.
1.3 Potential Mechanisms of Muscle Mass Loss in Cachexia
Inflammation
Inflammatory signaling has recently become a very active area of investigation in
cancer cachexia over the past two decades (Narsale & Carson, 2014; Onesti & Guttridge,
2014; Zimmers, Fishel, & Bonetto, 2016). Chronic inflammation has become a hallmark
of cancer cachexia in both clinical patients and pre-clinical rodent models. Numerous
pre-clinical mouse models of cachexia have demonstrated elevated circulating
inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor  (TNF-)
(Narsale & Carson, 2014; Onesti & Guttridge, 2014; Zimmers et al., 2016). IL-6 is
pleiotropic cytokine that has emerged as a critical regulator of skeletal muscle mass and
fat wasting during cancer cachexia (Garbers, Aparicio-Siegmund, & Rose-John, 2015).
IL-6 signals through the ubiquitously expressed glycoprotein 130 (gp130)(Cron, Allen, &
Febbraio, 2016). IL-6 has been extensively investigated in recent years by our laboratory
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and has been demonstrated by others l to play a role in the regulation of both muscle
protein synthesis and degradation(J. L. Chen et al., 2016; Hardee et al., 2018; Pettersen et
al., 2017; Puppa, Gao, et al., 2014; Puppa et al., 2012; White, Baltgalvis, et al., 2011;
White, Puppa, Gao, et al., 2013; White et al., 2012). Elevated circulating IL-6 can be
observed in cachectic cancer patients and is strongly correlated to body weight and
muscle mass loss (Kuroda et al., 2007).
Increased circulating IL-6 has been clearly demonstrated to activate immediate
downstream target signal transducer and activator of transcription 3 (STAT3) as well as
extracellular regulated signaling kinase (ERK), and AMPK signaling (Bonetto et al.,
2012; Garbers et al., 2015; Hardee et al., 2018). The activation of these signaling
pathways by IL-6 in tumor bearing mice has been demonstrated to induce muscle mass
loss through the suppression of muscle protein synthesis (mTORC1) signaling and
induction of muscle protein breakdown in the Min mouse model of cancer cachexia
(White, Puppa, Gao, et al., 2013). This imbalance disrupts muscle proteostasis (balance
between synthesis and degradation) and leads to not only decreased muscle mass but also
a suppression of skeletal muscle function and metabolism(Guo, Wang, Wang, Qiao, &
Tang, 2017; Narsale & Carson, 2014; Pettersen et al., 2017; Shyh-Chang, 2017; White,
Puppa, Gao, et al., 2013). Over-expression of IL-6 accelerates cancer cachexia induced
skeletal muscle wasting in Min mice(White, Puppa, Gao, et al., 2013; White et al., 2012).
Additionally, the elevated IL-6 has also been demonstrated to suppress basal protein
synthesis signaling in tumor and non-tumor-bearing mice(Hardee et al., 2018).
Interestingly, the suppression of protein synthesis in non-tumor bearing mice occurred
independent to muscle mass loss (Hardee et al., 2018).
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Pharmacological inhibition targeting IL-6 and its downstream signaling targets
STAT3 and ERK has demonstrated an attenuation of skeletal muscle mass loss; however,
it was not sufficient to completely block cachexia (Au, Desai, Koniaris, & Zimmers,
2016; Bonetto et al., 2012; Zimmers et al., 2016). Recently, a role for the IL-6 signaling
pathway has also been described in the regulation of muscle oxidative metabolism and
mitochondrial quality control during cancer cachexia (B. N. VanderVeen, Fix D.K.,
Carson J.A., 2017; White et al., 2012).

IL-6 has been demonstrated to disrupt

mitochondrial remodeling and suppress mitochondrial biogenesis in tumor and non-tumor
bearing mice (Puppa et al., 2012; White et al., 2012). Our laboratory has also collected
preliminary data demonstrating that elevated circulating plasma IL-6 is capable of
suppressing mitochondrial respiration at Complex I.

These findings suggest that there

may be a link between muscle protein turnover and muscle oxidative metabolism in the
net regulation of muscle mass. It is interesting to speculate if the disrupted mitochondrial
function is a consequence of decreased skeletal muscle protein synthesis or a driver of
this process.
Furthermore, in human cancer cachexia studies, elevated serum IL-6 is
consistently associated with weight loss and a reduced survival rate in various types of
cancer patients, especially in those presenting with pancreatic and colorectal cancer.
Clinical trials of IL-6 antibody therapies in cancer patients have yielded some fairly
promising results (Mueller, Bachmann, Prokopchuk, Friess, & Martignoni, 2016b). A
clinical trial of ALD518 in patients with non-small cell lung cancer showed that this
treatment has the potential to improve anemia, reduce cachexia related fatigue all while
having minimal adverse effects (Bayliss, Smith, Schuster, Dragnev, & Rigas, 2011;
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Maccio, Madeddu, & Mantovani, 2012). Additionally, others IL-6 targeted therapies
such as Selumetinib have also been shown to be well tolerated while improving fatigue
and attenuating the loss of lean body mass (C. M. M. Prado et al., 2012). While IL-6 has
been studied extensively as a potential driver of cancer cachexia, there appears to be no
definitive answer as to how it elicits such a detrimental effect on skeletal muscle. Further
research is warranted to examine the IL-6 signaling pathway to further establish a
concrete mechanism of action.
TNF- is another pro-inflammatory cytokine that is also elevated in several preclinical models of cancer cachexia and pharmacological inhibition of this cytokine
demonstrated a reduction in weight loss due to cancer (Catalano et al., 2003). However,
it is of note to state that the TNF- (like IL-6) appears to only be a major player in certain
pre-clinical models such as the Yoshida hepatoma and the Lewis Lung Carcinoma (LLC)
model of cancer cachexia, which are commonly viewed as non-IL-6 models(Baracos,
2000). In humans, several studies have demonstrated correlations of TNF- serum levels
with cachexia(Karayiannakis et al., 2001).

Pancreatic cancer patients often exhibit

elevated serum TNF- and are inversely correlated with BMI, hematocrit, hemoglobin,
and serum albumin levels(J. Nakashima et al., 1998; Pfitzenmaier et al., 2003).
Additionally, it has also been shown that the expression of TNF- gene was elevated in
pancreatic cancer patients and was normalized following surgical resection (Ariapart et
al., 2002). Recently, TNF- and ubiquitin were also shown to be upregulated in the
skeletal muscle of 102 gastric cancer patients and was strongly correlated to disease stage
and degree of weight loss. These findings suggest that the TNF- is a potent induces of
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weight and muscle mass loss in both pre-clinical models and human patients during
cancer cachexia (Sun, Ye, Qian, Xu, & Hu, 2012).
The transforming growth factor  (TGF- ) family of cytokines is a super family
that consists of 34 different proteins that are capable of regulating multiple signaling
pathways and cellular processes (Greco et al., 2015; Guttridge, 2015). Activin A, TNF
like weak inducer of apoptosis (TWEAK) and myostatin are all members of this family
and bind to either type I or type II activin receptors in skeletal muscle (Mathew, 2011).
Upon binding these cytokines can activate the SMA, mothers against decapentaplegic
(SMAD) signaling proteins (Dschietzig, 2014). These proteins are capable of regulating
multiple catabolic signaling processes such the activation of the ubiquitin proteasome
system and suppression of Protein Kinase B (AKT) (Guttridge, 2015). Activin A in
particular has even been demonstrated to induce muscle wasting in non-tumor bearing
mice (J. L. Chen et al., 2014). Treatment of mice with a specific Activin A antibody was
able to prevent cachexia and death (Mathew, 2011). While the evidence for TGF-
signaling as a regulator of muscle mass in mouse models has shown great promise,
studies that have examined this cytokine in human cancer patients are scarce.
1.4 Accelerated Degradation in Cachexia
The Ubiquitin Proteasome System:
A hallmark feature of cancer cachexia is the net loss of skeletal muscle protein
through an imbalance of synthesis and degradation. As mentioned above, nearly all preclinical mouse models of cachexia as well as human cancer patients exhibit elevated
muscle protein degradation with a suppression of muscle protein synthesis.
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This

disruption of muscle proteostasis leads to a net loss of skeletal muscle protein leading to
mass loss. While cancer cachexia may be a multifactorial condition, clear evidence
suggest that the ubiquitin proteasome system is a major contributor muscle mass
regulation.

The following section will discuss the ubiquitin proteasome system of

degradation in detail highlighting important studies that have examined this system and
its regulation.
The ubiquitin proteasome system (UPS) is an essential ATP dependent process
that mediates the degradation of misfolded and mutated proteins as well as many proteins
involved in the regulation of development, differentiation, cell proliferation, signal
transduction, and apoptosis (Tisdale, 2009). The UPS has an established regulatory role
in skeletal muscle mass and has been widely investigated in numerous catabolic
conditions as an essential part of skeletal muscle quality(Attaix, Combaret, Tilignac, &
Taillandier, 1999b; Fanzani, Conraads, Penna, & Martinet, 2012; Lazarus et al., 1999b).
Failure of this system can lead to catastrophic metabolic dysfunction.

A hallmark

feature of the UPS is the ability to target specific proteins for degradation in very highly
regulated manner (Cohen et al., 2009). This complex and tightly regulated process
occurs through hierarchical ordered series of enzymes, including the activation enzymes
(E1), ubiquitin- conjugating enzyme (E2), and finally the heavily studied ubiquitin (E3)
ligases (Bilodeau, Coyne, & Wing, 2016b). The E3 ligases allow for targeted proteins to
be recognized by the 26S proteasome and ensure specificity of the UPS and additional
adaptor proteins(Murton, Constantin, & Greenhaff, 2008). It is important to note that the
conjugation of ubiquitin to a substrate protein is repeated until a minimum of four
ubiquitin molecules have been attached (Murton et al., 2008). While only one E1 has

16

been characterized, there are several dozen E2s and now hundreds of E3s as research has
progressed over recent years (Attaix et al., 2005).

In skeletal muscle this particular

system has many different regulatory points (Murton et al., 2008; Yuan et al., 2015). In
the past two decades a number of genes have been implicated in the skeletal muscle
wasting through the UPS (Attaix et al., 1999b; Bodine, Latres, et al., 2001). These genes
are part of a group known as “atrogenes” that mediate muscle mass through degradation
and inhibitory regulation of synthesis (Lecker et al., 2004).
The muscle specific E3 ligases muscle-specific RING-finger 1 (MuRF1) and
MAFbx (Atrogin-1) were initially discovered to be elevated in various catabolic
conditions such as fasting, diabetes, cancer, immobilization, inactivity, and denervation
(Bodine, Latres, et al., 2001; Lecker et al., 2004). Conditions of decreased muscle use
were a major part of characterizing muscle proteolytic activity and accelerated
degradation through the induction of E3 ligases and the UPS (Murton et al., 2008).
Disuse has been deemed a potent inducer of muscle MuRF1 and Atrogin-1, often being
activated in as little as 3 days post-disuse (Bodine, 2013). These specific ligases have
been extensively studied over the years and have been demonstrated to regulate muscle
protein breakdown through both loss and gain of function studies both in-vivo and invitro (Bodine, 2013; Bodine, Latres, et al., 2001). Mice lacking MuRF-1 and Atrogin-1
appeared to be resistant to denervation induced muscle atrophy as well as hindlimb
unloading and immobilization (Bodine & Baehr, 2014; Phillips, Glover, & Rennie, 2009).
Often coinciding with the activation of E3 ligases is the suppression of AKT, induction of
AMPK and the subsequent muscle protein synthesis signaling through mTOR (Kwak et
al., 2004; Phillips et al., 2009; Sandri, 2016; White, Baynes, et al., 2011a). Interestingly,
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the targeted of substrates by Atrogin-1 are often regulatory proteins involved in protein
synthesis and regeneration such as myogenin, while MuRF-1 has been shown to target
contractile and structural proteins such as myosin heavy chain (Bilodeau, Coyne, &
Wing, 2016a). These processes are tightly regulated and controlled by various upstream
signaling pathways, while some of these have been characterized extensively others are
still being discovered and elucidated.
A critical regulator of MuRF-1 and Atrogin-1 is the process of muscle protein
synthesis that occurs through the canonical Insulin like growth factor-1 (IGF-1)/AKT
signaling pathway which will be discussed in greater detail later in this review. Briefly,
the activation of AKT will then promote the activation of mTOR leading to protein
synthesis (Glass, 2010). In addition to this process, AKT also is a regulator of protein
degradation (Glass, 2010). The induction of AKT through stimuli such as feeding, or
exercise promotes the phosphorylation and inactivation of FOXO (Sandri et al., 2004). If
un-phosphorylated by AKT such as during starvation or in a diseased state such as
cachexia, FOXO will translocate to the nucleus where it transcriptionally controls a host
of catabolic genes and processes such as the E3 ligases (Sandri, 2016; Sandri et al., 2004;
White, Puppa, Gao, et al., 2013). Thus, the activation of AKT and sub-sequent inhibition
of FOXO has been a target of interest when studying the regulation of MuRF-1 and
Atrogin-1 (Brunet et al., 1999; Pallafacchina, Calabria, Serrano, Kalhovde, & Schiaffino,
2002; Stitt et al., 2004). The catabolic pathways of skeletal muscle are initiated through
various stimuli as briefly mentioned above. Metabolic stressors such as reactive oxygen
species, inflammatory cytokines brought on by tumors or even acute exercise, are all
capable of inducing MuRF-1 and Atrogin-1 (Dohm, Kasperek, Tapscott, & Beecher,
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1980; Foletta, White, Larsen, Leger, & Russell, 2011; Forbes, Little, & Candow, 2012;
Frost, Nystrom, Jefferson, & Lang, 2007; Romanello et al., 2010; Romanello & Sandri,
2015).

These ligases are among the most widely studied under various atrophic

conditions and are believed to be key regulators of muscle mass.
Initial evidence suggesting the UPS is a major contributor to muscle wasting
during came from studies that observed inhibition of calpains and lysosomal proteases
only accounted for about 10-20% reduction in total proteolysis (Medina, Wing, Haas, &
Goldberg, 1991). Since the UPS is an ATP dependent system, ATP depletion studies
produced much higher degrees of protein breakdown inhibition (Muscaritoli M., 2006).
Upregulation of the UPS pathway has been reported in many experimental models of
cancer cachexia (Attaix, Combaret, Tilignac, & Taillandier, 1999a; Busquets et al., 2000;
Combaret, Ralliere, Taillandier, Tanaka, & Attaix, 1999; Costelli et al., 1995; Costelli et
al., 2006; Khal, Wyke, Russell, Hine, & Tisdale, 2005; Lazarus et al., 1999a; White,
Baynes, et al., 2011b). The degree of activation of the UPS may vary from model and
tumor type, however activation of the system remains constant across nearly all preclinical models of cancer cachexia. Early cachexia studies using hepatoma-bearing rats
demonstrated the robust activation of proteolytic activity through gastrocnemius mRNA
expression as well as cleavage of fluorogenic substrates (Temparis et al., 1994).
Additionally, our laboratory has demonstrated that the UPS is robustly induced in
cachectic Min mice as well as the LLC model of cancer cachexia (Puppa, Gao, et al.,
2014; White, Baynes, et al., 2011b; White, Puppa, Gao, et al., 2013; White, Puppa,
Narsale, et al., 2013).

Treatments using inflammatory cytokine inhibitors have

demonstrated some effectiveness and have further provided evidence that, at least in part,
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the activation of the UPS may be driven by inflammation during cancer cachexia (White,
Baltgalvis, et al., 2011; White et al., 2012). However, it is important to state that while
these animals did indeed show improved muscle mass, very few studies have examined
functional outcomes and how inhibiting the UPS could alter muscle function and quality.
In recent years, more attention has been given to the E3 ligases in the pathogenesis of
muscle atrophy during cachexia (Romanello & Sandri, 2015; Sandri, 2016; Sandri et al.,
2004). Over-expression of these ligases has been shown to induce atrophy independent of
disease (Romanello & Sandri, 2015; Sandri, 2016; Sandri et al., 2004). Treatments
utilizing new small molecule inhibitors of MuRF-1 have been recently shown to be
effective in counter-acting muscle atrophy in cancer cachexia (Bowen et al., 2017). With
all the evidence suggesting that the UPS is a major contributor to muscle atrophy during
cancer cachexia, the degrees and mechanisms of activation appear to vary depending on
the severity of cachexia and type of tumor.
It remains mostly unclear how tumors initiate the signal to stimulate muscle
protein degradation and cachexia.

The often anatomically distant location between

tumors and the wasting muscles are suggestive of tumor derived factors such as cytokines
into circulation to initiate signaling processes that cause muscle wasting. As mentioned
above, such factors such as IL-6 and TNF are often elevated in pre-clinical models of
cancer cachexia and are thought to be main drivers of chronic inflammation (Bye et al.,
2016; Han, Meng, Shen, & Wu, 2018; Narsale & Carson, 2014; Onesti & Guttridge,
2014). Recent evidence has also demonstrated that chronic inflammation is capable of
disrupting metabolic homeostasis and producing reactive oxygen species (Brown, RosaCaldwell, Lee, Blackwell, et al., 2017; Narsale et al., 2016b; B. N. VanderVeen, Fix
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D.K., Carson J.A., 2017). The activation of numerous transcription factors by tumor
derived factors such as inflammatory cytokines and reactive oxygen species has become
an interesting target of investigation in cancer cachexia (B. N. VanderVeen, Fix, &
Carson, 2017). As mentioned previously, the FOXO family of transcription factors is the
most widely studied, as they have been shown to directly control the expression of E3
ligases MuRF-1 and Atrogin-1 (Judge et al., 2014; Sandri et al., 2004). Furthermore, the
activation of the Smad2/3 signaling pathway also has been demonstrated to increase the
expression of these proteins via FOXO (Winbanks et al., 2016). Our laboratory has
previously demonstrated that over-expression of IL-6 in Min mice induced Atrogin-1
independent to MuRF-1 via the STAT3 signaling pathway (White, Baynes, et al., 2011b).
Reactive oxygen species produced from dysfunctional mitochondria have also been
reported to activate FOXO and induce atrophy both in tumor and non-tumor bearing mice
(Abrigo et al., 2018; Powers, Morton, Ahn, & Smuder, 2016).

While these E3 ligases

may have similar effects (muscle degradation) their regulation and protein expression
levels appear to be mediated by a variety of up-stream signaling pathways.
When compared to the clear-cut results and literature from pre-clinical animal
models, studies of human skeletal muscle have so far produced ambivalent results in
regard to the UPS system in cancer cachexia. Increased activity of the UPS has been
clearly shown to correlate with disease severity in the skeletal muscle of gastric cancer
patients, even before the clinical onset of cachexia (Bossola et al., 2001; Bossola et al.,
2003; DeJong et al., 2005). In addition, it was also observed that systemic inflammation
markers (IL-6) correlated with increased total ubiquitin of biopsies obtained from
cachectic patients with pancreatic cancer (DeJong et al., 2005).
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Furthermore, this

increase also correlated with the degree of weight loss (severity of cachexia) (DeJong et
al., 2005). Muscle mRNA of the proteasome subunits were also elevated in colorectal
cancer patients and where returned to normal control levels following tumor resection (J.
P. Williams et al., 2012). However, a study on pancreatic cancer patients only reported
elevations in the UPS in subjects that presented with greater than 10% bodyweight loss
(DeJong et al., 2005). Interestingly, studies that have examined lung cancer patients did
not find any alteration in the skeletal muscle UPS system (Schmitt et al., 2007).
Furthering the spread of ambivalent data, other studies reported no alteration in muscle
MuRF-1 or Atrogin-1 protein expression of gastric and colorectal cancer patients
(Schmitt et al., 2007).
It is clear that the UPS system is a major player in the disruption of muscle
proteostasis during cancer cachexia. However, the exact role it plays in the regulation of
skeletal muscle mass during cachexia is still often debated. Due to inconsistent results
between animal and human studies, there remains much to be determined in the exact
role the UPS has in cancer cachexia.

Studies have demonstrated some promise in

attempting to treat the hyper-activity of the UPS during cancer, however some have also
reported no beneficial effects (Tisdale, 2005).
The Lysosomal Proteasome System: Autophagy
In addition to the UPS discussed above is another critical non-ATP driven system
of protein degradation known as the lysosomal proteasome (cathepsins) system (Bechet,
Tassa, Taillandier, Combaret, & Attaix, 2005; Sandri, 2011). Commonly, this system of
cellular process of degradation is referred to as autophagy (Vainshtein & Hood, 2015).
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Autophagy plays a critical role in the turnover of cell components in response to various
stimuli, such as cellular stress, nutrient deprivation, exercise, and cytokines (Vainshtein
& Hood, 2015). Three separate types of autophagy have been characterized for delivery
of autophagic cargo to the lysosome (Glick, Barth, & Macleod, 2010). Macro autophagy
(general autophagy), chaperone-mediated autophagy, and micro autophagy (Glick et al.,
2010). The majority of research regarding autophagy in skeletal muscle pertains to macro
autophagy (Glick et al., 2010). This process of macro autophagy (hereafter referred to as
autophagy) is a highly conserved homeostatic mechanism used for degradation and
recycling, through the lysosomal machinery, of long-lived proteins and organelles
(Sandri, 2010). The turnover of proteins via autophagy has recently become an area of
high interest in cancer cachexia as the upstream regulators of autophagy are often
activated during the disease progression (Penna, Baccino, & Costelli, 2014).
Interestingly, recent studies have begun to elucidate cross-talk or overlap between
autophagy and the UPS suggesting that both systems respond to similar stimuli and are
capable of regulating one another to induce protein degradation (Lilienbaum, 2013). The
following section will encompass the process of autophagy as well as its newly
established role in cancer cachexia.
Under normal physiological conditions autophagy plays a balanced role in
maintaining cellular homeostasis through the careful degradation of cellular debris and
dysfunctional intracellular organelles (Sandri, 2010; Yu, Chen, & Tooze, 2018).
Autophagy consists of a small portion of the cytoplasm that includes organelles or
proteins being sequestered by a phagophore to form an autophagosome (Sandri, 2010; Yu
et al., 2018). The autophagosome will then fuse with the lysosome which then degrades
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the cellular cargo contained within it (Sandri, 2011). These processes require a family of
proteins known as the autophagy related genes (Atg) which control the major steps of
autophagy including initiation, nucleation, and lysosomal function/degradation (Yu et al.,
2018). Autophagy can be either a non-selective (e.g., starvation) or selective process that
degrades specific organelles such as mitochondria (mitophagy) (Mammucari, Schiaffino,
& Sandri, 2008; Schwalm et al., 2015). Overall, general non-selective autophagy is
initiated classically through the induction of AMPK which serves as the cells energy
sensor (Mammucari et al., 2008; Schwalm et al., 2015).
When a metabolic stressor such as nutrient deprivation or acute exercise occurs,
AMPK is induced and will suppress the metabolically expensive process of protein
synthesis in order to induce energy generating pathways such as autophagy (Koh et al.,
2008; Sanchez, Csibi, et al., 2012). AMPK will phosphorylate downstream target Unc51 like kinase (ULK-1) which then serves to initiate the formation of the phagophore
through the complex of ATG13 and FIP2000 (Koh et al., 2008).

Studies have

demonstrated the importance of AMPK in the initiation of autophagy, even suggesting
AMPK is required for the initiation of autophagy during fasting conditions (Y. Kim,
Triolo, & Hood, 2017; Sanchez, Csibi, et al., 2012). Once activated, ULK-1 will activate
Beclin-1 and microtubule-associated proteins 1A/1B light chain 3A (LC3) which is
responsible for the development of the autophagosome (Sandri, 2010; Schwalm et al.,
2015; Yu et al., 2018).

Damaged proteins and organelles are then targeted to the

developing autophagosome by sequestosome 1 (p62) which is a poly-ubiquitin tag
(Komatsu & Ichimura, 2010; Sandri, 2010; Schwalm et al., 2015; Yu et al., 2018).
Following formation of the autophagosome, fusion with a lysosome will complete the
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degradation process (Glick et al., 2010). An important key step in this process is the
conversion of cytosolic LC3 I to LC3 II by conjugation to phosphatidylethanolamine
(Komatsu & Ichimura, 2010; Sandri, 2010; Schwalm et al., 2015; Yu et al., 2018). Upon
fusion of the autophagosome with the lysosome LC3 II and p62 are degraded which
makes them the most widely investigated targets in determining autophagy capacity and
flux (Glick et al., 2010). The process of autophagy has recently gained a great deal of
attention in numerous disease and atrophic conditions.
Autophagy in Cachexia: A New Target?
Numerous pre-clinical models of muscular dystrophy report a chronic suppression
of autophagy that exacerbates the dystrophic phenotype (De Palma et al., 2012; Grumati,
Coletto, Sandri, & Bonaldo, 2011). Mice that have a deletion of Atg 7 actually display a
phenotype similar to muscular dystrophy due to the accumulation of protein aggregates
and dysfunctional organelles (Masiero et al., 2009). Disorders in which autophagic
vacuoles are seen in the skeletal muscle are generally referred to as autophagic vacuolar
myopathies such as Pompei and Danon disease (Sandri, 2010).

Cancer cachexia and

skeletal muscle autophagy has become a very intriguing area of investigation (Penna et
al., 2014). Numerous mouse models of cancer cachexia have demonstrated elevations in
LC3 as well as p62 (Penna, Costamagna, et al., 2013; Tessitore, Costelli, & Baccino,
1994; Tessitore, Costelli, Bonetti, & Baccino, 1993). The gastrocnemius muscle of C26
and LLC tumor bearing mice exhibited robust inductions of Beclin-1, LC3 II, and p62 at
11 and 14 days which coincided with a reduction in cathepsin activity(Pettersen et al.,
2017; Talbert, Metzger, He, & Guttridge, 2014; White, Baltgalvis, et al., 2011). Our
laboratory has also demonstrated that LC3 II and Beclin-1 are also induced in the Min
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mouse model of cancer cachexia (White, Baynes, et al., 2011a).

Interestingly, some

researchers argue that the elevation in LC3 and p62 is indicative of dysfunctional
clearance of the autophagosome by the lysosome.

The induction of skeletal muscle

autophagy in tumor bearing animals is typically demonstrated by increased LC3 II levels,
which are further induced in the presence of a lysosomal inhibitor such as colchicine (a
recently employed technique to determine true autophagy flux(Ju, Varadhachary, Miller,
& Weihl, 2010). The common link in pre-clinical models of cachexia appears to be LC3
II and p62, which are often reported as accumulated in cachectic mice (Pigna et al.,
2016b).
In an effort to further examine the autophagy blockade and improve autophagic
clearance studies have employed exercise treatments. Exercise has often been deemed a
potent regulator of autophagy, stimulating it acutely and actually improving efficiency
and clearance with chronic training (restoring normal levels of autophagy) (Pigna et al.,
2016b; Schwalm et al., 2015; Vainshtein & Hood, 2015; Yu et al., 2018). Exercise
training has been proposed as a method to counteract cachexia (Pigna et al., 2016b;
Schwalm et al., 2015; Vainshtein & Hood, 2015; Yu et al., 2018). Furthermore, electrical
stimulation of muscle contraction has been shown to reduce muscle wasting in tumor
bearing mice by both our laboratory and others (Hardee et al., 2018; Hardee et al., 2016).
Voluntary wheel running in C26 tumor bearing mice improved indices of cachexia by
suppressing LC3II and attenuating P62 protein accumulation. These results suggest that
exercise training has the capacity to improve or lower the chronic activation of autophagy
during cancer cachexia (Pigna et al., 2016b). It is intriguing to speculate if the use of
exercise training to lower chronically activated AMPK and suppress the upstream
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regulators of autophagy are a potential mechanism of action during cancer cachexia. This
could have important ramifications as a therapy in the treatment of cachexia and
regulation of muscle mass.
As mentioned previously, IL-6 has been deemed a potent regulator of cancer
cachexia and systemic inflammation, a recent study demonstrated a role for IL-6 trans
(non-classical) signaling in the induction of autophagy during cancer cachexia (Pettersen
et al., 2017).

Serum from cachectic cancer patients containing elevated IL-6 was

incubated on C2C12 myotubes, both p62 and LC3 were robustly induced (Pettersen et al.,
2017). Additionally, blockage of lysosomal activity using Bafilomycin demonstrated a
true increase in autophagy flux in these IL-6 treated C2C12 myotubes (Pettersen et al.,
2017). Our laboratory also demonstrated that the administration of an IL-6 receptor
antibody to Min mice after the initiation of cachexia was able to lower chronic AMPK
activation and suppress downstream markers of skeletal muscle autophagy (White,
Puppa, Gao, et al., 2013; White et al., 2012). Furthermore, skeletal muscle biopsies taken
from cachectic cancer patients exhibited elevated mRNA for Beclin-1(Aversa, Pin, Lucia,
Penna, Verzaro, Fazi, Colasante, Tirone, Rossi Fanelli, et al., 2016; Chacon-Cabrera et
al., 2014). Protein expression of LC3 II and P62 were also elevated in cachectic cancer
patients again suggesting either increased overall autophagy or impaired clearance of the
autophagosome. It is interesting to suggest also that the accumulation of p62 without
changes in LC3 II have also been reported (Aversa, Pin, Lucia, Penna, Verzaro, Fazi,
Colasante, Tirone, Fanelli, et al., 2016). These results suggest a possible role for p62
accumulation in the regulation of lysosomal function. Another very interesting research
study showed that while no differences in proteasome, calpain and caspase activities were
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detected in skeletal muscle of esophageal cancer patients, activities are increased
(Anandavadivelan & Lagergren, 2016; Schersten & Lundholm, 1972). These studies
clearly demonstrate that multiple signaling pathways pertaining to degradation are
activated with cancer and cachexia. However, these processes appear to differ greatly
depending on the type of tumor/cancer present in these patients and pre-clinical models.
Some researchers have suggested the induction of autophagy in cancer hosts is
likely associated with a negative energy balance that arises either from reduced food
intake, mitochondrial damage, or dysfunctional metabolism (Abrigo et al., 2018; Aversa,
Pin, Lucia, Penna, Verzaro, Fazi, Colasante, Tirone, Fanelli, et al., 2016; Penna et al.,
2014; Sanchez, Csibi, et al., 2012). It is apparent from a recent influx of evidence that
autophagy is a major contributor to skeletal muscle wasting during cancer cachexia.
However, the cancer cachexia field suffers from a lack of mechanistic investigation into
the question of autophagy.

Studies that examine upstream regulators and cellular

signaling are desperately needed to provide molecular details that could lead to new and
innovative therapeutic targets in the regulation of skeletal muscle mass during cancer
cachexia.
1.5 -Suppressed Protein Synthesis in Cachexia
Often debated in cancer cachexia and muscle mass regulation as a whole is the
concept of muscle protein synthesis. Researchers have often argued that degradation
being accelerated is only one side of muscle mass regulation. It has long been postulated
that muscle atrophy in cancer cachexia is also due to decreased protein synthesis not just
an increase in degradation(Eley & Tisdale, 2007; Sakuma & Yamaguchi, 2012). Skeletal
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muscle responds to both systemic and local environmental stimuli. Inflammation, insulin
resistance, and hypogonadism are systemic perturbations associated with cancer that can
disrupt metabolism and proteostasis during cancer cachexia (Carson et al., 2016; Narsale
& Carson, 2014; B. N. VanderVeen, Fix D.K., Carson J.A., 2017; White, Puppa, Narsale,
et al., 2013). While cancer induced suppression of basal protein synthesis has been
reported in patients and pre-clinical cachexia models, this suppression does not appear to
fully account for severe muscle wasting observed with cachexia (Mueller, Bachmann,
Prokopchuk, Friess, & Martignoni, 2016a).
Translational Capacity
The regulation of basal protein synthesis in skeletal muscle is tightly regulated
through translational efficiency (polypeptide synthesis per ribosome) and capacity (total
number of ribosomes) (Hershey, Sonenberg, & Mathews, 2012). Translational Efficiency
is regulated at initiation, elongation, and termination steps(Hershey et al., 2012;
Hinnebusch & Lorsch, 2012). Recent advances have improved our understanding of the
regulation of initiation in skeletal muscle. Translation initiation includes binding of the
GTP-bound form of eukaryotic initiation factor 2 (eIF2) and initiator methionyl-tRNA
(met-tRNA) complex to the small (40S) ribosomal subunit to form the 43S preinitiation
complex (Hershey et al., 2012; Hinnebusch & Lorsch, 2012).

Secondly, this 43S

complex will bind to the 7-methyguanosine cap to the 5’ end of mRNA (Kimball,
Horetsky, Jagus, & Jefferson, 1998). Finally, the 43S complex will scan the mRNA for
the AUG initiation codon (Hershey et al., 2012). Upon codon recognition, the large 60S
ribosomal subunit will join with the 40S subunit to form the 80S initiation complex
capable of promoting elongation (Hershey et al., 2012). Several different eukaryotic
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initiation factors and binding proteins play critical roles in this process and are capable of
being regulated by various stimuli such as stress or nutrient availability (Hershey et al.,
2012; Kimball, 1999).

However, eIF2 is believed to be the rate limiting step for

translation initiation and can be influenced by multiple post-translational modifications
such as phosphorylation (Wek, Jiang, & Anthony, 2006). Several nutrient and energy
sensitive kinases regulate eIF2 phosphorylation in response to atrophic stimuli (Wek et
al., 2006). Overall, translation is a critical step in the regulation of skeletal muscle
protein synthesis and is tightly linked to cellular stress and nutrient availability.
Mechanistic Target of Rapamycin-A Brief Overview
The IGF-1/AKT signaling pathway is the primary signaling cascade that activates
protein synthesis. Stimuli such as feeding (insulin spike) or muscle contraction (exercise)
will induce PI3K to phosphorylate AKT primarily at T308 (Bodine, Stitt, et al., 2001).
The activation of AKT will then signal downstream to phosphorylate tuberous sclerosis
complex 1/2 and release Ras homologue enriched in brain (Rheb) allowing for the
activation of the mechanistic target of rapamycin. The mechanistic target of rapamycin is
a serine/threonine kinase that interacts with several different intracellular signaling
proteins and kinases to form two distinct complexes, mTOR complex 1 (mTORC1) and
mTOR complex 2 (mTORC2) (Laplante & Sabatini, 2009). mTORC1 has been widely
investigated for role in the regulation of anabolic signaling process related to protein
synthesis (Yoon, 2017). Moreover, mTORC2 is still being examined and is thought to be
essential for cellular survival, cytoskeletal organization, and metabolism (Laplante &
Sabatini, 2009). mTORC1 serves as a critical regulatory point for anabolic stimuli such
as growth factors, nutrients, and mechanical signaling or loading (Schiaffino &
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Mammucari, 2011).

Briefly, upon activation mTORC1 will directly phosphorylate

eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) and P70 S6 kinase 1 to
promote protein synthesis (Schiaffino & Mammucari, 2011). This signaling has been
well established in multiple rodent models of both health and disease and is believed to
be a critical aspect of regulating basal skeletal muscle protein synthesis (Schiaffino &
Mammucari, 2011; Tessitore et al., 1993; White, Baynes, et al., 2011a).

The

phosphorylation of 4E-BP1 prevents binding to eIF4E and the formation of the complex
between these two proteins, resulting in the assembly of eIF4F complex and translation
initiation (Kimball, 1999; Sonenberg & Hinnebusch, 2009). Recent evidence has also
suggested a role for mTORC1 in cap-dependent translation, elongation, and ribosomal
biogenesis (Kressler, Hurt, & Bassler, 2010a). Related to ribosomal capacity, mTORC1
has also been demonstrated to regulate translational machinery through the synthesis of
mRNAs encoding ribosomal proteins and the transcription of ribosomal RNA (Kressler et
al., 2010a).

In summary, mTORC1 is a critical regulatory point that serves as a

crossroads for growth and metabolic alterations that make it a target of interest in muscle
wasting conditions.
Suppressed Protein Synthesis in Cachexia:
The suppression of skeletal muscle protein synthesis in pre-clinical animal models
of cachexia has been investigated and reported upon extensively (Hardee et al., 2018;
Johns et al., 2012; Tessitore et al., 1993; White, Puppa, Gao, et al., 2013). However, an
exact mechanism as to how the suppression of protein synthesis occurs during cancer
cachexia is still open to debate (Baracos, 2000). Some have postulated that that
dysfunctional oxidative metabolism is to blame due to a lack of sufficient ATP
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production and the chronic activation of AMPK (Koh et al., 2008; White, Puppa, Gao, et
al., 2013).

Others have suggested that a lack of sensitivity to nutrients (anabolic

resistance) is to blame for the simple fact that nutrition appears to have a minimal effect
on protein synthesis during cachexia (Burd, Gorissen, & van Loon, 2013; Cuthbertson et
al., 2005). Furthermore, some have begun to argue that a lack of activity or increased
disuse during cancer cachexia contributes to the suppression of protein synthesis (Argiles,
Busquets, Lopez-Soriano, Costelli, & Penna, 2012). Inflammation has also been shown
to regulate protein synthesis during cancer cachexia in Min mice (Hardee et al., 2018;
White, Puppa, Gao, et al., 2013; Zimmers et al., 2016). Overall, there are multiple lines
of evidence each demonstrating an effect on muscle protein synthesis during cancer
cachexia.

However, there appears to be no clear answer as to what causes these

conditions as cachexia is a multifactorial syndrome further mechanistic investigation is
warranted to more closely examine these mechanisms of regulation.
Dysfunctional Oxidative Metabolism and Protein Synthesis
Recently a role for oxidative metabolism in the regulation of protein synthesis
during cancer cachexia has been suggested (Carson, Hardee, & VanderVeen, 2015).
Mitochondrial respiration and ATP synthesis are linked tightly to cellular energy
utilization (Buttgereit & Brand, 1995). Thus, it is not surprising that mitochondrial
function/oxidative metabolism exert regulation over processes related to protein
synthesis.

Protein synthesis is a high energy demanding process accounting for

approximately 20-30% of mammalian ATP consumption (Rolfe & Brown, 1997).
Additionally, many non-ribosomal kinases are required for the synthesis and maintenance
of ribosomes (Kressler, Hurt, & Bassler, 2010b). As briefly mentioned previously, the
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adenosine monophosphate protein kinase AMPK regulates many different metabolic
processes including protein synthesis and degradation (Koh et al., 2008). AMPK serves
as a cellular energy sensor and is activated in times of low ATP or high AMP, and has a
direct role in the regulation of mTORC1 signaling through the phosphorylation of TSC2
and Raptor (Shaw, 2009). TSC2 phosphorylation inhibits mTORC1 signaling through
the Rheb keeping it in its GDP-bound inactive state (Shaw, 2009).
Mitochondrial dysfunction has recently been shown to precede the loss of muscle
mass in LLC tumor bearing mice (Brown, Rosa-Caldwell, Lee, Blackwell, et al., 2017).
It is possible that the dysfunctional ATP production produce reactive oxygen species that
stimulate AMPK and suppress protein synthesis in these mice.

Dysfunctional

mitochondrial quality control has also been implicated in the activation of AMPK
(Romanello & Sandri, 2015). Altered mitochondrial dynamics and lack of mitophagy
contribute to the buildup of damaged organelles alerting functional oxidative metabolism
and producing metabolic stress (Suliman & Piantadosi, 2016). The Min model of cancer
cachexia has been shown to induce mitochondrial remodeling and reduce mitochondrial
biogenesis (White, Baltgalvis, et al., 2011). These alterations begin to appear in mildly
cachectic animals and are exacerbated as cachexia reaches the sever stage.

Through this

signaling cascade it has been demonstrated that dysfunctional mitochondria and ATP
production activate AMPK and suppress the metabolically expensive process of protein
synthesis through the inhibition of mTORC1(Romanello & Sandri, 2015; White,
Baltgalvis, et al., 2011).
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Anabolic Resistance
Of recent interest in cancer cachexia and protein synthesis is the new concept of
anabolic resistance (A. M. H. Horstman, Damink, Schols, & van Loon, 2016). Many
cancer patients experience weight loss at the time of diagnosis and as mentioned
previously, muscle loss is indicative of poor prognosis in many cancers (Baracos, 2006a,
2011; Baracos et al., 2018; Romanello & Sandri, 2015). An intriguing question among
researchers is whether cachectic muscle retains anabolic plasticity. This could prove
beneficial for clinicians looking to provide treatment and improve muscle mass and
function. While circadian fluctuations in protein turnover are the established norm in
muscle mass regulation, it has become evident that protein synthesis is highly responsive
to environmental stimuli.

Nutrients or feeding and exercise are extremely potent

stimulators of skeletal muscle protein synthesis in basal healthy conditions; however,
numerous wasting conditions have demonstrated reduced sensitivity to these anabolic
signals (Argiles, Lopez-Soriano, & Busquets, 2015; Bodine, 2013; Bowen, Schuler, &
Adams, 2015). Even the smallest decrement in daily protein synthesis could significantly
impact muscle maintenance in wasting conditions, it is logical to suggest that anabolic
resistance could also contribute to muscle loss during cancer cachexia (Cuthbertson et al.,
2005).
It is established that feeding can stimulate whole body and skeletal muscle protein
synthesis when compared to fasted healthy individuals (Rennie et al., 1982).
Furthermore, ingestion of essential amino acids, especially leucine, can directly stimulate
protein synthesis in young individuals (Paddon-Jones et al., 2004). This activation of
protein synthesis is directly due to the activation of mTORC1 signaling.
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Upon

stimulation from amino acids, the Ragualtor-Rag complex directly targets mTORC1 to
the lysosome where it will become activated by Rheb (Liu, Jahn, Wei, Long, & Barrett,
2002). Initial studies examining anabolic resistance occurred in aged individuals who
exhibit a blunted response to both food and essential amino acids such as leucine (Sancak
et al., 2010). The ability to stimulate mTORC1 and protein synthesis in these individuals
remains intact but required larger doses than that of younger subjects (Paddon-Jones et
al., 2004). These results suggested that while the machinery for the activation of protein
synthesis remains intact a certain threshold of activation must be reached to achieve the
desired result. Overall, these studies characterize the reduced sensitivity of skeletal
muscle to feeding in both the aged and diseased state.
Since cancer cachexia cannot be observed by conventional nutritional
supplementation, it is necessary to further our understanding of anabolic resistance.
Growing evidence is supporting the disruption of protein synthesis during cancer
cachexia; however, very few studies have examined if nutrients or feeding can stimulate
anabolic signaling. Cancer patients are still capable of inducing protein synthesis in
response to protein ingestion however, the degree of activation appears to be severely
impaired (Dillon et al., 2012). A newer approach using specially formulated medical
food that is high in protein and leucine has shown promise in cancer patients with
involuntary weight loss (Deutz et al., 2011). Surprisingly, the cancer cachexia field is
actually lacking in the study of pre-clinical model studies examining anabolic resistance.
However, our laboratory has demonstrated blunted mTORC1 activation in response to
glucose administration in cachectic skeletal muscle (White, Puppa, Gao, et al., 2013).
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Inactivity-A Role for Exercise Training
Many cancer patients suffer from chronic fatigue, either from the disease itself or
its treatment, which is often a confounder that limits regular exercise practice (Grande,
Silva, & Maddocks, 2015).

This lack of physical activity or exercise has been

demonstrated to occur in both the clinic and pre-clinical models (Grande et al., 2015;
Roberts, Frye, Ahn, Ferreira, & Judge, 2013). Pre-clinical models have demonstrated
that voluntary activity actually precedes weight loss further establishing its importance in
the progression of the condition (Baltgalvis et al., 2010). Voluntary muscle strength and
exercise capacity are also found to be reduced in pre-clinical models and in human cancer
patients (Glaus, 1998; Stewart, Skipworth, & Fearon, 2006).

Furthermore, muscle

contractile properties related to fatigue resistance are also disrupted during experimental
cancer cachexia (B. N. VanderVeen, Hardee, et al., 2017). However, our mechanistic
understanding of the role of exercise training to counter-act these deficits and stimulate
protein synthesis are not well described.
The field of exercise oncology is limited by a lack of studies that examine
cachectic cancer patients. However, initial progress has been made to improve our
understanding of exercise adaptations during the development and progression of
cachexia in pre-clinical models(Grande et al., 2014; Hardee et al., 2016; Mehl et al.,
2005). Aerobic treadmill training either alone or with nutritional supplementation has
been demonstrated to reduce tumor growth and improve muscle mass (Baltgalvis et al.,
2008). Our laboratory has also demonstrated a role for treadmill training during systemic
IL-6 overexpression to enhance mTORC1 signaling and improve mitochondrial quality
control in tumor bearing mice (Puppa et al., 2012). The improvement of mitochondrial
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quality control can lead to a reduction in the activation of AMPK and improve the ability
to activate mTORC1 and stimulate protein synthesis. Resistance exercise using overload
hypertrophy models and electrical stimulation have also demonstrated attenuated or
preserved muscle mass (Hardee et al., 2018; Hardee et al., 2016). Additionally, our
laboratory has also demonstrated that repeated high frequency electrical stimulation is
capable of inducing myofiber hypertrophy in cachectic skeletal muscle (Hardee et al.,
2016). Furthermore, this eccentric contraction training paradigm suppressed the cachexia
induction of AMPK and robustly stimulated mTORC1 signaling and protein synthesis
when compared to the contralateral control leg (Hardee et al., 2016). These findings were
also found to coincide with improved muscle oxidative capacity in tumor-bearing mice
(Hardee et al., 2016). Whether these alterations could improve basal protein synthesis
long-term remains to be further investigated. Collectively, these studies suggest a role
for exercise training to improve skeletal muscle mass during cancer cachexia. Further
studies are required to determine exact mechanisms and if an interaction between feeding
and exercise could provide beneficial effects on protein synthesis and aid in the treatment
of cachectic cancer patients.
1.6 AMPK-Muscle Mass and Metabolism Regulation
AMPK an Overview
Skeletal muscle is a highly dynamic tissue often characterized by dramatic
changes in energy turnover in response to various environmental stimuli (Koh et al.,
2008). AMPK is a sensor of intracellular energy status that maintains energy stores by
regulating anabolic and catabolic pathways (Kjobsted et al., 2018). AMPK’s role as an
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energy sensor is critical in tissues that display high turnover such as skeletal muscle
(Mounier, Theret, Lantier, Foretz, & Viollet, 2015). Recent advances have highlighted
the relevance of AMPK both as a multi-task gatekeeper and as an energy regulator in
skeletal muscle (Kjobsted et al., 2018) . In this section AMPK’s function as well as up
and downstream regulators will be highlighted.

Furthermore, cancer cachexia and

AMPK will be discussed and its potential role in regulating muscle mass.
The adenosine monophosphate protein kinase (AMPK) exists as a heterotrimeric
complex comprised of an  catalytic subunit, a scaffolding  subunit, and a regulatory 
subunit. In mammals each of these subunits have multiple isoforms (1 2, 1, 2, 1,
2, and 3) (Kemp, Oakhill, & Scott, 2007). These subunits are all encoded by separate
genes, which enable the formation of diverse combinations of the heterotrimeric complex
(Kemp et al., 2007). AMPK activation involves two steps; reversible phosphorylation at
threonine 172 (T172) in the  subunit and allosteric binding of AMP with the C-terminal
region in the  subunit (Witczak, Sharoff, & Goodyear, 2008).

The  subunit is

responsible for carbohydrate binding and has actually been demonstrated to inhibit
AMPK activity (Kemp et al., 2007; Witczak et al., 2008). In skeletal muscle the major
activator of AMPK is upstream liver kinase B1 (LKB1) and primarily is responsible for
phosphorylating AMPK at T172 inducing its activation (Koh et al., 2008).

This

activation can be further enhanced by conformational changes caused by the allosteric
binding of AMP and/or ADP to the  subunit which promotes phosphorylation and
protects AMPK from protein phosphatases (Kemp et al., 2007). The combined effect of
phosphorylation at T172 and allosteric regulation can alter kinase activity >1000 fold
making AMPK extremely sensitive to very subtle changes in energy status (Kemp et al.,
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2007). It is also worth noting that Ca2+ has also been demonstrated to induce AMPK
phosphorylation

through calmodulin-dependent

kinase kinase beta

(CaMKK)

independent of any changes in AMP: ATP or ADP:ATP ratio (Jensen et al., 2007) . This
mechanism has been investigated and characterized in response to mild tetanic muscle
contractions.
As briefly mentioned above the most commonly studied upstream activator of
AMPK is LKB1(Sakamoto, Goransson, Hardie, & Alessi, 2004; Sakamoto et al., 2005).
LKB1 is what is known as a tumor suppressor that is commonly mutated in a variety of
cancers. However, physiologically LKB1 possess many different cellular functions in the
regulation of skeletal muscle metabolism and systemic metabolism (Sakamoto et al.,
2004; Taylor et al., 2004; Thomson et al., 2007). A little over a decade ago, researchers
established that LKB1 was the missing kinase that phosphorylates and activates AMPK
to induce its downstream signaling effects (Koh et al., 2006). The importance of LKB1
in this process has been demonstrated through loss and gain of function studies as muscle
specific LKB1 knockout mice exhibit ablated AMPK2 activity (Koh et al., 2006;
Sakamoto et al., 2005). These results further established LKB1 as the major AMPK
kinase regulator in skeletal muscle. AMPK is also activated in response to various
cellular energy stressors and pathways regulating insulin sensitivity and glucose transport
(Kjobsted et al., 2018). Such stimuli include exercise, hypoxia, leptin and adiponectin.
Furthermore, inflammation through the IL-6 signaling pathway has been demonstrated to
induce AMPK in cultured C2C12 myotubes (White, Puppa, Gao, et al., 2013). Treatment
of myotubes with an IL-6 inhibitor restored mTORC1 signaling and suppressed AMPK.
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Another common regulator of AMPK is the alteration of energy status or energy
availability most commonly seen and studied with nutrient deprivation or fasting. A fast
will alter the metabolism of skeletal muscle leading to an increased flux of free fatty
acids and alters the AMP:ATP ratio thus inducing the activation of AMPK (de Lange et
al., 2007). AMPK will then induce Acetyl CoA carboxylase (ACC) to stimulate the
breakdown and uptake of the fatty acids for oxidation in the mitochondria (Galic et al.,
2018). Interestingly, studies have demonstrated that LKB1 is not sensitive to AMP and
actually remains constitutively active (Lizcano et al., 2004). The binding of AMP to
AMPK causes it to become a better substrate and increases the affinity of LKB1 to
AMPK (Hawley et al., 2003) . Furthermore, multiple studies have examined acute
exercise (a potent metabolic stressor) in rats and mice as a very potent inducer of AMPK
(Friedrichsen, Mortensen, Pehmoller, Birk, & Wojtaszewski, 2013). The duration and
intensity of exercise also directly has an effect on the degree of AMPK activity in skeletal
muscle (Friedrichsen et al., 2013; Sakamoto et al., 2004). Acute exercise stimulation of
AMPK also appears to regulate the same genes related to a fast (Park et al., 2002; Terada
et al., 2002). Interestingly, in mice lacking the 2 subunit the AMPK activation of was
blunted following an acute exercise bout (Jorgensen et al., 2005). However, the genes
related to exercise that were investigated were not found to be altered in either 1 or 2
muscle specific knockout mice (Jorgensen et al., 2005). Conversely to acute exercise, far
less is understood regarding exercise training (Taylor et al., 2004). Aerobic exercise
training has been demonstrated to induce LKB1 rather than AMPK protein expression as
well as mitochondrial biogenesis markers in rat skeletal muscle (Taylor et al., 2004;
Taylor et al., 2005). Surprisingly, these changes occurred despite a decrease in AMPK
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kinase activity (Taylor et al., 2005). In human skeletal muscle exercise training has been
demonstrated to suppress AMPK activity following a prolonged bout of exercise
suggesting that training improves the skeletal muscle capacity to handle metabolic stress,
possibly through improved mitochondrial function (McConell et al., 2005; Taylor et al.,
2005). However, similar studies have also reported either no significant change in AMPK
or an induction of activity (Z. P. Chen et al., 2000). These results are ambivalent and the
examination of exercise trainings effects on AMPK require far more investigation to be
considered conclusive.

Muscle specific LKB1 knockout mice have demonstrated that

LKB1 is actually an important regulator of exercise capacity and mitochondrial function
(Taylor et al., 2004). Contrasting to these results the training induction of GLUT4,
hexokinase II, and mitochondrial content markers were all intact (Sakamoto et al., 2005).
These results suggest that LKB1-AMPK signaling is an important factor in skeletal
muscle physiology, but the contradicting results suggest that other pathways regulate the
response to exercise training.
AMPK- Regulation of Metabolic Downstream Targets
The activation of AMPK results in the phosphorylation of multiple downstream
substrates who overall effects are to suppress ATP consuming pathways such as protein
synthesis and induce ATP generating pathways and events such as fatty acid oxidation,
glucose transport, and autophagy. The activation or suppression of these various
downstream kinases have metabolic consequences that can affect the metabolism and
cellular environment systemically in addition to skeletal muscle.
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Fat and Glucose Metabolism-Metabolic Enzymes
AMPK was initially characterized as the upstream kinase regulating metabolic
enzymes such as ACC and HMG-CoA reductase, these serve as the rate limiting steps for
fatty acid control and sterol synthesis(Mihaylova & Shaw, 2011). In tissues that are
metabolically active such as skeletal muscle, AMPK controls the uptake of glucose
through AS160 and also is a key regulator of GLUT4 trafficking following exercise and
insulin stimulation(Mihaylova & Shaw, 2011).

ACC is responsible for generating

malonyl coA, an allosteric inhibitor of CPT1, which is responsible for the uptake fatty
acids into the mitochondria for  oxidation (Mihaylova & Shaw, 2011; Mills, Foster, &
McGarry, 1983; Watt et al., 2006). The phosphorylation of ACC by AMPK inactivates
the enzyme leading to decreased lipid synthesis rates and alleviates CPT1 inhibition
(Hardie & Pan, 2002). The alleviation of CPT1 then increases fatty acid flux into the
mitochondria where it is oxidized to generate ATP (Hardie & Pan, 2002). AMPK also
increases the phosphorylation of hormone sensitive lipase (HSL) which serves to break
down fat stores into free fatty acids to be oxidized for energy (Watt et al., 2006). In
addition to activating HSL to induce lipolysis, AMPK will also induce the activation
adipocyte triglyceride lipase (ATGL) (Hardie & Pan, 2002). The regulation of ATGL by
AMPK has recently been demonstrated to be an important factor in pre-clinical models of
cancer cachexia.
Acute AMPK activation is also associated with the suppression of glycogen
synthesis rates. AMPK has been reported to directly phosphorylate glycogen synthase at
Ser7, thus inhibiting its activity. This mechanism is of interest as it is generally coupled
to an increase in glycolytic flux through the activation of 6-phosphofructo-2-kinase
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(PFK-2) which is the rate limiting step of glycolysis (Carling & Hardie, 1989). The
activation of PFK-2 by AMPK induces the synthesis of fructose 2,6 bisphosphate which
is considered an extremely potent stimulator of glycolysis (Carling & Hardie, 1989;
Marsin et al., 2000).

This mechanism of activation suggests that the rapid acute

activation of AMPK initiates this signaling cascade to induce the mobilization of glucose
into ATP.
Regulation of Transcription Factors
AMPK is also able to regulate metabolism through the regulation of numerous
transcription factors. These downstream targets have recently come to light through
various lines of investigation.

Notably, AMPK has recently been demonstrated to

phosphorylate and regulate acetyltransferase p300, which is a member of the histone
deacetylase family.

AMPK has also been reported to actually regulate histones

themselves in some cases (Suter et al., 2006). AMPK has also been deemed a master
controller of mitochondrial biogenesis and content (Suwa, Nakano, & Kumagai, 2003).
Sirtuin 1 (SIRT1) is a NAD+ dependent deacetylase that is proposed to be required for the
AMPK activation of mitochondrial biogenesis (Canto et al., 2010). Studies utilizing
AMPK activating compounds have reported increased mitochondrial biogenesis in
skeletal muscle and this biogenesis was not present with the loss of SIRT1 (Suwa et al.,
2003). Similarly, these AMPK activating agents have little to no effect in mouse models
with mutated or suppressed AMPK activity, suggesting that AMPK is a critical regulator
of mitochondrial biogenesis in skeletal muscle (Mercurio, 2002). These results were
further explored through numerous gain and loss of functions studies utilizing transgenic
mouse models (Mercurio, 2002; Viollet et al., 2009). Overexpression of a kinase dead 2
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subunit in muscle demonstrated less running activity and blunted endurance performance
when compared to wild type mice (Mu, Brozinick, Valladares, Bucan, & Birnbaum,
2001).

Furthermore, these results were also replicated in a whole body systemic

knockout of the 2 subunit (Jorgensen et al., 2005). Contrasting to these results were
different manipulations to activate AMPK activity and demonstrate increased
mitochondrial gene markers.
The effects of AMPK on different mitochondrial genes are achieved through the
regulation of multiple transcription factors and cofactors. AMPK is a master regulator of
peroxisome proliferator gamma co-activator 1 (PGC-1) (Jager, Handschin, St-Pierre,
& Spiegelman, 2007; Viollet et al., 2009). PGC-1 controls and coordinates a variety of
other transcription factors related to mitochondrial function, biogenesis, and content
(Handschin & Spiegelman, 2006). AMPK is proposed to directly phosphorylate PGC-1
at Thr177 and Ser538 and induce its translocation to the nucleus where its transcriptional
activity takes place (Jager et al., 2007). The establishment of AMPK and PGC-1 was
demonstrated when AMPK activating compound AICAR was unable to induce
mitochondrial biogenesis in the muscles of mice lacking PGC-1 (Jager et al., 2007).
AMPK is also capable of activating PGC-1 through deacetylation (Canto et al., 2010).
Interestingly, AMPK trimers containing the 3 subunit are actually responsible for the
deacetylation of PGC-1 during fasting conditions or exercise (Canto et al., 2010). This
is of particular interest as 3 subunits are only present in glycolytic muscles and are more
sensitive to exercise induced stressed in mouse skeletal muscle (Jensen, Wojtaszewski, &
Richter, 2009). Interestingly, the results from this study demonstrated that the activation
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of AMPK following exercise was dependent primarily on the 2 isoform (Jorgensen et
al., 2004). It appears however that no exercise genes were negatively affected by the loss
AMPK and actually suggest loss of one sub-unit leads to an increased activation of
activity of the other to compensate for the loss (Jorgensen et al., 2004).
Another interesting transcription factor that is a known target of AMPK is the
FOXO family of transcription factors. Studies examining FOXO have suggested an
important role for lifespan extension and are commonly associated with oxidative stress
defense in skeletal muscle (K. Nakashima & Yakabe, 2007). However, the primary two
pathways that are transcriptionally controlled by the FOXO family are the ubiquitin
proteasome and the autophagy lysosomal proteasome. FOXO is present in multiple
isoforms in skeletal muscle and the majority of research has examined FOXO1 and
FOXO3 which are controlled upstream by both AKT and AMPK (Greer et al., 2007).
Classically, phosphorylation by the latter is believed to drive FOXO3 and FOXO1 into
the nucleus inducing its transcriptional activity and often activating the atrophy program
of skeletal muscle (Stitt et al., 2004).

However, FOXO3 is capable of being

phosphorylated at six different residues each of which elicit a different transcriptional
response during glucose deprivation or fasting (Greer et al., 2007). Surprisingly, it is
worth noting that recent evidence suggests that FOXO3 phosphorylation by AMPK does
not necessarily affect its localization but rather its activity (Greer et al., 2007). In
addition to phosphorylation, FOXO is also capable of being regulated by
acetylation/deacetylation which again occurs through AMPK and SIRT1 (Fulco et al.,
2008). The fact that AMPK tightly controls the transcriptional regulation of a number of
genes has been known for some time. However, recent evidence has also demonstrated
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that some of these transcription factors are immediate targets for phosphorylation by
AMPK as well. An interesting challenge that has come to light and warrants further
investigation is how AMPK itself shuttles in and out of the nucleus to target promoters.
AMPK Regulation of mTORC1 and Protein Synthesis
In conditions where nutrients are unavailable or scarce, AMPK serves as the
metabolic checkpoint to inhibit growth (Guo, Cloughesy, Radu, & Mischel, 2010). The
most commonly described mechanism of this regulation is through the mTORC1
signaling pathway (Guo et al., 2010). As mentioned briefly above, AMPK is activated or
switched on during starvation to up-regulate energy conservation.

More evidence has

come to light that demonstrates the critical role of AMPK and mTORC1 as antagonistic
forces that regulate muscles adaptations to nutrition, exercise, and overall growth
stimulation (Shaw, 2009).
AMPK negatively regulates the mTORC1 signaling complex through the
phosphorylation of tuberous sclerosis complex 1/2 (TSC1/2) (Corradetti, Inoki, Bardeesy,
DePinho, & Guan, 2004). While this is the most commonly studied mechanism, AMPK
has also been proven to phosphorylate mTORC1 directly at Thr 2446 (Shaw, 2009).
Finally, AMPK has also been shown to phosphorylate raptor, an mTORC1 binding
partner that is essential for its activity (Kwon & Querfurth, 2015). The phosphorylation
of raptor leads to sequestration of raptor by 14-3-3 proteins (Corradetti et al., 2004; J.
Kim, Kundu, Viollet, & Guan, 2011).

Phosphorylation of these sites suppresses

mTORC1 signaling and inhibits protein synthesis. In addition to its actions on mTORC1,
AMPK also regulates protein synthesis through the inhibition of eukaryotic elongation
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factor 2 (eEF2). Phosphorylation of eEF2 at Thr 56 inhibits binding to the ribosome thus
slowing elongation rate (Thomson, Fick, & Gordon, 2008). AMPK accomplishes this
phosphorylation by interacting with eEF2 kinase and inhibiting it (Thomson et al., 2008) .
Inhibiting the upstream kinase leads to the inhibition of eEF2 itself.

Classically,

translation initiation is often considered the rate limiting step in synthesis however,
inhibition of elongation can also be critical in the synthetic rate.
In many models that have impaired anabolic signaling such as cancer cachexia,
there is often an induction of AMPK activation (Brown, Rosa-Caldwell, Lee, Blackwell,
et al., 2017; Puppa, Gao, et al., 2014; White, Puppa, Gao, et al., 2013). These results
suggest that mTORC1 is an essential part of normal ATP production and its disruption
induces energetic stress and AMPK activity (Brown, Rosa-Caldwell, Lee, Blackwell, et
al., 2017). The suppression of AMPK in P70S6 kinase deficient myotubes has been
demonstrated to rescue myotube size and protein synthesis signaling further
demonstrating a role for AMPK in the regulation of mTORC1 dependent signaling
processes (White, Puppa, Gao, et al., 2013). Studies have also demonstrated that the
constant infusion of AICAR suppresses mTORC1 and P70S6 kinase activation leading to
suppressed synthesis rates (Suwa et al., 2003). This suppression is directly correlated to
the chronic activation of AMPK (Suwa et al., 2003). Conversely, activation of mTORC1
in AMPK deficient myotubes has been demonstrated to robustly induce synthesis rate and
lead to a 1.5 fold increase in myotube size (White, Puppa, Gao, et al., 2013).
Recent advances in genetic mouse models have allowed researchers to further
examine the role of AMPK in-vivo. Mice that have a skeletal muscle specific knockout
of AMPK1 demonstrated greater overload induced hypertrophy than that of their wild
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type littermates (Mounier et al., 2009).

Elevated P70S6 kinase and 4E-BP1 were

reported in overload induced hypertrophy AMPK1 knockout mice (Mounier et al.,
2009). However, it is worth noting that a knockout of AMPK2 actually suppressed the
overload induced hypertrophy response (Mounier et al., 2009). These results suggest that
AMPK2 may be necessary for the increase in muscle size following an overload
stimulus. More recent work has built upon these initial findings through the generation
of double 12 muscle knockout mice. Soleus muscles from these mice were larger by
mass and fiber diameter when compared to wild type littermates. However, loss of the
12 were not different in mass or fiber diameter when compared to wild type controls
(O'Neill et al., 2011). It is interesting to speculate however, if a difference in the cre
promoter could have contributed to this. The  knockout used a muscle creatine kinase
(MCK) promoter which is specific to cardiac and skeletal muscle, whereas the
researchers using the  catalytic subunit utilized the human skeletal actin (HSA)
promoter which is specific to just skeletal muscle and believed to be more efficient.
While these results clearly demonstrate a role for AMPK in the regulation of
mTORC1 during overload and exercise induced protein synthesis, less is understood
about its regulation of these processes during fasting or starvation induced conditions.
Furthermore, these genetic knockout rodents have yet to be utilized in disease models
such as cancer cachexia or other catabolic conditions that exhibit chronic AMPK
activation. The use of these knockout models in a catabolic state could provide new
insight and potential therapeutic targets to increase muscle mass and protein synthesis
rates during disease.
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AMPK- A Critical Regulator of Autophagy
As described previously above the process of autophagy includes the degradation
of cellular content and organelles under low energy conditions such as fasting or exercise.
The process of autophagy involves several signaling events that lead to engulfment of the
targeted cargo and subsequent degradation by the lysosomal proteasome (Glick et al.,
2010; Yu et al., 2018). The key regulatory kinase of autophagy is ULK-1 that serves as
the link between mTORC1 and AMPK (J. Kim et al., 2011).

During low energy

conditions ULK-1 is phosphorylated at Ser 555 by AMPK inducing this signaling process
to provide nutrients and amino acids from the degraded cargo (J. Kim et al., 2011).
During periods of high energy availability such as a meal, mTORC1 will actually
phosphorylate ULK-1 and inhibit the induction of autophagy (J. Kim et al., 2011).
AMPK has long been known to be a key regulator of autophagy (Kjobsted et al.,
2018).

While some initial studies reported conflicting results on AMPK’s role in

autophagy, it was later determined that these results were dependent on cell type and
conditions used.

Under normal basal conditions both mTORC1 and AMPK are

associated with ULK-1 (J. Kim et al., 2011). Classically, a fast or nutrient deprivation
will lead to AMPK activation and suppress mTORC1 which promotes autophagy through
the direct phosphorylation of ULK-1 (Bagherniya, Butler, Barreto, & Sahebkar, 2018).
However, it is now known that starvation is not the only stimulus capable of initiating
autophagy. This phosphorylation up-regulates the ULK-1 kinase activity and disrupts the
association of ULK-1 with mTORC1 (J. Kim et al., 2011). Before this was discovered it
was believed that AMPK controlled autophagy solely through the regulation of mTORC1
itself (J. Kim et al., 2011). ULK-1 then phosphorylates Atg 13 and FIP2000 to induce the
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initiation of autophagy (J. Kim et al., 2011; Masiero et al., 2009; Yu et al., 2018). AMPK
also phosphorylates Beclin-1 which activates the pro-autophagy Vps34 complex. These
initial signaling events lead to autophagosome formation through the activation and
lipidation of LC3 and subsequent tagging of cargo for degradation by p62 (J. Kim et al.,
2011; Masiero et al., 2009; Yu et al., 2018). Studies recently examining the loss of the
AMPK 12 demonstrated a blunted autophagy response to fasting and aging in skeletal
muscle (Bujak et al., 2015; Zhao & Klionsky, 2011). Loss of these AMPK subunits
diminished AMPK phosphorylation and downstream ULK-1 activity mirrored AMPK
activity perfectly (Bujak et al., 2015; Zhao & Klionsky, 2011).

This study was

instrumental in further establishing AMPK’s role in fasting induced autophagy as it was
one of the first studies to examine these outcomes using a genetic muscle specific
knockout. Furthermore, a similar study using a kinase dead AMPK 2 actually yielded
higher LC3 lipidation content than its vector treated litter mates (Zong et al., 2002).
While the authors were unable to provide an explanation for this finding, they did suggest
that a loss of 2 alone is not sufficient to suppress autophagy protein expression following
a fast. These results further establish that simply deleting one of that  catalytic subunits
results in the up-regulation of activity of the remaining subunit as a compensatory
mechanism and may actually lead to accelerated autophagy.
The activation of AMPK by acute exercise has been recently reported to be a
critical factor in the activation of ULK-1 and the initiation of autophagy as well as
mitophagy processes (Laker et al., 2017). Utilizing both a dominant negative AMPK as
well as a constitutively active AMPK the researchers were able to demonstrate that the
exercise activation of ULK-1 is dependent on AMPK (Zhao & Klionsky, 2011).
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Additionally, the researchers also were able to show that exercise induced metabolic
adaptations required ULK-1 (Laker et al., 2017). These findings provide direct evidence
of exercise-induced autophagy/mitophagy and demonstrate the importance of AMPKULK-1 signaling in skeletal muscle.
In addition to its regulation of ULK-1, AMPK is also capable of inducing FOXO
transcriptional activity as discussed previously in this review (Sanchez, Csibi, et al.,
2012). Both FOXO1 and FOXO3 have been implicated in the transcriptional regulation
of both autophagy related genes and lysosomal activity (Sanchez, Csibi, et al., 2012).
However, FOXO is also capable of regulating a host of atrophy related genes both in the
autophagy lysosomal system and the ubiquitin proteasome. Since FOXO is capable of
regulating multiple different processes downstream, this mechanism of autophagy is
often considered indirect when compared to the direct interaction AMPK has with ULK-1
and mTORC1.
AMPK in Cachexia – A Lack of Investigation
AMPK has been very well characterized for its roles in exercise and metabolism
(K. Nakashima & Yakabe, 2007; Sanchez, Csibi, et al., 2012) . However, only a few
researchers have examined AMPK’s role in cancer induced muscle wasting. These
studies have provided putative mechanisms of action and provided the initial evidence
that place AMPK at the center of muscle wasting. Few studies have mechanistically tried
to investigate the role it plays in regulating protein synthesis and degradation during the
progression of the disease (Hall et al., 2018; Rohm et al., 2016; White, Puppa, Gao, et al.,
2013). AMPK as described above is a master energy sensor and regulator of skeletal
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muscle metabolism and is capable of being activated by numerous stimuli. Downstream it
regulates a host of signaling processes related to lipid metabolism, glucose metabolism,
protein synthesis, degradation, and mitochondrial biogenesis which are all disrupted in
cancer cachexia (Argiles, Busquets, et al., 2015; Carson et al., 2016; Sandri, 2016). Our
laboratory has previously demonstrated a role for AMPK in the regulation of skeletal
muscle protein synthesis signaling through mTORC1 during cancer cachexia (White,
Baynes, et al., 2011a; White, Puppa, Gao, et al., 2013). Utilizing an IL-6 receptor
antibody, our research group was able to establish a link between cachectic inflammation
and the AMPK suppression of protein synthesis (White, Baynes, et al., 2011a; White,
Puppa, Gao, et al., 2013). Furthermore, we have also established a potential role for
mitochondrial quality control in the activation of AMPK during cachexia. Utilizing a
potent anti-oxidant our laboratory demonstrated attenuated AMPK activation and
improved indices of mitochondrial biogenesis and dynamics (Miao et al., 2017; Narsale
et al., 2016a). However, an exact mechanism of action has yet to be established.
There are conflicting ideologies about AMPK in cancer cachexia, while many
studies examining pre-clinical models have reported an elevation of skeletal muscle
AMPK, very few have gone on to actually examine the ramifications of this activation
(Brown, Rosa-Caldwell, Lee, Blackwell, et al., 2017; White, Puppa, Gao, et al., 2013).
Some researchers argue that stimulation of AMPK during cachexia is needed and can
actually attenuate fat mass loss however, these findings may have pertained solely to
white adipose tissue(Hall et al., 2018; Rohm et al., 2016). Our laboratory has extensively
characterized the ApcMin/+ and LLC mouse models of cachexia and demonstrated that
AMPK is induced as the severity of cachexia progresses following a standard 5 hour
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fasting paradigm used to measure mTORC1 signaling and protein synthesis (Baltgalvis et
al., 2010; Hardee, Montalvo, & Carson, 2017; Puppa, Gao, et al., 2014; White, Baynes, et
al., 2011b). Accompanying this induction is the suppression of anabolic signaling and
increased degradation through both the ubiquitin proteasome system and autophagy
lysosomal system. The disruption and chronic activation of AMPK is also accompanied
by mitochondrial loss and decreased biogenesis, suggesting that normal AMPK
regulation of these processes is no longer intact during cachexia (White, Baltgalvis, et al.,
2011). Through the manipulation of IL-6 using a receptor antibody, our laboratory was
able to demonstrate that elevated circulating IL-6 contributes to the chronic activation of
AMPK and suppressing this signaling attenuates the AMPK mediated suppression of
mTORC1(White, Baynes, et al., 2011b). Additionally, inhibition of myotube AMPK
using Compound C during LLC treatment improved mTORC1 signaling and protein
synthesis (White, Puppa, Gao, et al., 2013).
AMPK - Cachexia and Exercise
While it is well established that acute exercise activates AMPK our laboratory
demonstrated that exercise training was able to attenuate the cachexia induced chronic
activation of this pathway and improve muscle mass loss (Hardee et al., 2016; Puppa et
al., 2012).

These results suggest that exercise training may improve mitochondrial

function during cancer cachexia and alleviate the chronic deficit of energy (ATP
generation) thus lowering AMPK’s activity. Similar results were also demonstrated
using high frequency electrical stimulation in cachectic muscle (Hardee et al., 2016).
Seven repeated bouts of high frequency stimulation were able to lower AMPK
phosphorylation in cachectic ApcMin/+ and stimulate muscle protein synthesis 3 hours post
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the final treatment (Hardee et al., 2016). These results demonstrate that exercise training
in the cachectic state has the ability to improve skeletal muscle AMPK signaling and
alleviate the AMPK mediated inhibition of mTORC1 signaling and protein synthesis.
While both exercise and cytokine treatments have been demonstrated to improve
AMPK signaling during cancer cachexia, less is understood about the role of fasting and
feeding in these signaling processes. As mentioned previously, numerous models of
cancer cachexia have reported both elevated AMPK and indices of autophagy (Pigna et
al., 2016a; White, Baltgalvis, et al., 2011).

While many pre-clinical models have

reported food intake as being similar between cachectic animals and healthy controls,
there are very few studies that have examined defined fasting and feeding during cancer
cachexia. The majority of protein synthesis literature in cancer cachexia utilizes a fast
(usually 5 hours) to account for acute effects of feeding. As previously described, our
laboratory has always noted an increase in AMPK following this time period. This
proposal will focus more on the role of skeletal muscle AMPK in the fasting and feeding
response of cachectic skeletal muscle. Additionally, the role of exercise training in the
regulation of these processes during cancer cachexia will also be explored. Key
preliminary data from our laboratory suggest that cachectic Min mice are not necessarily
anabolic resistant but rather hyper sensitive to a fast due to the chronic activation of
AMPK that occurs in the fed state. This chronic activation is exacerbated further through
an acute 12-hour fast and may suppress protein synthesis and induce autophagy when
compared to normal healthy controls.
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CHAPTER 2
THE ROLE OF AMPK SIGNALING IN SKELETAL MUSCLE PROTEIN
TURNOVER DURING CANCER CACHEXIA
2.1 Abstract.
Cancer cachexia is a debilitating condition that is characterized by the progressive
loss of muscle mass. The loss of muscle mass during cachexia is often attributed to
altered protein turnover.

The adenosine monophosphate kinase (AMPK) signaling

pathway exerts regulatory control over skeletal muscle protein synthesis (mTORC1
activity), degradation, and mitochondrial quality control. Our laboratory and others have
demonstrated that AMPK is chronically elevated in cachectic skeletal muscle. The
elevation of AMPK coincides with suppressed mTORC1, increased degradation, and
disrupted mitochondrial quality control. While these findings suggest a role for AMPK
very little is understood about its downstream signaling and the regulation of protein
turnover during cachexia. Therefore, the purpose of this study was to determine the role
of AMPK signaling in skeletal muscle protein turnover during cancer cachexia.

Male

C57BL/6 (B6, N=8), AMPK12 skeletal muscle specific knockout (KO), ApcMin/+ (Min,
N=10), and AMPK12 ApcMin/+ (Min KO, N=6) were tracked until ~19 weeks of age
and fasted for a duration of 12 hours during the light cycle. Following completion of
each treatment, hindlimb muscles were harvested and the gastrocnemius homogenized for
protein analysis. Loss of AMPK in Min mice attenuated fasting induce bodyweight loss
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and gastrocnemius mass. AMPK (T172) phosphorylation was induced in Min mice and
suppressed by Min KO. TSC2 phosphorylation was induce in Min mice and rescued in
Min KO mice. There was also a main effect of Min to induce Raptor and ULK-1 while
also a main effect of KO to suppress Raptor and ULK-1 phosphorylation. E3 ligases
MuRF-1 and Atrogin-1 were both induced in Min mice, but were rescued by Min KO.
Furthermore, autophagy markers P62 and LC3B were also elevated in Min mice and
rescued by Min KO. There was a main effect of KO and Min to suppress PGC-1,
MFN-1 was suppressed in Min mice but restored by Min KO. DRP-1 was induced in
Min mice and this induction was attenuated in Min KO mice. Our results demonstrate
that AMPK is required for the cachexia induction of E3 ligases and autophagy.
Furthermore, our results also suggest that the cachexia regulation of mitochondrial
dynamics proteins DRP-1 and MFN-1 occur through AMPK.
2.2 Introduction
Cancer cachexia is the unintentional loss of bodyweight loss which also includes
skeletal muscle mass (Baracos, 2006a, 2011; Baracos et al., 2018). Perturbations in
protein synthesis and protein degradation disrupt muscle proteostasis and metabolism
(Bruggeman et al., 2016; Dodesini, Benedini, Terruzzi, Sereni, & Luzi, 2007; Duval,
Jeanneret, Santoro, & Dormond, 2018; Johns et al., 2012). The underlying causes of
these alterations in protein turnover are poorly understood and may depend a multitude of
factors including inflammation, oxidative metabolism, type of cancer, and severity of
cachexia (Hardee et al., 2017; Hatakeyama et al., 2016; Hetzler, Hardee, LaVoie,
Murphy, & Carson, 2017; A. M. Horstman, Olde Damink, Schols, & van Loon, 2016;
Mattox, 2017; Porporato, 2016). In human cancer patients, fasted protein synthesis rates
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are suppressed in severe cachexia (Baracos, 2006a; A. M. Horstman et al., 2016; Lindsey
& Piper, 1985; Wheelwright et al., 2016). Furthermore, our laboratory and others have
demonstrated similar findings in pre-clinical models of cancer cachexia (Baltgalvis et al.,
2009; Carson et al., 2015; Hardee et al., 2017; Narsale & Carson, 2014; White,
Baltgalvis, et al., 2011; White, Baynes, et al., 2011a; White, Puppa, Gao, et al., 2013).
While the suppression of protein synthesis has been established, many cancer cachexia
clinical studies and pre-clinical models also report an acceleration of protein degradation
(Attaix et al., 1999b; Aversa, Pin, Lucia, Penna, Verzaro, Fazi, Colasante, Tirone, Rossi
Fanelli, et al., 2016; Baracos, 2006a; Bennani-Baiti & Walsh, 2011). This imbalance of
synthesis and degradation leads to a net loss of muscle mass and can directly influence
the response to interventions such as chemotherapy and exercise (Dillon et al., 2012;
Kimura et al., 2015; Narsale & Carson, 2014; C. M. Prado et al., 2013; Ryan et al., 2016;
Sadeghi et al., 2018).
The adenosine monophosphate protein kinase (AMPK) is a nutrient sensitive
kinase that has the unique ability of regulating skeletal muscle protein synthesis,
degradation, and mitochondrial quality control (Bujak et al., 2015; Z. P. Chen et al.,
2000; Guo et al., 2010; Gwinn et al., 2008; Kemp et al., 2007; J. Kim et al., 2011;
Kjobsted et al., 2018; Mounier et al., 2015). Our laboratory has previously reported that
the degree of activation of AMPK progressively increases with the severity of cachexia in
the ApcMin/+ mouse model of cachexia and is tightly associated with muscle mass loss
(White, Baynes, et al., 2011b). AMPK activation in normal healthy skeletal muscle will
suppress mTORC1 activity through phosphorylation of TSC2 and Raptor (Sengupta,
Peterson, & Sabatini, 2010; Shaw, 2009). In particular, the phosphorylation of Raptor is
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especially important as it has been required for the suppression of mTORC1 activity
(Gwinn et al., 2008). We have previously demonstrated that Raptor and TSC2 are
induced in cachectic skeletal muscle while AMPK is robustly activated (White, Baynes,
et al., 2011a; White, Puppa, Gao, et al., 2013). Coinciding with the induction of TSC2
and Raptor, AMPK also regulates the Forkhead Box O family of transcription factors
(FOXO3a) increasing its transcriptional activity and E3 ligases Atrogin-1 and MuRF-1
(Hulmi, Silvennoinen, Lehti, Kivela, & Kainulainen, 2012; Jorgensen et al., 2005; K.
Nakashima & Yakabe, 2007). The use of AMPK activator AICAR in-vitro and in-vivo
has demonstrated that chronically elevating AMPK will induce FOXO3a and the
expression of Atrogin-1 and MuRF-1 leading atrophy (Greer et al., 2007; K. Nakashima
& Yakabe, 2007). Additionally, AMPK inhibitors have also been utilized to demonstrate
a suppression of E3 ligases both in-vivo and in-vitro, further establishing the regulatory
role of AMPK (Viollet et al., 2009). FOXO3a has been demonstrated to be robustly
activated in various pre-clinical models of cancer cachexia, acute exercise, and
fasting(Greer et al., 2007; Reed, Sandesara, Senf, & Judge, 2012; White, Baynes, et al.,
2011b). Our laboratory and other research groups have previously reported elevated
FOXO3a, Atrogin-1 and MuRF-1 signaling in both cachectic ApcMin/+ and LLC mice
(Puppa, Gao, et al., 2014; White, Baynes, et al., 2011a). AMPK also controls the
autophagy lysosomal system through the phosphorylation of Unc-51 like kinase (ULK-1)
at serine 555 (Bujak et al., 2015; Laker et al., 2017; Sanchez, Csibi, et al., 2012; Zhao &
Klionsky, 2011). The activation of ULK-1 by AMPK is required for the initiation of
autophagy (Wong, Puente, Ganley, & Jiang, 2013; Zachari & Ganley, 2017).
Furthermore, recent evidence also suggest that this initiation of autophagy also requires
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the phosphorylation of Raptor by AMPK in order to suppress mTORC1 and alleviate the
hold mTORC1 exerts on ULK-1 (Gwinn et al., 2008; Hindupur, Gonzalez, & Hall, 2015).
Autophagy has recently become a highly debated topic in cachexia and is reported
elevated in many pre-clinical models and human cancer patients(Penna et al., 2014;
Penna, Costamagna, et al., 2013).

Previous research from our laboratory has

demonstrated that both ubiquitin proteasome activity (ATP dependent) and autophagy
lysosomal activity (ATP independent) both increase as the severity of cachexia and
AMPK also increase (White, Baynes, et al., 2011a).
The final pathway of interest that AMPK directly regulates is the process of
mitochondrial quality control (Laker et al., 2017; Mishra & Chan, 2016; O'Neill et al.,
2011; Romanello et al., 2010; Romanello & Sandri, 2015). AMPK is activated during
energy deficiency (fasting and exercise) and will induce the activation of peroxisome
proliferator gamma co-activator 1 (PGC-1) (Jager et al., 2007; Jorgensen et al., 2005).
PGC-1 is induced by AMPK to compensate for a lack of energy availability and
increase the amount of ATP production by the generation of new mitochondria (Canto &
Auwerx, 2009; Jager et al., 2007). Studies utilizing AMPK activators have demonstrated
that PGC-1 is required for AMPK mediated mitochondrial biogenesis(Canto et al.,
2010; Jager et al., 2007; Terada et al., 2002). Interestingly, despite the chronic elevation
of AMPK in cachectic skeletal muscle, PGC-1 is actually suppressed demonstrating a
disconnect between the two proteins(Puppa, Gao, et al., 2014; Puppa et al., 2012; White,
Baltgalvis, et al., 2011). The reason for this dysregulation remains to be elucidated but
some have speculated that chronic inflammation through IL-6 as well as disrupted sirtuin
activity may play a role in the elevation of AMPK and suppression of PGC-1(Puppa,
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Gao, et al., 2014; Puppa et al., 2012; White, Baltgalvis, et al., 2011). Another key
component of mitochondrial quality control is the process of mitochondrial dynamics or
the constant remodeling of the mitochondrial network through fission and fusion.
Mitochondrial dynamics have been implicated in cancer cachexia and have also been
demonstrated to induce muscle atrophy (Marzetti et al., 2017; Mishra & Chan, 2016;
Romanello & Sandri, 2015; Suliman & Piantadosi, 2016; Vitorino, Moreira-Goncalves,
& Ferreira, 2015). Dynamin related protein (DRP-1) and mitofusion 1 (MFN-1) are two
key regulators of fission and fusion and have emerged as interesting targets in cancer
cachexia and inflammation (Suliman & Piantadosi, 2016). A recent publication by our
laboratory has demonstrated a role for inflammatory signaling through gp130/ERK1/2
signaling to induce DRP-1 and increased fission (Fix, VanderVeen, Counts, & Carson,
2019). Chronic mitochondrial fission has been demonstrated by our laboratory and
others in severe cancer cachexia(Brown, Rosa-Caldwell, Lee, Blackwell, et al., 2017;
Puppa, Gao, et al., 2014; White et al., 2012). Furthermore, mitochondrial fusion appears
to be an early target of cachexia as suppression of MFN-1 worsens as the degree of
cachexia increases(White, Baltgalvis, et al., 2011; White et al., 2012). Dysregulation of
mitochondrial dynamics has been directly shown to influence muscle atrophy through
FOXO3a signaling and the E3 ligases in non-tumor bearing mice (Romanello et al., 2010;
Romanello & Sandri, 2015; Sandri et al., 2004). Recent evidence has suggested that
these processes (especially mitochondrial fission), are AMPK sensitive targets and that
the chronic elevation of AMPK can disrupt mitochondrial quality further contributing to
energetic stress and muscle mass loss (Toyama et al., 2016). The chronic elevation of
fission and suppression of fusion coupled with a lack of mitochondrial biogenesis through
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PGC-1 suggest a lack of sufficient mitochondrial ATP generation to handle the
metabolically expensive process of protein synthesis.

The concept of oxidative health

and metabolism regulating protein synthesis has been suggested by our laboratory before
and evidence of mitochondrial function and quality regulating mTORC1 activity in
skeletal muscle has become a new investigative target of cancer cachexia (Hardee et al.,
2017; Suliman & Piantadosi, 2016).
While AMPK is an established regulator of muscle mass and metabolism, very
little has been done to examine this signaling kinase in cachectic skeletal muscle. The
chronic elevation of AMPK in the cachectic environment suggest a chronic energy deficit
that disrupts protein turnover and contributes to the loss of muscle mass through an
induction of protein degradation and suppression of metabolically expensive protein
synthesis. While our laboratory has suggested a role for AMPK in these processes, very
little has been done to determine if AMPK is required for the cachexia disruption of
protein turnover. Therefore, the role of AMPK signaling in skeletal muscle protein
turnover during cancer cachexia.

We hypothesize that loss of AMPK in cachectic

skeletal muscle will improve protein synthesis and degradation signaling.

We also

hypothesize that AMPK loss in cachectic skeletal muscle will restore mitochondrial
dynamics to basal levels.
2.3 Methods
Animals
The ApcMin/+ mouse is a genetic model of colorectal cancer and cachexia [83].
These mice harbor a heterozygous mutation in the adenomas polyposis coli (APC) gene,
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which promotes the development of intestinal tumors beginning as early as 4 weeks of
age. Mice develop an IL-6-dependent cancer cachexia phenotype between 3 and 6
months of age. Due to the slow onset and progression of body weight loss this model is
advantageous as treatments can be started after the initiation of cancer cachexia. Male
ApcMin/+ mice on a C57BL/6 background were originally purchased from Jackson
Laboratories (Bar Harbor, ME, USA) and bred at the University of South Carolina’s
Animal Resource Facility. All mice used in the current study were obtained from the
investigators breeding colony within the Center for Colon Cancer Research Mouse Core.
At 3-wk of age mice were genotyped as previously described [298]. Mice were
individually housed, kept on a 12:12-h light-dark cycle, and had access to standard rodent
chow (#8604 Rodent Diet; Harlan Teklad, Madison, WI) and water ad libitum. 12 hours
prior to sacrifice all mice had food removed from cage. Body weight measurements were
taken weekly and the percentage body weight loss from peak body weight (~12-20 weeks
of age) was calculated. Mice lacking the ApcMin/+ mutation (C57BL/6) served as controls
for all experiments. The University of South Carolina’s Institutional Animal Care and
Use Committee approved all animal experimentation in this study.
Skeletal Muscle Deletion of AMPK12
To generate a skeletal muscle specific knockout of AMPK12, mice that
contained individually floxed alleles for AMPK1and AMPK2 were a kind gift from Dr.
Hoh-Jin Koh at the University of South Carolina. These mice were then crossed together
to generate a double floxed AMPK12mouse. The AMPKa1a2 was then crossed with
ApcMin/+ mice to generate an AMPK12 ApcMin/+ mouse. Tamoxifen inducible Mer Cre
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Mer driven by a Human Skeletal Actin promoter (HSA) mice were purchased from
Jackson Laboratories (Bar Harbor, ME, USA).These mice were then crossed with our
AMPK12 to generate AMPK12 HSA Cre mice. Finally, the AMPK12 HSA Cre
mice were crossed with AMPK12 ApcMin/+ mice giving a 50% chance of the offspring
producing an AMPK12

ApcMin/+ HSA Cre mouse. Tamoxifen injection via

intraperitoneal cavity deletes skeletal muscle AMPKa1a2 in the ApcMin/+ mouse (Min
KO).
Tissue Collection
Mice

were

anesthetized

via

a

subcutaneous

injection

of

ketamine/xylazine/acepromazine cocktail (1.4 ml/kg body weight) prior to sacrifice. Hind
limb muscles were rapidly excised, cleared of excess connective tissue, rinsed in PBS,
weighed, and snap frozen in liquid nitrogen. The gastrocnemius muscle was cut at the
mid-belly, and the proximal portion was split laterally and medially for protein. The left
and right soleus muscles were weighed and processed for protein analysis. Blood was
collected prior to muscle collection via retro-orbital eye bleed with heparinized capillary
tubes, placed on ice, and centrifuged (10,000 x g for 10 min at 4°C). The supernatant was
removed and stored for plasma IL-6 analysis. Plasma and tissue samples were stored at 80°C until further analysis.
Western Blotting
Western blot analysis was performed as previously described. Frozen
gastrocnemius muscle was homogenized in ice-cold Mueller buffer and protein
concentration was determined by the Bradford method. Crude muscle homogenates were
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fractionated on 6 – 15% SDS polyacrylamide gels and transferred to PVDF membranes
overnight. Membranes were stained with Ponceau red to verify equal loading and transfer
for each gel. Membranes were blocked at room temperature for 1 – 2 hrs. in 5% Trisbuffered saline with 0.1% Tween-20 (TBST) milk. Primary antibodies for p-AKT (T308),
AKT, puromycin, p-FOXO3(S253), FOXO3, p-ULK-1 (S555), ULK-1, P62, LC3II/I,
MuRF-1, Atrogin-1 (ECM Biosciences), p-AMPK (T172), AMPK, p-ACC (S79) , ACC,
p-TSC2 (S1387), TSC2, p-raptor (S792), raptor, DRP-1, FIS-1, MFN-1 (Abcam),PGC-1a
(Abcam), and GAPDH will be diluted 1:5000 – 1:2000 in 5% TBST-milk followed by a
4-8-hr incubation with membranes at 4 degrees. Anti-rabbit or anti-mouse IgG
horseradish peroxidase conjugated secondary antibody was incubated with the
membranes at 1:2000 dilutions for 1 hour in 5% TBST-milk at room temperature.
Enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was
used to visualize the antibody-antigen interactions. Images were digitally scanned and
quantified by densitometry using imaging software (Image J;NIH). All antibodies were
from Cell Signaling unless otherwise stated.
Plasma IL-6 concentrations
Plasma IL-6 concentrations were determined as previously described [300]. A
commercially available IL-6 enzyme-linked immunosorbent assay kit was obtained from
BD Biosciences (San Diego, CA, USA) and the manufacturer’s protocol was followed.
Briefly, a Costar clear 96-well plate (Corning, NY, USA) was coated with IL-6 capture
antibody and allowed to incubate overnight. The next morning, the plate was blocked
with assay diluent buffer, washed, and IL-6 standards and plasma samples were added in
duplicate to the plate. The plate was again washed and sAV-HRP reagent was added to
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each well. After several washes, TMB substrate was added and the reaction was
developed for 20 minutes. The reaction was stopped with sulfuric acid and absorbance
was read in a Bio-Rad iMark plate reader (Hercules, CA, USA) at 450 nm.
Statistical Analysis
Results are reported as the means ± standard error. A Two-Way ANOVA or
students pre-planned t-test was utilized to analyze the data where appropriate . Post-hoc
analyses were performed with Tukey method when appropriate. The accepted level of
significance was set at p<0.05 for all analysis. Statistical analysis was performed using
Prism GraphPad 7 (GraphPad Software Inc., La Jolla, CA).
2.4 Results
Animal Characteristics of AMPK KO Mice
AMPK KO loss had no effect on gastrocnemius mass, bodyweight loss, stomach
weight, spleen weight, seminal vesicles, testes or epididymal fat (Table 2.1). There was a
significant age difference between Min mice and Min KO mice (Table 2.1). Bodyweight
loss was similar prior to fasting in Mins and Min KO mice. Bodyweight loss after a 12
hour fast was attenuated in Min KO mice when compared to Mins (Table 2.1).
Gastrocnemius mass was also rescued in Min KO mice when compared to Min mice.
Stomach, liver, and spleen mass was also reduced in Min KO compared to Min mice
(Table 2.1). No differences in tibia length were detected in any group suggesting all mice
were approximately the same size (Table 2.1).
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Skeletal Muscle AMPK12 Loss
In order to determine AMPK’s role in the regulation of protein turnover during
cachexia we first verified our knockout model in WT and Min mice (Figure 2.1).
Treatment with tamoxifen for 5 days followed by a 1 week washout period was sufficient
to induce human skeletal actin (HSA) cre deletion AMPK1 and AMPK2 from skeletal
muscle in both WT and Min mice (Figure 2.1).

As expected, the loss of AMPK

suppressed the induction of AMPK phosphorylation (T172) in Min mice (Figure 2.1). In
order to further verify our knockout model, we examined acetyl co-a carboxylase (ACC)
phosphorylation (S79) (Figure 2.1). There was an interaction of Min ACC
phosphorylation to be different than all groups. These results demonstrate that the use of
a tamoxifen inducible HSA cre was sufficient to generate a skeletal muscle specific
knockout of AMPK12 (Figure 2.1).
AMPK Regulation of Immediate Downstream Targets During Cancer Cachexia
After verification of our knockout model was complete we next examined the role
of AMPK in the regulation of immediate downstream targets regulating mTORC1
activity and degradation (Figure 2.2). There was an interaction of TSC2 phosphorylation
(S1387) to be induced in Min mice which was different to all groups (Figure 2.2). There
was also a main effect of Min to induce Raptor phosphorylation (S729) and a main effect
of KO to suppress raptor phosphorylation (Figure 2.2). We next examined ULK-1 and
FOXO3a phosphorylation which are known regulators of both autophagy and E3 ligase
expression respectively (Figure 2.2).

In line with our other immediate AMPK

downstream targets, there was a main effect of Min to induce ULK-1 phosphorylation
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(S555) and a main effect of KO to suppress ULK-1 phosphorylation (Figure 2.2). There
was an interaction of FOXO3a phosphorylation in Min and Min KO mice to be different
than all other groups.
AMPK Regulation of Protein Turnover During Cancer Cachexia
Given the results from the immediate AMPK downstream targets we examined
protein expression for E3 ligases, autophagy, and protein synthesis (puromycin
incorporation) (Figure 2.3). There was an interaction of MuRF-1 to be significantly
elevated in Min mice when compared to all groups (Figure 2.3). Interestingly, Atrogin-1
was induced in Min mice and was only different to WT Flox mice and this induction was
suppressed by Min KO (Figure 2.3). Similar to Atrogin-1, P62 which is a ubiquitin tag
used to mark cargo for degradation by the lysosome was only elevated in Min mice
compared to WT Flox and this induction was suppressed by Min KO (Figure 2.3). There
was an interaction of LC3B (II/I) ratio to be induced in Min mice and this induction was
different to all groups (Figure 2.3).

We next examined puromycin incorporation as an

indices of protein synthesis through utilization of the Surface Sensing of Translation
technique (SUnSET) . There was a main effect of KO to induce puromycin incorporation
and a main effect of Min to suppress puromycin incorporation (Figure 2.3). Collectively
these results demonstrate that the cachexia disruption of skeletal muscle protein turnover
requires AMPK.
AMPK Regulation of Mitochondrial Quality Control During Cancer Cachexia
We lastly examined the role of AMPK in the regulation of mitochondrial quality
control. We first examined PGC-1 as an index of mitochondrial biogenesis and content.
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There was a main effect of Min and KO to suppress PGC-1 which corresponds to
previously published literature demonstrating similar results with AMPK suppression
(Figure 2.4). Interestingly, there was an interaction for MFN-1 to be elevated compared
to Min Flox mice (Figure 2.4). There was also an interaction for DRP-1 to be elevated in
Min Flox mice compared to WT Flox mice (Figure 2.4).

Furthermore, Min KO

suppressed DRP-1 protein expression compared to Min Flox. Collectively these results
demonstrate that AMPK is not required for the cachexia suppression of PGC-1 (Figure
2.4).

Additionally, These results also suggest that MFN-1 and DRP-1 are AMPK

sensitive targets and loss of AMPK restores these proteins to WT levels.
2.5 Discussion
The disruption of protein turnover has been widely investigated in various
catabolic conditions including cancer cachexia (Sandri, 2016; Suzuki, Asakawa, Amitani,
Nakamura, & Inui, 2013; Tisdale, 2005; White, Puppa, Gao, et al., 2013; Yoshida &
Delafontaine, 2015). Many researchers advocate that the net loss of muscle mass during
cancer cachexia occurs primarily through an acceleration of degradation signaling via the
ubiquitin proteasome and autophagy lysosomal system (Penna et al., 2014; Sandri, 2016;
Schersten & Lundholm, 1972). Conversely, while degradation signaling is often elevated
skeletal muscle protein synthesis is often suppressed (Jeevanandam, Horowitz, Lowry, &
Brennan, 1984; Johns et al., 2012; A. J. MacDonald et al., 2015; Pettersen et al., 2017;
Pisters & Pearlstone, 1993). While this has been studied and characterized in cancer
cachexia, very little has been done to formally elucidate a clear mechanism of regulation
that drives this proteostasis disruption. However, a constant finding in severely cachectic
muscle is the chronic elevation of AMPK (Hardee et al., 2017; Sadeghi et al., 2018;
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Sanchez, Csibi, et al., 2012; Sandri, 2016; White, Baynes, et al., 2011b; White, Puppa,
Gao, et al., 2013). The elevation of AMPK in cachectic skeletal muscle suggest an
energy deficit that may suppress the ability of skeletal muscle to induce muscle protein
synthesis in response to various stimuli such as contraction or feeding.

We have

previously suggested that IL-6 in the Min model of cachexia may be a potential driver of
AMPK activation and muscle mass loss (White, Baynes, et al., 2011a; White, Puppa,
Gao, et al., 2013). In line with previous our laboratories previous studies we also report
elevated AMPK in fasted Min mice (White, Baynes, et al., 2011a; White, Puppa, Gao, et
al., 2013). In the current study we report that IL-6 levels were similar in Min KO mice
when compared to Mins. We report the novel finding that loss of AMPK in Min mice
attenuated gastrocnemius mass loss, spleen weight and interestingly circulating IL-6
levels.

We also report the novel findings that AMPK is required for the cachexia

induction of TSC2 and Raptor which serves to inhibit mTORC1 activity and suppress
muscle protein synthesis. Furthermore, we also report the novel finding that the cachexia
induction of ULK-1 and FOXO3a mediated degradation requires AMPK in Min mice.
Furthermore, we also report that mitochondrial dynamics proteins MFN-1 and DRP-1 are
regulated by AMPK in the cachectic environment. Taken together, these results suggest
that the cachexia disruption of skeletal muscle protein turnover occurs through AMPK
mediated downstream signaling.
AMPK is an energy sensitive kinase and has been referred to as a cellular fuel
gauge. The purpose of AMPK activation in healthy skeletal muscle is to suppress energy
consuming pathways and activate energy generating pathways (Thomson, 2018;
Thomson et al., 2008; Viollet et al., 2009). Previous studies have demonstrated through
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the infusion of AMP mimetic AICAR that chronic elevation of AMPK induces muscle
atrophy (K. Nakashima & Yakabe, 2007; Suwa et al., 2003).

Furthermore, recent

evidence suggests that loss of AMPK in normal healthy skeletal muscle is capable of
inducing mTORC1 anabolic signaling (Thomson, 2018; Thomson et al., 2008).

In the

cachectic environment the degree of AMPK activity is tightly associated with the severity
of cachexia or degree of bodyweight loss (White, Baynes, et al., 2011a, 2011b). In the
current study, AMPK was induced following a short term 12-hour fast in Min mice and
this induction was suppressed by loss of AMPK. Immediate downstream target ACC was
also suppressed, corroborating the loss of AMPK activity. AMPK activation classically
serves to suppress the metabolically expensive process of protein synthesis through
phosphorylation of TSC2 and Raptor (Gwinn et al., 2008; Inoki, Zhu, & Guan, 2003).
Recent evidence suggest that the phosphorylation of Raptor by AMPK is actually
required for the suppression of mTORC1 (Gwinn et al., 2008).

In line with previous

research from our laboratory Raptor and TSC2 phosphorylation were both induced in
Min mice while puromycin incorporation was suppressed. However, in the current study
we demonstrate that the loss of AMPK in Min mice suppresses the cachexia activation of
these proteins and restores puromycin incorporation which is indicative of protein
synthesis. It is interesting to speculate whether the activation of Raptor or TSC2 is vital
for the cachexia suppression of protein synthesis or if this process requires both proteins
to be phosphorylated by AMPK.
The AMPK regulation of skeletal muscle degradation has been widely
investigated in many different conditions and models of disease (Bujak et al., 2015; Di
Magno et al., 2016; K. Nakashima & Yakabe, 2007; Sanchez, Candau, et al., 2012;
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Sanchez, Csibi, et al., 2012; Thomson, 2018). They elevation of skeletal muscle protein
degradation in cancer cachexia has been established and investigated by our research
group and numerous others (Hardee et al., 2017; White, Baynes, et al., 2011a; White,
Puppa, Gao, et al., 2013). The focus of skeletal muscle protein degradation in cancer
cachexia has been primarily related to the classical FOXO3a control of E3 ligases
Atrogin-1 and MuRF-1(Blackwell et al., 2018; Reed et al., 2012; White, Baynes, et al.,
2011a).

In the current study we demonstrate the cachexia induction of FOXO3a

mediated skeletal muscle degradation requires AMPK and that loss of AMPK inhibited
the cachexia induction of MuRF-1 and Atrogin-1.

AMPK phosphorylates FOXO3a at

S413 to increase its transcriptional activity (Kjobsted et al., 2018). We have previously
demonstrated that AKT phosphorylation of FOXO3a is suppressed in cachectic skeletal
muscle which is suggestive of its translocation to the nucleus. The current data further
builds on these findings by adding the AMPK mediated phosphorylation site that
demonstrates increased activity of FOXO3a which is reflected by the downstream
suppression of E3 ligases Atrogin-1 and MuRF-1. Another component of degradation
that is often ignored or poorly investigated in cancer cachexia is the autophagy lysosomal
system.

The process of autophagy is the selective degradation of cellular cargo,

organelles, and protein aggregates that are removed to improve the quality and metabolic
health of the tissue (Sandri, 2010). AMPK is a known regulator of autophagy and has
been shown to be critical in the initiation of the process through its phosphorylation of
ULK-1 at S555 (Bujak et al., 2015; Mihaylova & Shaw, 2011; Sanchez, Csibi, et al.,
2012; Zhao & Klionsky, 2011). AMPK and mTORC1 both regulate ULK-1 and have
competing effects through phosphorylation events (J. Kim et al., 2011). Autophagy has
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become a relatively new target in cancer cachexia and has been linked to cancer induced
inflammation through the IL-6/gp130 signaling pathway in pre-clinical models and
human cancer patients (Aversa, Pin, Lucia, Penna, Verzaro, Fazi, Colasante, Tirone,
Rossi Fanelli, et al., 2016; Penna, Costamagna, et al., 2013; Pettersen et al., 2017).
Recent studies in C26 tumor bearing mice demonstrate elevated autophagy and this is
dependent on AMPK signaling (Penna, Costamagna, et al., 2013). Furthermore, data
from our laboratory has established that Beclin-1 and LC3B is elevated in severely
cachectic Min mice (White et al., 2012). Additionally, the more severe body weight loss
in cachexia the higher the actual activity of the autophagy lysosome system (White,
Baynes, et al., 2011a). In the current study we demonstrate that the cachexia induction of
autophagy following a short term fast requires the AMPK phosphorylation of ULK-1.
Loss of AMPK in Min mice suppressed ULK-1 and downstream targets LC3B (II/I) ratio
and P62. When taken collectively the loss of skeletal muscle AMPK in cachectic skeletal
muscle appears to suppress protein degradation and improve muscle protein synthesis
through regulation of immediate downstream targets and the processes these targets
control.
The concept of mitochondrial quality control involves the processes of
mitochondrial biogenesis and dynamics (Mishra & Chan, 2016). AMPK has recently
emerged as a critical regulator of these processes. The AMPK regulation of PGC-1 has
been widely investigated has been deemed the primary method of inducing mitochondrial
biogenesis during energetic stress such as fasting or exercise (Canto & Auwerx, 2009).
However, in cachectic skeletal muscle the chronic elevation of AMPK is dissociated from
PGC-1. Numerous studies have demonstrated elevated AMPK and suppressed PGC-1
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protein and mRNA expression in a variety of pre-clinical cachexia models.

Not

surprisingly, our data demonstrates that AMPK is not required for the suppression of
PGC-1 in cachectic skeletal muscle (Brown, Rosa-Caldwell, Lee, Blackwell, et al.,
2017; Brown, Rosa-Caldwell, Lee, Brown, et al., 2017; Puppa, Gao, et al., 2014; Puppa et
al., 2012). These results and previous studies suggest an alternative mechanism of
regulation for PGC-1. Interestingly, a recent publication suggest that mitochondrial loss
may occur actually prior to the initiation of cachexia (Brown, Rosa-Caldwell, Lee,
Blackwell, et al., 2017). The loss of mitochondria early and a lack of biogenesis in
severe cachexia may be a powerful driver of metabolic dysfunction and muscle mass loss
in

cachexia.

Further

research

investigating

the

role

of

SIRT-1

and

acetylation/deacetylation of PGC-1 in cachectic skeletal muscle are warranted in order
to elucidate the mechanism that governs mitochondrial biogenesis.
The process of mitochondrial dynamics involves the constant fission and fusion of
mitochondria (Dahlmans, Houzelle, Schrauwen, & Hoeks, 2016; Mishra & Chan, 2016).
AMPK has been identified as a powerful regulator of these processes, in particular a
recently published study demonstrated that AMPK when activated targets mitochondrial
fission downstream to induce remodeling (Toyama et al., 2016). Mitochondrial dynamics
in cachexia have been deemed an important hallmark of the disease, although an exact
mechanism of regulation has yet to be elucidated (B. N. VanderVeen, Fix, et al., 2017).
A recent investigation by our laboratory suggest a role for IL-6/gp130/ERK1/2
inflammatory signaling axis in the regulation of mitochondrial fission proteins DRP-1
and FIS-1 (Fix et al., 2019). In cachectic skeletal muscle FIS-1 is induced and MFN-1 is
suppressed suggesting mitochondrial remodeling is imbalanced (White et al., 2012).
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Accelerated mitochondrial fission has been investigated in conjunction with
AMPK/FOXO3a signaling and is capable of driving muscle atrophy (Romanello et al.,
2010). Interestingly, much less is understood about the regulation of fusion in regard to
the AMPK signaling pathway. We provide evidence that AMPK negatively regulates
mitochondrial fusion protein MFN-1 in cachexia. Loss of AMPK in Min mice restored
MFN-1 to wildtype levels. Furthermore, we also establish fission protein DRP-1 as an
AMPK sensitive target in cachectic skeletal muscle. DRP-1 protein expression was
induced in Min mice but was suppressed to basal levels by the loss of AMPK.
Collectively these results suggest that the cachexia suppression of PGC-1 does not
require AMPK. Furthermore, we identify mitochondrial dynamics proteins DRP-1 and
MFN-1 as AMPK sensitive targets in cachectic muscle. The chronic elevation of fission
and suppression of fusion when coupled with a lack of biogenesis could be a contributing
factor to the disruption of proteostasis due to dysfunctional oxidative metabolic capacity.
The disruption of protein turnover that favors skeletal muscle degradation over
synthesis has become a hallmark of cancer cachexia (Pisters & Pearlstone, 1993; Sandri,
2016; White, Baynes, et al., 2011b). Identifying a mechanism of regulation that governs
these processes are critical to combating muscle mass lass and improving quality of life
in cancer patients. In the current study we provide evidence that the cachexia suppression
of protein synthesis and acceleration of degradation occurs through AMPK.
Interestingly, we also identify that AMPK regulates skeletal muscle mitochondrial
dynamics in cachectic skeletal muscle. The AMPK regulation of mitochondrial quality
control further establishes the kinase as a critical regulator of muscle metabolism in
tumor bearing mice. In particular, the current data identifies MFN-1 as a potential
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AMPK sensitive target in cachexia. Our results demonstrate a clear role for AMPK in the
regulation of both skeletal muscle protein synthesis and degradation. Taken collectively,
these results identify the AMPK signaling pathway as a critical checkpoint regulating
muscle mass and mitochondrial quality control during cancer cachexia.
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Table 2.1. Characteristics of Skeletal Muscle AMPK Loss in Wildtype and ApcMin/+ Mice.
WT

AMPK KO

Min

Min KO

Sex
Age (weeks)
N

Male
16.1
8

Male
15.9 ± 0.1
8

Male
21.2 ± 1.0
10

Male
19.0 ± 1.3 *
10

Max BW (g)
BW @ Sac
% BWL After Fast
Sac Glucose (mg/dL)
Food (g/day)
IL-6 (pg/ML)
Total Polyps

23.5 ± 0.5
22.5 ± 0.5
3.0 ± 1.0
140.7 ± 7.3
3.4 ± 0.2
0.0 ± 0.0
0.0 ± 0.1

23.7 ± 0.5
22.3 ± 0.6
4.0 ± 0.1
125.7 ± 7.1
3.2 ± 0.1
0.0 ± 0.0
0.0 ± 0.1

23.8 ± 0.4
21.2 ± 0.8
9.4 ± 3.0
112.7 ± 5.3
2.9 ± 0.3
15.6 ± 4.6
36.3 ± 6.7

23.1 ± 0.7
22.7 ± 0.6
4.0 ± 1.0*
132.8 ± 10.7 *
3.1 ± 0.2
17.7 ± 3.8
36.9 ± 10.2

Gastrocnemius (mg)
Gastrocnemius/BW ratio (mg/g)
Stomach (mg)
Stomach/BW ratio (mg/g)
Liver (mg)
Liver/BW ratio (mg/g)
Spleen (mg)
Spleen/BW ratio (mg/g)

120.2 ± 3.0
5.3 ± 0.1
250.7 ± 22.7
11.4 ± 1.1
1007 ± 40.7
44.5 ± 1.2
60.7 ± 2.2
2.7 ± 0.1

118.8 ± 2.1
5.4 ± 0.1
257.6 ± 9.8
11.9 ± 0.5
970.5 ± 26.9
44.8 ± 0.9
83.9 ± 16.9
3.4 ± 0.8

99.9 ± 6.9
4.6 ± 0.2
423.9 ± 38.1
20.1 ± 1.8
1287.3 ± 56.7
60.7 ± 2.3
344 ± 39.2
16.3 ± 1.9

119.8 ± 3.6 *
5.1 ± 0.1 *
283.3 ± 21.7*
12.7 ± 0.8 *
1039.7 ± 104.9 *
46.4 ± 3.1 *
150.7 ± 29.8 *
16.3 ± 1.10 *

Sem Vesicles (mg)
Sem Vesicles/BW ratio (mg/g)
Testes (mg)
Testes/BW ratio (mg/g)
Epdidymal Fat (mg
Epididymal Fat/BW ratio (mg/g)

176.4 ± 11.6
7.8 ± 0.5
165.8 ± 10.5
7.3 ± 0.4
237.3 ± 30.3
8.4 ± 2.3

155.0 ± 14.4
7.2 ± 0.9
168.9± 1.9
7.8 ± 0.1
237.0 ± 22.3
10.9 ± 0.9

131.3 ± 24.0
5.9 ± 0.9
168.7 ± 11.4
7.8 ± 0.4
99.1 ± 39.3
4.2 ± 1.6

166.0 ± 18.5
7.2 ± 0.9
170.5 ± 3.1
7.3 ± 0.2
202.3 ± 15.0 *
8.7± 0.8 *

Tibia Length

16.9 ± 0.1

17.1 ± 0.1

16.8 ± 0.1

16.9 ± 0.1

Values are means ± SEM. Age given in weeks (wks). Body weights given in grams (g).
% BWL determined from peak weight to weight prior to sacrifice, %BWL after fast
determined from peak weight to sacrifice weight. All tissue weights expressed in
milligrams (mg). AMPK floxed controls (Flox). ApcMin/+ mice (Min). AMPK floxed HSA
Cre/+ ApcMin/+ (MIN KO). *Significantly different from Flox. p<0.05 (students preplanned t-test within genotype). ). All mice were fasted 12 hours during the light cycle
and sacrificed at 7PM.
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Figure 2.1. Verification of Skeletal Muscle AMPK Loss .A) Experimental design of
AMPK inducible knockout and fasting paradigm. B) Representative western blot of
AMPK12 in gastrocnemius of WT and Min mice. C) Representative western blot and
quantification of p-AMPK (T172), p-ACC (S79), and ACC. WT is wildtype AMPK flox
control, Min is ApcMin/+, KO is AMPK12 knockout. † denotes different to all groups. *
denotes different to WT Flox. Significance was set at p<0.05. Two-Way ANOVA.
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Figure 2.2. AMPK Regulation of Immediate Downstream Targets in Cachexia. Left:
Representative western blots of p-Raptor (S792), Raptor, p-TSC2 (S1387), TSC2, pFOXO3a (S413), FOXO3a, p-ULK-1 (S555), and ULK-1 in gastrocnemius of WT and
Min mice. Right: Quantification of Western Blots. WT is wildtype AMPK flox control,
Min is ApcMin/+, Flox AMPK12 intact controls. KO is AMPK12 knockout. †
denotes different to all groups. # denotes main effect of KO. $ denotes main effect of
Min. Significance was set at p<0.05. Two-Way ANOVA.
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Figure 2.3. AMPK Regulation of Protein Turnover in Cachectic Skeletal Muscle. Left:
Representative western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, and Puromycin in
gastrocnemius of WT and Min mice. Right: Quantification of Western Blots. WT is
wildtype AMPK flox control, Min is ApcMin/+, Flox AMPK12 intact controls. KO is
AMPK12 knockout. † denotes different to all groups. # denotes main effect of KO. $
denotes main effect of Min. * denotes different to WT Flox. ** denotes different to Min
Flox. Significance was set at p<0.05. Two-Way ANOVA.
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Figure 2.4. AMPK Regulation of Mitochondrial Quality Control During Cachexia. Left:
Representative western blots of PGC-1, MFN-1, and DRP-1 in the gastrocnemius of
WT and Min mice. Right: Quantification of Western Blots. WT is wildtype AMPK flox
control, Min is ApcMin/+, Flox AMPK12 intact controls. KO is AMPK12 knockout.
† denotes different to all groups. # denotes main effect of KO. $ denotes main effect of
Min. * denotes different to WT Flox. ** denotes different to Min Flox. Significance was
set at p<0.05. Two-Way ANOVA.
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CHAPTER 3
CANCER CACHEXIA ACCELERATES PHYSIOLOGICAL AMPK
SIGNALING BY FASTING AND FEEDING
3.1 Abstract
Cancer cachexia is a characterized by accelerated skeletal muscle protein turnover
that contributes to muscle mass loss. While the basal regulation of muscle protein
turnover during cancer cachexia has been widely investigated, there is far less understood
about the dynamic regulation of skeletal muscle turnover with feeding, fasting, and
physical activity. Skeletal muscle’s physiological response to fasting involves a diverse
network of metabolic pathways that serve to maintain metabolic homeostasis, and
adenosine monophosphate protein kinase (AMPK) is a critical regulator and effector of
this response.

The cancer environment’s effect on skeletal muscle fasting and feeding

regulation of protein turnover warrants further investigation. Therefore, the purpose of
this study was to examine the effect of the cancer environment on skeletal muscle’s
physiological response to fasting and feeding. Male C57BL/6 (B6, N=23) and ApcMin/+
(Min, N=25) mice were subjected to either ad libitum feeding, a 12 hour fast, or a 12
hour fast followed by a 1 ad libitum re-feed. Following the completion of each treatment,
hindlimb muscles were harvested and the gastrocnemius homogenized for protein
analysis. Min mice exhibited body weight loss and reduced gastrocnemius mass when
compared to B6 mice. In the ad libitum fed state muscle AMPK phosphorylation (T172)
was induced in the Min compared to B6. Fasting did not induce AMPK, Raptor (S792),
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TSC2 (S1347), ULK-1 (S555), and FOXO3a (S416) phosphorylation in B6 mice;
however, AMPK, Raptor (S792), TSC2 (S1347), ULK-1 (S555), and FOXO3a (S416)
phosphorylation were induced in Min mice following a fast and were suppressed by refeeding. PGC-1 was induced in fasted B6 mice only and was not altered by re-feeding.
MFN-1 and DRP-1 were not altered by fasting, but were robustly induced by re-feeding
in both B6 mice. DRP-1 was induced in fasted Min mice only and was not altered by refeeding. Additionally, P62, LC3 II/I, Atrogin-1, and MuRF-1 protein expression were
only induced in fasted Min mice and were also suppressed by re-feeding. Our results
suggest that cancer increases skeletal muscle sensitivity to a short-term fast, which could
serve to accelerate wasting with cancer. Furthermore, our results also demonstrate that a
short-term fast sensitizes cachectic skeletal muscle to re-feeding.
3.2 Introduction
Cancer-induced cachexia is a wasting syndrome that occurs in approximately 80%
of all cancer patients and results in 30% of deaths (Argiles et al., 2010; Narsale &
Carson, 2014; Puppa et al., 2012). Cancer-induced cachexia is a debilitating disease that
diminishes quality of life due to severe loss of skeletal muscle mass and function
(Baracos, 2011, 2013; Baracos et al., 2018). There are currently no approved therapeutic
approaches for cancer-induced cachexia, therefore it is necessary to elucidate key
underlying factors and processes as potential therapeutic targets. Skeletal muscle wasting
during cancer cachexia occurs through altered protein turnover (suppressed anabolic
signaling/increased degradation) (Aversa, Pin, Lucia, Penna, Verzaro, Fazi, Colasante,
Tirone, Fanelli, et al., 2016; Baracos, 2000). Our laboratory and others have
demonstrated suppressed anabolic signaling through mechanistic target of rapamycin
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(mTORC1) and the induction of muscle protein degradation in pre-clinical models of
cancer cachexia (White, Puppa, Gao, et al., 2013). Coinciding with the suppression of
mTORC1 signaling is the chronic activation of the adenosine monophosphate protein
kinase (AMPK) (White, Puppa, Gao, et al., 2013). AMPK has been deemed a critical
regulator of skeletal muscle degradation through the regulation E3 ligases and the process
of autophagy, defined as the removal of organelles and protein aggregates through the
lysosomal proteasome system (Lira et al., 2013). While altered protein turnover has been
well characterized in the cachectic skeletal muscle of tumor bearing mice, less is
understood about the role of AMPK in this process.
Skeletal muscle proteostasis fluctuates diurnally depending on different fasting
and feeding durations as well as in response to activity and exercise stimuli. Adequate
nutrient availability is key in the net loss and gain of skeletal muscle protein. AMPK is a
nutrient sensitive energy sensor and is essential for skeletal muscle metabolic
homeostasis (Romanello et al., 2010; Romanello & Sandri, 2015). AMPK is capable of
being activated by many different stimuli as well as diseases such as cancer cachexia.
During severe cancer cachexia, skeletal muscle AMPK is dysregulated and chronically
activated which could have dire consequences regarding muscle proteostasis. The most
widely investigated activators of skeletal muscle AMPK is the process of prolonged
energy deficiency (fasting). While fasting has been proposed to have beneficial effects in
regard to aging and some cancers, less is understood about its role in cancer cachexia and
the regulation of muscle proteostasis. AMPK has long been established as a critical
regulator of both protein synthesis and protein degradation. AMPK exerts its regulation
the process of muscle protein synthesis through two inhibitory phosphorylation events.
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When activated, AMPK will phosphorylate tuberous sclerosis protein 2 (TSC2) and
Raptor which inhibit mTORC1 activity. Inhibition of mTORC1 activates 4EBP1 and
inhibits P70S6K, thus inhibiting the initiation of translation and ribosomal proteins. The
activation of degradation targets by AMPK induces both the ATP-independent autophagy
lysosomal proteasome and the ATP-dependent ubiquitin proteasome respectively
(FOXO3a is capable of regulating both degradation systems).

The degradation of

proteins through the ubiquitin proteasome is a highly coordinated process and in skeletal
muscle utilizes the muscle specific E3 ligases Atrogin-1 and MuRF-1 which are
controlled upstream by FOXO3a and were discovered initially through the studies
examining starvation and fasting conditions. These E3 ligases allow for targeted proteins
to be recognized by the 26S proteasome and ensure specificity of the UPS and additional
adaptor proteins(Murton et al., 2008). The process of autophagy is induced through the
AMPK activation of

ULK-1 and has been extensively investigated with numerous

catabolic conditions including fasting (Yan, Lira, & Greene, 2012). Autophagy is a
highly conserved cellular degradation pathway that can be initiated selectively and nonselectively by sequestering cytosolic substrates within a phagophore which is then
conjugated with ubiquitination-linked proteins and degraded by a lysosome (Sanchez,
Csibi, et al., 2012; Vainshtein & Hood, 2015).
Conversely, a common suppressor of AMPK is nutrient stimulation through the
consumption of glucose, a mixed meal (feeding), or amino acids (Koh et al., 2008; Long
& Zierath, 2006). Feeding has been widely investigated as a regulator of mTORC1 and
AMPK. The consumption of glucose or a mixed meal will induce a glucose and insulin
response activating the IGF-1/AKT signaling cascade (Sengupta et al., 2010). AKT will
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then phosphorylate TSC2 releasing its inhibition of mTORC1(Sengupta et al., 2010).
Both AMPK and mTORC1 are energy sensing kinases and regulate one another through
pathway cross talk. AMPK and mTORC1 negatively regulate one another, for example
during energy demand AMPK is activated thereby suppressing energy consuming
pathways (mTORC1) and stimulating energy generating pathways (ULK-1, FOXO3a)
(Koh et al., 2008; Long & Zierath, 2006; Sanchez, Csibi, et al., 2012). Muscle mTORC1
signaling is activated with both exercise and feeding and will phosphorylate ULK-1 at
Ser 757 and inhibit the ULK-1 activation of downstream autophagy signaling (Laker et
al., 2017; Sanchez, Csibi, et al., 2012). To date, our lab and others have demonstrated that
the cachectic environment elevates skeletal muscle AMPK following a 5 hour fast,
showing that a very short period of fasting is capable of inducing AMPK in the cancer
environment, suggestive of metabolic dysregulation (Penna et al., 2010; White, Baynes,
et al., 2011a; White, Puppa, Gao, et al., 2013). Concomitant with the induction of AMPK,
our laboratory has demonstrated mTORC1 suppression during cancer cachexia,
signifying a role for AMPK in the suppression of anabolic signaling (Hardee et al., 2018;
Hardee et al., 2016; White, Puppa, Gao, et al., 2013).
While the chronic activation of AMPK and its potential role in anabolic
suppression has been examined previously examined during cachexia, the role of this
signaling axis in the regulation of protein turnover in response to fasting and feeding is
poorly understood in the skeletal muscle of cachectic mice. Therefore, the purpose of this
study was to determine if cancer cachexia disrupts the physiological regulation of AMPK
signaling by fasting and feeding in skeletal muscle.
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3.3 Methods
Male C57BL/6 (B6) and ApcMin/+ (Min) were purchased from Jackson
Laboratories and were bred at the University of South Carolina’s Animal Resources
Facility. All animals were group housed and kept on a 12:12-h light-dark cycle. Body
weights were measured weekly, and animals were monitored for signs of distress.
Animals were given food and water ad libitum throughout the duration of the study. All
animals were fasted 12 hours or were allowed ad libitum access to food prior to tissue
collection. Mice were anesthetized with a ketamine-xylazine-acepromazine cocktail, and
hindlimb muscles and select organs were carefully dissected and snap frozen in liquid
nitrogen and stored at -80⁰C until further analysis. All animal experiments were approved
by the University of South Carolina’s Institutional Animal Care and Use Committee.
experimentation outline in this proposal.
Fasting and Re-Feeding
Mice were separated into either ad libitum fed (n=8 B6, N=8 Mins), 12-hour fast
(n=8 B6, n=10 Mins), or 12-hour fast followed by a 1 hour refeed (n=7 B6, N=8 Mins).
Ad libitum fed mice were sacrificed at 7 AM following the dark cycle to ensure that food
was consumed, and they were in the fed state. 12 hour fasted mice had food removed
during the 12-hour light cycle to ensure that a true fast had occurred and were sacrificed
at 7 PM. The re-feed mice were fasted for 12-hours during the light cycle but were
allowed 1 hour ad libitum access to a food pellet following the fast and were sacrificed at
immediately upon completion of the 1 hour time limit.
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Western Blotting
Western blot analysis was performed as previously described (Fix et al., 2018).
Briefly, frozen gastrocnemius muscle was homogenized in ice-cold Mueller buffer and
protein concentration was determined by the Bradford method. Crude muscle
homogenates were fractionated on 6 – 15% SDS-polyacrylamide gels and transferred to
PVDF membranes overnight. Membranes were stained with Ponceau red to verify equal
loading and transfer for each gel. Membranes were blocked at room temperature for 1 – 2
hrs. in 5% Tris-buffered saline with 0.1% Tween-20 (TBST) milk. Primary antibodies for
puromycin, p-FOXO3a (S416), FOXO3a, p-ULK-1 (S555) (S757), ULK-1, P62, LC3II/I,
MuRF-1, Atrogin-1 (ECM Biosciences), p-AMPK (T172), AMPK, p-ACC (S79) , ACC,
p-TSC2 (S1387), TSC2, p-raptor (S792), raptor, DRP-1, MFN-1 (Abcam), PGC-1
(Abcam), and GAPDH were diluted 1:5000 – 1:2000 in 5% TBST-milk followed by a 48-hr incubation with membranes at 4 degrees. Anti-rabbit or anti-mouse IgG horseradishperoxidase conjugated secondary antibody was incubated with the membranes at 1:4000
dilutions

for

1

hour

in

5%

TBST-milk

at

room

temperature.

Enhanced

chemiluminescence (ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was used to
visualize the antibody-antigen interactions. Images were digitally scanned and quantified
by densitometry using imaging software (Image J; NIH). All antibodies were from Cell
Signaling unless otherwise stated.
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Plasma IL-6 concentrations
Plasma IL-6 concentrations were determined as previously described (Hardee et
al., 2016). A commercially available IL-6 enzyme-linked immunosorbent assay kit was
obtained from BD Biosciences (San Diego, CA, USA) and the manufacturer’s protocol
was followed. Briefly, a Costar clear 96-well plate (Corning, NY, USA) was coated with
IL-6 capture antibody and allowed to incubate overnight. The next morning, the plate was
blocked with assay diluent buffer, washed, and IL-6 standards and plasma samples were
added in duplicate to the plate. The plate was again washed and sAV-HRP reagent was
added to each well. After several washes, TMB substrate was added and the reaction was
developed for 20 minutes. The reaction was stopped with sulfuric acid and absorbance
was read in a Bio-Rad iMark plate reader (Hercules, CA, USA) at 450 nm.
Statistical Analysis
Results are reported as the means ± standard error. An unpaired student’s preplanned t-test or Two-way ANOVA was employed when appropriate. Post-hoc analyses
were performed with Student-Newman-Keuls methods when appropriate. The accepted
level of significance was set at p<0.05 for all analysis. Statistical analysis was performed
using Prism GraphPad 7 (GraphPad Software Inc., La Jolla, CA).
3.4 Results
Animal Characteristics Fed vs. Fast
There were no significant differences between B6 fed and fasted mice in terms of
age, max bodyweight, sac glucose or circulating IL-6 (Table 3.1). Body weight at sac
was lower in B6 fasted mice when compared to fed (Table 3.1). Interestingly, Min fasted
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mice had lower circulating plasma IL-6 when compared to min fed mice (Table 3.1).
Bodyweight loss percentage was not different between fed and fasted Min mice.
Furthermore, B6 mice demonstrated decreased stomach and liver size following the fast
and this finding was not present in Min mice.
AMPK Activation During Fasting
In order to examine the AMPK signaling pathway in fed and fasted B6 and Min
mice we examined the phosphorylation of AMPK at T172 in the gastrocnemius (Figure
3.1A-B). We next examined if AMPK phosphorylation was altered by a short term fast
in B6 and Min mice (Figure 3.1). AMPK phosphorylation was not altered by fasting in
B6 mice, however Min mice demonstrated robust activation of AMPK T172 and was
significantly different to all groups (Figure 3.1A-B).

In order to further verify the

activation of AMPK we also examined the phosphorylation of Acyl CoA Carboxylase
(ACC) at S79 (Figure 3.1A-B). Interestingly, ACC was induced with fasting in B6 mice
despite AMPK not being activated upstream (Figure 3.1B). Min mice also exhibited an
increase in the phosphorylation of ACC in the fasted state (Figure 3.1B).
AMPK Downstream Signaling During Fasting
In order to examine if the cancer environment alters the fasting regulation of
mTORC1 signaling we next examined further downstream of AMPK to determine the
activation of its immediate downstream targets TSC2 (S1347) and Raptor (S792) (Figure
3.2) . Both TSC2 and Raptor are key regulators of mTORC1 activity. AMPK has been
demonstrated to phosphorylate these targets and negatively regulate mTORC1 in various
catabolic conditions. As expected there were no significant alterations to TSC2 or Raptor
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phosphorylation in fasted B6 mice (Figure 3.2A). However, Min mice demonstrated a
robust induction of TSC2 (S1347) and Raptor (S792) phosphorylation in the fasted
condition (Figure 3.2B). We next examined the phosphorylation of ULK-1 (S555) and
FOXO3a (S413). These proteins are responsible for the regulation of both autophagy and
E3 ligases and are immediate AMPK downstream targets. The phosphorylation of ULK-1
was induced in fasted Min mice only (Figure 3.2B). However, FOXO3a was induced in
both B6 and Min mice with fasting (Figure 3.2A-B). These results suggest that the
cancer environment plus a short term fast is capable of inducing the AMPK activation of
TSC2, Raptor, FOXO3a, and ULK-1 which serve to suppress the activation of mTORC1
signaling and increase muscle degradation.
AMPK Mediated Protein Turnover During Fasting
In order to establish that the cancer environment is altering the fasting regulation
of protein turnover We next examined the protein expression of E3 ligases MuRF-1 and
Atrogin-1 and autophagy proteins P62 and LC3B II/I . E3 ligase protein expression of
Atrogin-1 and MuRF-1 were both induced in fasted Min mice only (Figure 3.3B).

B6

mice exhibited no significant difference in the expression of these proteins in the fasted
condition (Figure 3.3A). Interestingly, P62 was suppressed in fasted Min mice while
LC3B II/I was induced robustly (Figure 3.3B). These results are suggestive of increased
clearance of the autophagosome by the lysosome during a fast. To further examine
protein turnover, we next examined puromycin incorporation using the SunSET
technique as previously described (Goodman & Hornberger, 2013). A short term fast
was sufficient to suppress puromycin incorporation in Min mice only which is indicative
of suppressed muscle protein synthesis (Figure 3.3B).
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AMPK and Mitochondrial Quality Control in the Fasted State
AMPK has recently come to light as an important regulator of mitochondrial
quality control or the processes of biogenesis and dynamics (fission and fusion). We next
examined if immediate downstream target PGC-1 was altered by the cancer
environment and fasting (Figure 3.4 A-B). Despite a lack of AMPK activation, PGC-1
was induced in fasted B6 mice (Figure 3.4A). Interestingly, despite the elevated AMPK
activation upstream, PGC-1 was not induced in fasted Min mice when compared to fed
Min mice (Figure 3.4B).

These results are similar with previous reports from our

laboratory that have demonstrated elevated AMPK signaling with suppressed or unaltered PGC-1 expression downstream.

We next examined mitochondrial fission

marker DRP-1 and mitochondrial fusion marker MFN-1. DRP-1 protein expression was
only induced in fasted Min mice (Figure 3.4B). MFN-1 was not altered with either
fasting or genotype.
Animal Characteristics Fast vs. Re-Feed
We next examined if the cancer environment alters the response to nutrients or
feeding (re-feeding). B6 re-feed mice were significantly older in age (Table 3.2). B6 refeed mice also had smaller spleen weight when compared to their fasted counterparts
(Table 3.2). Min re-feed mice exhibited increased sac glucose and decreased circulating
plasma IL-6 when compared to the fasted state. Gastrocnemius, testes, and epididymal
fat to bodyweight ratio were all reduced in Min re-feed mice compared to fasted.
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AMPK Activation During Re-Feeding
In order to examine the AMPK signaling pathway in fasted and re-feed B6 and
Min mice we examined the phosphorylation of AMPK at T172 in the gastrocnemius.
AMPK T172 phosphorylation was not altered by re-feeding in B6 mice when compared
with the fasted state (Figure 3.5A). However, Min mice demonstrated robust suppression
of AMPK T172 and when compared with the fasted state (Figure 3.5B). In order to
further verify the suppression of AMPK we next examined the phosphorylation of Acyl
CoA Carboxylase (ACC) at S79. As expected, ACC was not altered in B6 re-feed mice.
In line with our AMPK phosphorylation Min re-feed mice also exhibited a suppression of
ACC phosphorylation compared to the fasted state (Figure 3.5B).
AMPK Regulation of Immediate Downstream Signaling During Fasting and Re-Feeding
Keeping in line with our fasting analysis targets, we moved to examine immediate
downstream signaling targets of AMPK. The phosphorylation of Raptor was no affected
by re-feeding in B6 mice when compared to fasting (Figure 3.6A). However, Raptor
phosphorylation was suppressed by re-feeding in Min mice when compared to the fasted
condition (Figure 3.6B). Despite no alteration to Raptor phosphorylation in B6 mice,
TSC2 phosphorylation was suppressed by re-feeding compared to the fasted state in both
B6 and Min mice when compared to the fasted state (Figure 3.6A-B). In order to
determine muscle protein turnover, we examined the same markers as utilized above in
the fasting condition.

Phosphorylation of immediate AMPK downstream targets

FOXO3a and ULK-1 demonstrated a suppression following re-feeding in Min mice only
as the B6 remained un-altered when compared to fasting (Figure 3.6A-B).
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AMPK Mediated Protein Turnover During Fasting and Re-Feeding
We next examined indices of protein turnover during re-feeing. Protein
expression of muscle specific E3 ligases Atrogin-1 and MuRF-1 were both suppressed by
re-feeding in B6 mice when compared to the fasted state (Figure 3.7A). Only MuRF-1
was suppressed in re-feed Min mice when compared to fasting (Figure 3.7B). We also
examined autophagy proteins P62 and LC3B (II/I). P62 was suppressed in both B6 and
Min mice by re-feeding compared to fasting (Figure 3.7B). Interestingly, despite a
reduction of P62 by re-feeding in both genotypes, LC3 II/I was only suppressed in Min
mice which suggest an attenuation of autophagy initiation and clearance when compared
to the fasted condition (Figure 3.7B). In order to examine if the changes in Raptor and
TSC2 are reflected downstream by muscle protein synthesis we next examined
puromycin incorporation. Re-feeding induced puromycin incorporation in both B6 and
Min mice when compared to the fasted state (Figure 3.7B). Collectively these results
demonstrate that fasting during cancer cachexia sensitizes skeletal muscle to re-feeding.
AMPK and Mitochondrial Quality Control During Re-Feeding
We next examined if immediate downstream target PGC-1 was altered by the
cancer environment and re-feeding. PGC-1 was not altered by re-feeding in B6 or Min
mice when compared with fasting (Figure 3.8A-B). We next examined mitochondrial
fission marker DRP-1 and mitochondrial fusion marker MFN-1. DRP-1 protein
expression was induced B6 re-feed mice and was not altered by re-feeding in Min mice
(Figure 3.8A-B). Shockingly, MFN-1 was robustly induced by re-feeing in both B6 and
Min mice when compared to the fasted state (Figure 3.8A-B).
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3.5 Discussion
Cancer cachexia is a debilitating disease that is associated with poor response to
cancer treatment and increased mortality (Baracos, 2006a; Baracos et al., 2018). The loss
of skeletal muscle mass can have dire consequence on metabolic health and quality of life
(Bachmann et al., 2008; Baracos, 2018). Often associated with cachexia are changes in
appetite and nutrient status (Ali, Chen, & Garcia, 2013; Ali & Garcia, 2014). Recent
evidence has suggested that short term fasting is capable of improving the response to
chemotherapy and other therapeutics (Brandhorst & Longo, 2016).

However, the

majority of these studies have only investigated fasting in non-cachectic cancer patients
and even less has been done to examine if fasting and the cancer environment alters the
response to feeding. The AMPK signaling pathway has been well established as a potent
metabolic regulator and controller of muscle mass (Kemp et al., 2007; Koh et al., 2008;
Mihaylova & Shaw, 2011; White, Puppa, Gao, et al., 2013).

AMPK is critical for

maintaining energy status and metabolic homeostasis, in times of energy deficiency or
stress (fasting) AMPK will activate energy generating pathways such as the FOXO3a
controlled E3 ligases or the ULK-1 mediated autophagy lysosomal system (Bujak et al.,
2015; Mihaylova & Shaw, 2011; Sanchez, Csibi, et al., 2012). Furthermore, AMPK will
suppress the metabolically expensive process of protein synthesis through the
phosphorylation of TSC2 and Raptor (Corradetti et al., 2004; Gwinn et al., 2008; Shaw,
2009). This signaling axis is critical to maintain metabolic homeostasis and disruption of
these normal physiological signaling events can drastically influence muscle mass and
metabolism(Kemp et al., 2007; Koh et al., 2008; Mihaylova & Shaw, 2011; Mounier et
al., 2015; K. Nakashima & Yakabe, 2007). Our laboratory and others have previously
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established that AMPK is chronically induced in severe cachexia and this induction may
be responsible for the suppression of mTORC1 activity and muscle protein synthesis
(White, Baynes, et al., 2011b; White, Puppa, Gao, et al., 2013). However, many of these
earlier studies failed to consider fasting or feeding and the influence of these stimuli on
the AMPK signaling pathway in cachectic skeletal muscle.

In line with previous

literature from our laboratory, we report that AMPK is elevated in cachectic skeletal
muscle (Hardee et al., 2018; Hardee et al., 2016; White, Baynes, et al., 2011b; White,
Puppa, Gao, et al., 2013). However, we report the novel finding that fasting accelerates
the activation of AMPK and its downstream targets controlling muscle protein turnover.
Furthermore, we also report that a short term fast followed by re-feeding is capable of
suppressing the fasting induced activation of AMPK signaling and restoring protein
turnover to basal levels in cachectic skeletal muscle. Collectively we demonstrate that
the cancer environment accelerates the fasting and feeding regulation of the AMPK
signaling pathway and protein turnover.
The chronic activation of AMPK during severe cancer cachexia is not a new
phenomenon and has been reported by many research groups (Gould, Lahart, Carmichael,
Koutedakis, & Metsios, 2013; Pigna et al., 2016b; Sandri, 2016; White, Puppa, Gao, et
al., 2013). However, the underlying cause of this activation remains un-elucidated.
Some evidence has suggested a role for IL-6 driven inflammation inducing AMPK, thus
activating the signaling cascade downstream and suppressing muscle protein synthesis
through the negative regulation of mTOR(Haddad, Zaldivar, Cooper, & Adams, 2005;
Hardee et al., 2018; Hardee et al., 2016; Puppa et al., 2012; White, Baynes, et al., 2011b;
White, Puppa, Gao, et al., 2013). However, a common activator of AMPK is energy
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deficiency, or a lack of nutrients commonly referred to as fasting, the fasting activation of
AMPK in normal physiological conditions typically does not occur in rodent skeletal
muscle until anywhere from 24-48 hours of continual fasting has been achieved (Bujak et
al., 2015; Canto et al., 2010; Galic et al., 2018). Furthermore, with this activation of
AMPK, it has been recently demonstrated that the downstream activation of ACC is
required for fatty acid metabolism to maintain metabolic homeostasis (Galic et al., 2018).
In the current study, AMPK and ACC were elevated in fed Min mice when compared to
fed B6 mice. However, a short term fast of only 12 hours was sufficient to induce
AMPK and ACC phosphorylation even further in Min mice only when compared to their
fed state counterparts.

The activation of AMPK in B6 mice remained un-altered

following a 12 hour fast as expected. Interestingly, ACC was actually induced in fasted
B6 mice when compared to fasting and is suggestive of metabolic substrate transition to
fatty acids. Furthermore, the fasting activation of AMPK and ACC phosphorylation was
blocked by a 1 hour re-feeding period Min mice only. These results suggest that the
cancer environment accelerates the physiological regulation of

AMPK by fasting.

However, our results also demonstrate that the acceleration of AMPK by fasting
sensitizes skeletal muscle to re-feeding, suggesting a hyper-metabolic phenotype during
cancer cachexia.
The AMPK regulation of mTORC1 has been well established and studied in
various atrophy and disease models (Gwinn et al., 2008; J. Kim et al., 2011; Mounier et
al., 2009; Sandri, 2016; Thomson et al., 2008). The induction of AMPK by stressors
such as disease and acute exercise serve to induce the phosphorylation of TSC2 and
Raptor (Corradetti et al., 2004; Gwinn et al., 2008; Thomson, 2018). During energy
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deficiency, AMPK will phosphorylate TSC2 and inhibit rheb activity which suppresses
mTORC1 activation (Hardee et al., 2017; Inoki et al., 2003). However, recent evidence
has demonstrated that TSC2 deficient cells are still responsive to energy stress thus
suggesting that another signaling molecule is required for the AMPK suppression of
mTORC1 during energy deficiency(Gwinn et al., 2008).

In line with this finding,

previous research has demonstrated that the phosphorylation of Raptor by AMPK is
required for the inhibition of mTORC1 and cell cycle arrest that is induced by energy
stress (Gwinn et al., 2008). Our laboratory has previously demonstrated that Raptor
phosphorylation by AMPK is induced during severe cachexia and may also be an IL-6
sensitive target (White, Puppa, Gao, et al., 2013). In the current study TSC2
phosphorylation by AMPK was induced by fasting in both B6 and Min mice.
Additionally, this fasting induction of TSC2 was inhibited by re-feeding. In line with
previous reports suggesting that Raptor phosphorylation is required for AMPK
suppression of mTOR we demonstrate that only fasted Min mice exhibited an increase in
Raptor. Further establishing the importance of this event, only Min mice demonstrated a
suppression of puromycin incorporation following a short term fast which is indicative of
suppressed protein synthesis. This suggest that the cancer environment accelerates the
AMPK suppression of mTORC1 following a short term fast and that the phosphorylation
of Raptor is a key event in this process. However, despite the suppression of TSC2 and
Raptor by re-feeding, there was no significant alteration to puromycin incorporation. We
recognize that a limitation of our analysis is reflected by the inability of re-feeding to
induce protein synthesis.

This may potentially be explained as an issue of timing

following the re-feeding paradigm as the mice were only allowed access to food for a

97

duration of 1 hour before collection. Furthermore, it is also possible that these mice may
be anabolic resistant or incapable of stimulating protein synthesis in response to a meal.
The concept of anabolic resistance has become a very interesting field of investigation
during cancer cachexia.
The regulation of protein degradation is a tightly controlled process that involves
multiple mechanisms of action (Baracos, 2000; Dohm et al., 1980; Johns et al., 2012;
Komatsu & Ichimura, 2010; Sandri, 2016; Sandri et al., 2013; White, Baynes, et al.,
2011b; Whitehouse et al., 2001). AMPK has been demonstrated to exert regulation over
two key downstream targets that regulate both the E3 ligases and the autophagy
lysosomal system (Bujak et al., 2015; K. Nakashima & Yakabe, 2007; Sanchez, Csibi, et
al., 2012; Thomson, 2018). Expression of atrophy related genes Atrogin-1 and MuRF-1
are regulated through the forkhead box O (FOXO) family of transcription factors, in
particular FOXO3a (Greer et al., 2007). Catabolic stimuli such as fasting, inflammation,
cachexia, and oxidative stress increase MuRF-1 and Atrogin-1 in skeletal muscle (Sandri,
2016; White, Baynes, et al., 2011b; Whitehouse et al., 2001; A. Williams, Sun, Fischer,
& Hasselgren, 1999).

AMPK stimulates FOXO activity, activation of AMPK using

AICAR in-vivo and in-vitro has been demonstrated to induce both FOXO1 and FOXO3a
expression which induces both Atrogin-1 and MuRF-1 gene and protein expression(Suwa
et al., 2003; Tong, Yan, Zhu, & Du, 2009). Recent evidence has demonstrated that
AMPK will phosphorylate FOXO3a at serine 413 inducing its activity(Sanchez, Csibi, et
al., 2012). However, it should be noted that this event does not necessarily affect the
localization of FOXO to the nucleus but rather its transcriptional activity(Sanchez,
Candau, et al., 2012). In the current study fasting induced FOXO3a phosphorylation by
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AMPK in B6 and Min mice (Jorgensen et al., 2005). Interestingly, Atrogin-1 and MuRF1 were only induced in fasted Min mice. These results suggest that despite AMPK
phosphorylating FOXO3a in B6 mice, FOXO3a was only in the nucleus actively
transcribing these genes in Min mice only. Re-feeding was sufficient to suppress the
fasting induction FOXO3a in B6 and Min mice however,

only MuRF-1 in was

suppressed in Min mice suggesting that this may be a more sensitive target to feeding
stimuli. To our surprise, both Atrogin-1 and MuRF-1 were suppressed in B6 re-feed
mice when compared to the fasted condition and could be attributed to an acute increased
sensitivity to nutrient stimuli following a fast.
Another target controlled by AMPK that regulates protein degradation is Unc-51
like kinase 1 (ULK-1) (Bujak et al., 2015; Zhao & Klionsky, 2011). ULK-1 is crucial for
the initiation of autophagy or the selective degradation of damaged and dysfunctional
proteins. ULK-1 is capable of being controlled by both mTORC1 (during anabolic
stimuli such as feeding) and AMPK (during catabolic stimuli such as fasting) (J. Kim et
al., 2011).

Phosphorylation of ULK-1 by AMPK at serine 555 during catabolic

conditions will initiate the activation of downstream autophagy related signaling such as
LC3 and P62 (Laker et al., 2017; Sanchez, Csibi, et al., 2012; Zhao & Klionsky, 2011).
Under energy abundance, mTORC1 will phosphorylate ULK-1 at serine 757 and
suppress the initiation of autophagy signaling and formation of the autophagosome (J.
Kim et al., 2011). Interestingly, autophagy has become a recent target of cancer cachexia
research has been demonstrated to be elevated in both human and pre-clinical rodent
models of cachexia although the exact mechanism behind this activation remains largely
unknown (Penna et al., 2014; Pettersen et al., 2017; Pigna et al., 2016b). It is reasonable
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to suggest that the chronic activation of AMPK often reported in various pre-clinical
models of cachexia is likely responsible for the activation of autophagy, however many
studies fail to report the duration of fasting or feeding in their animal models and this
could directly affect these signaling events. In the current study fasting robustly induced
ULK-1 phosphorylation by AMPK in Min mice. Furthermore, we report that P62 was
suppressed by fasting and LC3B was induced in Min mice which is suggestive of
increased clearance of the autophagosome by the lysosome. Re-feeding however induced
the mTORC1 phosphorylation of serine 757 on ULK-1 which is indicative of a
suppression of autophagy initiation. Indeed, we noted a strong reduction in both P62 and
LC3B (II/I ratio) in the Min re-feed mice when compared to fasting. P62 was also
reduced in B6 re-feed mice, however no significant alteration occurred in LC3B II/I.
Collectively these results demonstrate that the cancer environment appears to
disrupt the physiological regulation of AMPK signaling in response to fasting and refeeding stimuli. Min mice exhibit a heightened sensitivity to a short term fast that is not
present in their wild type B6 counterparts.

This increase in AMPK activity and

downstream signaling may contribute to the acceleration of body and muscle mass loss.
Furthermore, we demonstrate that the increased sensitivity to fasting is also accompanied
by an accelerated response to feeding. The fasting induction of AMPK was suppressed by
re-feeding attenuating the suppression of protein synthesis and the acceleration of
degradation. While our fasting and re-feeding paradigm was short in duration we note
that the hyper-metabolism present in Min mice appears highly sensitive to these stimuli.
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Table 3.1. Animal Characteristics of Fed and Fasted B6 and Min Mice.
B6

Min

Ad Libitum Fed

Fast

Ad Libitum Fed

Fast

Sex
Age (weeks)
N

Male
12 ± 0.0
8

Male
12 ± 0.1
8

Male
19 ± 0.4
8

Male
21.2 ± 1.0
10

Peak BW (g)
BW (g)
Pre Fast BW (g)
BW @ Sac (g)

25.1 ± 0.3
25.2 ± 0.2
25.3 ± 0.3

23.8 ± 0.5
23.4 ± 0.5
23.5 ± 0.5
23.6 ± 0.4*

23.2 ±0.7
21.8 ±0.5
20.6 ± 0.8

23.9 ± 0.4
23.2 ± 0.4
23.1 ± 0.4
21.2 ± 0.8

BW Change % (BW-Peak BW/Peak BW)
Fasting BW Change % (Pre Fast BW-BW @ Sac/Pre Fast BW)
Sac Glucose (mg/dL)
IL-6 (pg/ml)
Total Polyps
Gastrocnemius (mg)

0.0 ± 0.0
122.3 ± 5.2
15.1 ± 15.0
0.0 ± 0.0
122.6 ± 1.7

2.0 ± 0.5
1.0 ± 0.01
128.4 ± 5.2
2.9 ± 3.0
0.0 ± 0.0
121.5 ± 1.7

5.7 ± 0.01
120.1 ± 5.0
41.7 ± 32.4
60.0 ± 9.0
89.1 ± 5.7

3.7 ± 0.01
9.8 ± 0.02
112.7 ± 5.3
15.6 ± 4.6
36.3 ± 6.7*
99.9 ± 6.9

Stomach (mg)
Liver (mg)
Spleen (mg)
Sem Vesicles (mg)
Testes (mg)
Epdidymal Fat (mg
Tibia Length

557.5 ± 43.5
1156.4 ± 45.0
158.8 ± 23.1
189.5 ± 13.5
187.8 ± 4.3
277.3 ± 21.4
16.8 ± 0.1

258.7 ± 22.7*
1043 ± 13.6*
142.2 ± 14.7
209.2 ± 9.1
184.6 ± 6.4
290.4 ± 26.3
16.7 ± 0.1

555.5 ± 69.1
1454.1 ± 149.1
386.5 ± 24.7
85 ± 17.5
142.7 ± 20.2
49.3 ± 24.6
16.8 ± 0.1

423.9 ± 38.1
1287.3 ± 56.7
344 ± 39.2
131.3 ± 24.0
168.7 ± 11.4
99.1 ± 39.3
16.8 ± 0.1

Min Fast group are the same Min mice from specific Aim 1. Values are means ± SEM.
Age given in weeks (wks). Body weights given in grams (g). BW Change is determined
from BW-Peak BW/Peak BW, Fasting BW Change determined from Pre-Fast BW-BW
@ Sac/Pre-Fast BW. All tissue weights expressed in milligrams (mg). Ad libitum Fed
denotes ad libitum food access during the dark cycle and sacrificed at 7AM. Fast denotes
12-hour fast during the 12-hour light cycle and sacrificed at 7PM. Min denotes ApcMin/+
mice . B6 denotes C57BL/6 mice *Significantly different from Fed state within genotype.
p<0.05 (students pre-planned t-test within genotype).
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Table 3.2. Animal Characteristics of Fasted and Re-Feed Mice.
B6

Min

Fast

Re-Feed

Fast

Re-Feed

Sex
Age (weeks)
N

Male
12.0 ± 0.0
8

Male
19.6 ± 1.5*
7

Male
21.2 ± 1.0
10

Male
20.0 ± 0.5
8

Peak BW (g)
BW (g)
Pre Fast BW (g)
BW @ Sac (g)

23.8 ± 0.5
23.4 ± 0.5
23.5 ± 0.5
23.6 ± 0.4

25.0 ± 0.8*
24.4 ± 0.7
24.5 ± 0.7
24.2 ± 0.6

23.9 ± 0.4
23.2 ± 0.4
23.1 ± 0.4
21.2 ± 0.8

23.6 ± 0.2
20.5 ± 0.3*
20.4 ± 1.1*
20.6 ± 1.1

BW Change % (BW-Peak BW/Peak BW)
Fasting BW Change % (Pre Fast BW-BW @ Sac/Pre Fast BW)
Sac Glucose (mg/dL)
IL-6 (pg/ml)
Total Polyps
Gastrocnemius (mg)

2.0 ± 0.5
1.0 ± 0.01
128.4 ± 5.2
2.9 ± 3.0
0.0 ± 0.0
121.5 ± 1.7

1.0 ± 0.01
126.0 ± 6.2
0.0 ± 0.0
0.0 ± 0.0
119.0 ± 4.2

3.7 ± 0.01
9.8 ± 0.02
112.7 ± 5.3
15.6 ± 4.6
36.3 ± 6.7
99.9 ± 6.9

8.0 ± 0.3*
143.7 ± 3.4*
13.7 ± 3.7
25.8 ± 11.6
84.4 ± 8.3

Food Consumed During 1hr Re-Feed
Stomach (mg)
Liver (mg)
Spleen (mg)
Sem Vesicles (mg)
Testes (mg)
Epdidymal Fat (mg
Tibia Length

258.7 ± 22.7
1043 ± 13.6
142.2 ± 14.7
209.2 ± 9.1
184.63 ± 6.4
290.4 ± 26.3
16.7 ± 0.1

0.5 ± 0.3
324.3 ± 27.5
1143 ± 49.9
69.4 ± 1.2*
230.4 ± 17.5
193.1 ± 6.3
323.4 ± 24.2
16.9 ± 0.1

423.9 ± 38.1
1287.3 ± 56.7
344 ± 39.2
131.3 ± 24.0
168.7 ± 11.4
99.1 ± 39.3
16.8 ± 0.1

0.7 ± 0.5
444.0 ± 61.0
1332.6 ± 78.4
425.6 ± 42.3
100.5 ± 26.5
127.4 ± 18.6*
88.3 ± 58.9
16.6 ± 0.1*

B6 Fast and Min Fast groups are the same mice as depicted in table 3.1. Values are
means ± SEM. Age given in weeks (wks). Body weights given in grams (g). BW Change
is determined from BW-Peak BW/Peak BW, Fasting BW Change determined from PreFast BW-BW @ Sac/Pre-Fast BW. All tissue weights expressed in milligrams (mg). Fast
denotes 12-hour fast during the 12-hour light cycle and sacrificed at 7PM. Re-Feed
denotes mice fasted for 12 hour fast during the 12-hour light cycle and allowed access to
a food pellet for 1 hour and sacrificed at 8PM. Min denotes ApcMin/+ mice. B6 denotes
C57BL/6 mice *Significantly different from Fed state within genotype. p<0.05 (students
pre-planned t-test within genotypee).
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Figure 3.1. AMPK Activation During Short Term Fasting In Cachectic Muscle. A)
Experimental design figure depicting 12-hour light cycle fasting protocol. B)
Representative western blots of p-AMPK (T172), p-ACC (S79), ACC, and quantification
of blots in B6 Fed and Fasted gastrocnemius muscle. C) Representative western blots of
p-AMPK (T172), p-ACC (S79), ACC, and quantification of blots in Min Fed and Fasted
gastrocnemius muscle. * denotes different to Fed state. Significance was set at p<0.05.
Students pre-planned t-test.
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Figure 3.2. AMPK Immediate Downstream Targets in Fasted Cachectic Skeletal Muscle.
A) Representative western blots of p-Raptor (S792), Raptor, p-TSC2 (S1387), TSC2, pFOXO3a (S413), FOXO3a, p-ULK-1 (S555), and ULK-1and quantification of blots in
gastrocnemius of in B6 Fed and Fasted gastrocnemius muscle. B) Representative
western blots of p-Raptor (S792), Raptor, p-TSC2 (S1387), TSC2, p-FOXO3a (S413),
FOXO3a, p-ULK-1 (S555), and ULK-1and quantification of blots in gastrocnemius of
and quantification of blots in Min Fed and Fasted gastrocnemius muscle. * denotes
different to Fed state. Significance was set at p<0.05. Students pre-planned t-test.
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Figure 3.3. Protein Turnover in Fasted Cachectic Skeletal Muscle. A) Representative
western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, Puromycin and quantification of
blots in gastrocnemius of in B6 Fed and Fasted gastrocnemius muscle. B) Representative
western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, Puromycin and quantification of
blots in gastrocnemius of and quantification of blots in Min Fed and Fasted
gastrocnemius muscle.* denotes different to Fed state. Significance was set at p<0.05.
Students pre-planned t-test.
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Figure 3.4. Mitochondrial Quality Control in Fed vs. Fasted Cachectic Skeletal Muscle.
A) Representative western blots of PGC-1, MFN-1, DRP-1 and quantification of blots
in gastrocnemius of in B6 Fed and Fasted gastrocnemius muscle. B) Representative
western blots of PGC-1, MFN-1, DRP-1 and quantification of blots in gastrocnemius of
and quantification of blots in Min Fed and Fasted gastrocnemius muscle.* denotes
different to Fed state. Significance was set at p<0.05. Students pre-planned t-test.
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Figure 3.5. AMPK Activation During Re-Feeding. A) Experimental design figure
depicting 12-hour light cycle fasting protocol and 1-hour re-feeding paradigm. B)
Representative western blots of p-AMPK (T172), p-ACC (S79), ACC, and quantification
of blots in B6 Fasted and Re-Feed gastrocnemius muscle. C) Representative western
blots of p-AMPK (T172), p-ACC (S79), ACC, and quantification of blots in Min Fasted
and Re-Feed gastrocnemius muscle. * denotes different to Fasted state. Significance was
set at p<0.05. Students pre-planned t-test.
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Figure 3.6. AMPK Downstream Signaling in Fasted and Re-Fed Cachectic Skeletal
Muscle. A) Representative western blots of p-Raptor (S792), Raptor, p-TSC2 (S1387),
TSC2, p-FOXO3a (S413), FOXO3a, p-ULK-1 (S555), ULK-1, and quantification of
blots in B6 Fasted and Re-Feed gastrocnemius muscle. C) Representative western blots
of p-Raptor (S792), Raptor, p-TSC2 (S1387), TSC2, p-FOXO3a (S413), FOXO3a, pULK-1 (S555), ULK-1, and quantification of blots in Min Fasted and Re-Feed
gastrocnemius muscle. * denotes different to Fasted state. Significance was set at
p<0.05. Students pre-planned t-test.
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Figure 3.7. Protein Turnover in Fasted and Re-Fed Cachectic Skeletal Muscle. A)
Representative western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, Puromycin, and
quantification of blots in B6 Fasted and Re-Feed gastrocnemius muscle.
C)
Representative western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, Puromycin, and
quantification of blots in Min Fasted and Re-Feed gastrocnemius muscle. * denotes
different to Fasted state. Significance was set at p<0.05. Students pre-planned t-test.
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Figure 3.8. Mitochondrial Quality Control During Re-Feeding. A) Representative
western blots of PGC-1, MFN-1, DRP-1 and quantification of blots in B6 Fasted and
Re-Feed gastrocnemius muscle. C) Representative western blots of PGC-1, MFN-1,
DRP-1 and quantification of blots in Min Fasted and Re-Feed gastrocnemius muscle. *
denotes different to Fasted state. Significance was set at p<0.05. Students pre-planned ttest.
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CHAPTER 4
THE EFFECT OF VOLUNTARY WHEEL ACTIVITY ON AMPK
SIGNALING IN RESPONSE TO PHYSIOLOGICAL FASTING DURING
CANCER CACHEXIA
4.1 Abstract
The adenosine monophosphate protein kinase (AMPK) is a key cellular energy
sensor and regulator of skeletal muscle metabolic processes such as protein turnover and
mitochondrial quality control. AMPK is chronically elevated during energy stress
conditions such as fasting and acute exercise. Cancer cachexia is a debilitating disease
that is often accompanied by decreased physical activity and chronic energy stress.
Increased physical activity has been demonstrated to improve indices of muscle protein
turnover and mitochondrial quality control under basal conditions. However, far less is
understood about physical activity and the regulation of AMPK signaling during fasting
and diseased conditions. Therefore, the purpose of this study was to determine the effect
of voluntary wheel activity on AMPK signaling in response to physiological fasting
during cancer cachexia. Male C57BL/6 (B6, N=16) and ApcMin/+ (Min, N=18) were
subjected to either a 4 weeks of voluntary wheel running followed by a 12 hour fast, or
a12 hour fast. Following completion of each treatment, hindlimb muscles were harvested
and the gastrocnemius homogenized for protein analysis. Fasted Min mice exhibited
body weight loss and reduced gastrocnemius mass when compared to fasted B6 mice
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however, voluntary wheel activity attenuated fasting induced bodyweight loss in Min
mice when compared to fasting alone. The fasting induction of AMPK (T172) and ACC
(S79) was not altered in B6 mice but was suppressed by voluntary wheel activity in Min
mice. Wheel activity induced PGC-1 in Min mice only, MFN-1 and DRP-1 were
induced in both B6 and Min mice when compared to fasted condition. The fasting
induction of FOXO3a (S416), Atrogin-1, MuRF-1, ULK-1 (S555), LC3 (II/I) and P62
were suppressed by wheel activity in Min mice only. Wheel activity induced TSC2
(S1347) in B6 and Min mice when compared to the fasted condition alone. Our results
demonstrate the 4 weeks of voluntary wheel activity is sufficient to improve cachectic
muscle AMPK signaling in response to a physiological fast. Furthermore, our results
suggest that wheel activity improves mitochondrial quality control and AMPK mediated
protein degradation signaling.
4.2 Introduction
Cancer cachexia is a debilitating wasting syndrome that occurs in
approximately 80% of all cancer patients and is responsible for approximately 30% of all
cancer related deaths (Argiles et al., 2010; Baracos, 2006a, 2006b, 2011; Evans et al.,
2008; K. Fearon et al., 2011; K. C. Fearon & Baracos, 2010). Cachexia is infrequently
identified or diagnosed and rarely treated(Baracos, 2011, 2013; Blum et al., 2010;
Bruggeman et al., 2016). Cachexia development is not associated with all cancers, but
the progression of cachexia is directly associated with cancer patient morbidity and
mortality (Baracos, 2006a; Sadeghi et al., 2018; Solheim et al., 2011; Solheim et al.,
2018). The loss of muscle mass and strength can result in increased fatigue and lead to a
decrease in physical activity which can potentially further exacerbate muscle mass loss
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and contribute to metabolic dysfunction (Drescher et al., 2016). A more recent study of
patients with cancer of the gastrointestinal tract also demonstrated a substantial loss of
mass and strength regardless of daily nutritional intake, suggesting a chronic energy
deficit (Drescher et al., 2016).
The adenosine monophosphate protein kinase (AMPK) serves as the cellular
energy sensor of the cell and is also responsible for regulating metabolic homeostasis and
muscle mass (Thomson, 2018; Thomson et al., 2008). In healthy skeletal muscle, AMPK
activation will suppress the metabolically expensive mTORC1 signaling pathway and
induce the activation of energy generating pathways through the activation of
downstream targets PGC-1, FOXO3a, and ULK-1 (Shaw, 2009; Thomson, 2018;
Thomson et al., 2008; Viollet et al., 2009; Zhao & Klionsky, 2011; Zong et al., 2002).
Activation of these proteins will induce muscle mitochondrial biogenesis/remodeling,
protein degradation, and autophagy which serve to free up amino acids for energy
metabolism and help maintain blood glucose levels during prolonged periods of fasting or
stress (Sandri, 2016; Schwalm et al., 2015; Thomson, 2018; Toyama et al., 2016; Zhao &
Klionsky, 2011). Short term fasting is a normal physiological process that often occurs
during sleep and contributes to the diurnal variation of protein turnover (Chang,
Yoshihara, Machida, & Naito, 2017; Harfmann, Schroder, & Esser, 2015). Research has
demonstrated that short term fasting in normal healthy skeletal muscle does not activate
the AMPK signaling pathway is well tolerated (Chang et al., 2017; Dethlefsen et al.,
2018; Martinez-Lopez et al., 2017; K. Nakashima, Yakabe, Yamazaki, & Abe, 2006).
Our laboratory has previously reported that despite normal food intake, AMPK is
chronically activated in cachectic skeletal muscle (Puppa, Gao, et al., 2014; Puppa et al.,
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2012; White, Puppa, Gao, et al., 2013). Furthermore, the chronic activation of AMPK
also coincides with decreased physical activity, disrupted mitochondrial quality control,
and protein turnover (Baltgalvis et al., 2010; Hardee et al., 2018; Puppa, Gao, et al.,
2014; Puppa, Murphy, Fayad, Hand, & Carson, 2014; White, Baltgalvis, et al., 2011;
White, Baynes, et al., 2011b; White, Puppa, Gao, et al., 2013).

These studies suggest

that cachexia induces a constant metabolic stress that results in energy deficiency and the
perpetual activation of AMPK.

However, since cachectic skeletal muscle already

presents with elevated AMPK, whether short term fasting could exacerbate this signaling
pathway requires further investigation.
The loss of body weight and skeletal muscle mass is often accompanied by
decreased physical activity and exercise (Baltgalvis et al., 2010). Our laboratory has
previously reported that the decrease of voluntary wheel running activity actually
precedes the initiation of body weight loss in ApcMin/+ mice (Baltgalvis et al., 2010).
Coinciding with decreased wheel running activity, our laboratory has also reported
elevated AMPK and suppressed oxidative metabolism occurring as early as 15 weeks
(Baltgalvis et al., 2010; Carson et al., 2015; Puppa et al., 2012; White, Baltgalvis, et al.,
2011; White et al., 2012).

Interestingly, increased activity and exercise have been

demonstrated to induce LKB1 rather than AMPK protein expression as well as
mitochondrial biogenesis markers in rat skeletal muscle (Taylor et al., 2004; Taylor et al.,
2005). Surprisingly, these changes occurred despite a decrease in AMPK kinase activity
(Taylor et al., 2005). In human skeletal muscle increased activity and exercise training
has been demonstrated to suppress AMPK activity following a prolonged bout of exercise
suggesting that training improves the skeletal muscle capacity to handle metabolic stress,
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possibly through improved mitochondrial function and quality control (McConell et al.,
2005; Taylor et al., 2005). While it is well established that acute exercise activates
AMPK our laboratory has established that exercise training was able to attenuate the
cachexia induced chronic activation of this pathway and improve muscle mass loss
(Hardee et al., 2016; Puppa et al., 2012). These results suggest that increased physical
activity and exercise training may improve metabolic capacity and mitochondrial quality
during cancer cachexia and alleviate the chronic deficit of energy (ATP generation) thus
lowering AMPK’s activity. Similar results were also demonstrated using high and low
frequency electrical stimulation in cachectic muscle (Hardee et al., 2016; Puppa, Murphy,
et al., 2014). Seven repeated bouts of high frequency stimulation were able to lower
AMPK phosphorylation in cachectic ApcMin/+ and stimulate muscle protein synthesis 3
hours post the final treatment (Hardee et al., 2016).
As mentioned previously, numerous models of cancer cachexia have reported
both elevated AMPK and disrupted aberrant downstream signaling related to protein
turnover and mitochondrial quality control (Brown, Rosa-Caldwell, Lee, Blackwell, et
al., 2017; Pigna et al., 2016a; White, Baltgalvis, et al., 2011). The use of exercise
training to attenuate or improve AMPK phosphorylation during cancer cachexia has been
demonstrated as an effective treatment however, whether this effect improves the protein
synthesis, degradation, and mitochondrial quality control response to a short term fast
remains to be determined. Therefore, the purpose of this study was to determine if 4
weeks of voluntary wheel running activity improves aberrant AMPK signaling in
response to physiological fasting during in tumor bearing mice.
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4.3 Methods
Animals
The ApcMin/+ mouse is a genetic model of colorectal cancer and cachexia
(Baltgalvis et al., 2008). These mice harbor a heterozygous mutation in the adenomas
polyposis coli (APC) gene, which promotes the development of intestinal tumors
beginning as early as 4 weeks of age (Moser et al., 1995). Mice develop an IL-6dependent cancer cachexia phenotype between 3 and 6 months of age (Baltgalvis et al.,
2008). Due to the slow onset and progression of body weight loss this model is
advantageous as treatments can be started after the initiation of cancer cachexia. Male
ApcMin/+ mice on a C57BL/6 background were originally purchased from Jackson
Laboratories (Bar Harbor, ME, USA) and bred at the University of South Carolina’s
Animal Resource Facility. All mice used in the current study were obtained from the
investigators breeding colony within the Center for Colon Cancer Research Mouse Core.
At 3-wk of age mice were genotyped as previously described. Mice were individually
housed, kept on a 12:12-h light-dark cycle, and had access to standard rodent chow
(#8604 Rodent Diet; Harlan Teklad, Madison, WI) and water ad libitum. 12 hours prior
to sacrifice all mice had food removed from cage. Body weight measurements were
taken weekly and the percentage body weight loss from peak body weight (~10-15 weeks
of age) was calculated. Mice lacking the ApcMin/+ mutation (C57BL/6) served as controls
for all experiments. The University of South Carolina’s Institutional Animal Care and
Use Committee approved all animal experimentation in this study.
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Voluntary Wheel Running
Voluntary wheel running was used as a marker of volitional physical activity and
was performed as previously described (Baltgalvis et al., 2010). At ~14-15 wks. of age,
wild-type and ApcMin/+ were housed individually in cages with 9.5-in.-diameter stainless
steel activity wheels (MiniMitter, Bend, OR). Running activity was monitored daily
from 14-15 weeks of age to 18-19 weeks of age. Bicycle computers (Specialized, Morgan
Hill, CA) with magnetic sensors measured average speed, distance, time, and maximum
speed, and the data were recorded daily.
Western Blotting
Western blot analysis was performed as previously described (Fix et al., 2018).
Briefly, frozen gastrocnemius muscle was homogenized in ice-cold Mueller buffer and
protein concentration was determined by the Bradford method. Crude muscle
homogenates were fractionated on 6 – 15% SDS-polyacrylamide gels and transferred to
PVDF membranes overnight. Membranes were stained with Ponceau red to verify equal
loading and transfer for each gel. Membranes were blocked at room temperature for 1 – 2
hrs. in 5% Tris-buffered saline with 0.1% Tween-20 (TBST) milk. Primary antibodies for
puromycin, p-FOXO3(S416), FOXO3, p-ULK-1 (S555), ULK-1, P62, LC3II/I, MuRF-1,
Atrogin-1 (ECM Biosciences), p-AMPK (T172), AMPK, p-ACC (S79) , ACC, p-TSC2
(S1387), TSC2, p-raptor (S792), raptor, DRP-1, FIS-1, MFN-1 (Abcam), PGC-1
(Abcam), and GAPDH will be diluted 1:5000 – 1:2000 in 5% TBST-milk followed by a
4-8-hr incubation with membranes at 4 degrees. Anti-rabbit or anti-mouse IgG
horseradish-peroxidase conjugated secondary antibody was incubated with the
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membranes at 1:2000 dilutions for 1 hour in 5% TBST-milk at room temperature.
Enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was
used to visualize the antibody-antigen interactions. Images were digitally scanned and
quantified by densitometry using imaging software (Image J; NIH). All antibodies were
from Cell Signaling unless otherwise stated.
Plasma IL-6 concentrations
Plasma IL-6 concentrations were determined as previously described (Hardee et
al., 2016). A commercially available IL-6 enzyme-linked immunosorbent assay kit was
obtained from BD Biosciences (San Diego, CA, USA) and the manufacturer’s protocol
was followed. Briefly, a Costar clear 96-well plate (Corning, NY, USA) was coated with
IL-6 capture antibody and allowed to incubate overnight. The next morning, the plate was
blocked with assay diluent buffer, washed, and IL-6 standards and plasma samples were
added in duplicate to the plate. The plate was again washed and sAV-HRP reagent was
added to each well. After several washes, TMB substrate was added and the reaction was
developed for 20 minutes. The reaction was stopped with sulfuric acid and absorbance
was read in a Bio-Rad iMark plate reader (Hercules, CA, USA) at 450 nm.
Cytochrome C Oxidase Enzyme Assay
Cytochrome-c oxidase (COX) activity was assessed in whole muscle
homogenates from the gastrocnemius muscle. For whole muscle analysis, gastrocnemius
tissues were homogenized in extraction buffer (0.1M KH2PO4/Na2HPO4 and 2 mM
EDTA, pH 7.2). COX enzyme activity was determined by measuring the rate of oxidation
of fully reduced cytochrome c at 550 nm as previously described (Fix et al., 2018).
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Statistical Analysis
Results are reported as the means ± standard error. An unpaired student’s preplanned t-test. The accepted level of significance was set at p<0.05 for all analysis.
Statistical analysis was performed using Prism GraphPad 7 (GraphPad Software Inc., La
Jolla, CA).
4.4 Results
Animal Characteristics Fasting vs. Wheel+Fasting
We first examined animal characteristics of our mice, there was a significant
difference in age between B6 fast and wheel+fast mice (Table 4.1). Interestingly, spleen
weight was decreased in the wheel+fast group compared to fasting alone. Additionally,
seminal vesicle weight was elevated in B6 wheel+fast mice compared to fasting. In Min
mice, there was no difference in pre-fast bodyweight loss (Table 4.1). However, fasting
(post-fast) bodyweight loss was reduced in Min wheel+fast mice when compared to
fasted Min mice alone (Table 4.1). Wheel access prior to fasting attenuated the loss of
gastrocnemius mass when normalized to bodyweight in Min mice. IL-6 values and total
polyps were similar between fast and wheel+fast Min mice (Table 4.1). Interestingly,
these changes occurred despite Min mice running significantly less kilometers per week
and per day on the wheels than B6 mice (Figure 4.1B-C) and suggest that even minimal
physical activity is sufficient to improve fasting induced changes during cancer cachexia.
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AMPK Activation in Wheel+Fasting Mice
In order to examine the activation of AMPK following wheel+fasting we
examined B6 and Min mice that had been subjected to a short term fast or allowed free
access to a wheel for 4 weeks and then subjected to a short term fast. In B6 mice there
was no significant alteration to AMPK or ACC with wheel+fast when compared to
fasting alone (Figure 4.2A). Interestingly, wheel access prior to fasting drastically
reduced AMPK and ACC phosphorylation in Min mice (Figure 4.2B). These results
suggest that increased physical activity over the course of 4 weeks was able to inhibit the
fasting induction of AMPK following a short term fast.
AMPK Immediate Downstream Targets in. Wheel+Fasting Mice
Due to the suppression of AMPK in Min mice and we next examined if the
changes in AMPK activation upstream were reflected downstream by mTORC1 signaling
(Figure 4.3A-B). We examined TSC2 and Raptor, two known immediate downstream of
AMPK targets that regulate mTORC1. In B6 mice wheel access prior to fasting did not
alter TSC2 and Raptor phosphorylation (Figure 4.3A).

In Min mice Raptor also

remained un-altered by wheel access when compared to fasting alone (Figure 4.3B).
Interestingly, TSC2 phosphorylation was induced nearly 2 fold by wheel access when
compared to fasting in Min mice. (Figure 4.3B). These results suggest that despite
changes in AMPK phosphorylation up-stream mTORC1 signaling appears largely unaffected by wheel access prior to fasting. Furthermore, while AMPK phosphorylation
may have been suppressed it is interesting to speculate if AMPK enzyme activity actually
still elevated or if the beta subunits may be compensating for a lack of alpha. We next
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examined the downstream signaling of AMPK pertaining to protein degradation related
to the ubiquitin proteasome (FOXO3a) and autophagy ULK-1. FOXO3a phosphorylation
was suppressed by wheel access prior to fasting in B6 and Min mice (Figure 4.3A-B).
ULK-1 phosphorylation at Serine 555 was only suppressed in Min mice with wheel
access when compared to fasting alone (Figure 4.3B).
AMPK Mediated Protein Turnover During Wheel+Fasting
Furthermore, downstream E3 ligases MuRF-1 and Atrogin-1 were suppressed in
B6 and Min with wheel access prior to fasting (Figure 4.4A-B). Downstream targets
LC3B (II/I) and P62 were both suppressed in wheel+fasting Min mice only. In line with
previous literature, P62 and LC3B were actually induced in wheel+fasting B6 mice
compared to fasting alone (Figure 4.4A). We next examined if wheel+ fasting had any
effect on puromycin incorporation which is indicative of protein synthesis. Puromycin
incorporation was only induced Min wheel+fast groups when compared to fasting alone
(Figure 4.4B). Collectively these results suggest that the suppression of fasting induced
AMPK by wheel access serves to inhibit the fasting induction of E3 ligases and indices of
autophagy in Min mice and prevent the fasting induced suppression of protein synthesis
in Min mice.
AMPK Mediated Mitochondrial Quality Control During Wheel+Fasting
AMPK has the unique ability to control and regulate mitochondrial quality control
through peroxisome proliferator gamma co-activator 1 (PGC-1) and dynamin related
protein 1 (DRP-1). We next examined if wheel access prior to fasting regulated these
processes. B6 mice demonstrated no alterations in PGC-1 protein expression despite an
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increase in cytochrome C oxidase (COX) activity (Figure 4.5A). Mitochondrial dynamics
proteins DRP-1 and MFN-1 were both induced suggesting that mitochondrial remodeling
is occurring with wheel access prior to fasting (Figure 4.5A). Interestingly, despite a
suppression of AMPK activation with wheel access, Min mice exhibited a robust
induction of PGC-1, DRP-1, and MFN-1 when compared to fasting alone (Figure 4.4B).
These changes were also accompanied by an induction of COX activity which is
indicative of increased mitochondrial content. COX enzyme activity was actually tightly
correlated to distance run in Min mice (Figure 4.4B).
4.5 Discussion
AMPK is an established regulator of skeletal muscle protein turnover and
metabolism (Kemp et al., 2007; Kjobsted et al., 2018; Koh et al., 2008; Sakamoto et al.,
2004; Sakamoto et al., 2005; Sanchez, Csibi, et al., 2012; Thomson, 2018; Thomson et
al., 2008; Zhao & Klionsky, 2011). During prolonged energy deficiency such as fasting
or strenuous exercise, AMPK exerts regulatory control of both mTORC1 signaling and
degradation through control of its downstream targets Raptor, TSC2, FOXO3a, and
ULK-1 (Bujak et al., 2015; Canto & Auwerx, 2009; Z. P. Chen et al., 2000; Friedrichsen
et al., 2013; Gwinn et al., 2008; Jager et al., 2007; J. Kim et al., 2011; Laker et al., 2017;
McConell et al., 2005; Mihaylova & Shaw, 2011; Mounier et al., 2015; K. Nakashima &
Yakabe, 2007; Sakamoto et al., 2004). Furthermore, AMPK evidence also suggest that
AMPK is an essential regulator of skeletal muscle mitochondrial quality control through
PGC-1 and DRP-1 (Z. Chen et al., 2019).

In healthy skeletal muscle, AMPK will

suppress the mTORC1 signaling pathway through TSC2/Raptor while activating
degradation pathways. Simultaneously AMPK will stimulate PGC-1 to generate more
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mitochondria to compensate for the chronic energy deficit (Canto & Auwerx, 2009).
However, our laboratory and others have demonstrated that despite the chronic elevation
of AMPK in cachectic skeletal muscle PGC-1 expression remains suppressed (Brown,
Rosa-Caldwell, Lee, Blackwell, et al., 2017; White, Baynes, et al., 2011b; White, Puppa,
Gao, et al., 2013).
Our laboratory has also demonstrated that TSC2 and Raptor are induced while
mTORC1 is suppressed in cachectic Min skeletal muscle (White, Puppa, Gao, et al.,
2013). Furthermore, this suppression of mTORC1 through AMPK coincides with a
robust induction of ubiquitin proteasome and autophagy lysosomal activity (Aversa, Pin,
Lucia, Penna, Verzaro, Fazi, Colasante, Tirone, Rossi Fanelli, et al., 2016; Baracos, 2000;
Penna, Costamagna, et al., 2013; Sandri, 2016; White, Baynes, et al., 2011a).
Expression of E3 ligases Atrogin-1 and MuRF-1 are controlled by FOXO3a, whose
activity is regulated by AMPK (K. Nakashima & Yakabe, 2007). Previous studies have
demonstrated that AMPK activation both in-vitro and in-vivo FOXO3a and increases the
expression of E3 ligases and autophagy markers (K. Nakashima & Yakabe, 2007; Puppa,
Gao, et al., 2014; Sanchez, Csibi, et al., 2012; White, Puppa, Gao, et al., 2013).
Additionally, AMPK is also a critical regulator of the autophagy lysosomal system
through ULK-1 (J. Kim et al., 2011; Laker et al., 2017; Sanchez, Csibi, et al., 2012).
During energetic stress such as acute exercise or fasting, ULK-1 is phosphorylated by
AMPK and initiates the activation of autophagy through downstream targets (Kemp et
al., 2007; J. Kim et al., 2011; Laker et al., 2017; Sanchez, Csibi, et al., 2012). Autophagy
has recently become a target of cancer cachexia researchers and has been reported as
elevated in human colorectal cancer patients and pre-clinical models (Aversa, Pin, Lucia,
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Penna, Verzaro, Fazi, Colasante, Tirone, Fanelli, et al., 2016; Penna et al., 2014; Penna,
Costamagna, et al., 2013; Pettersen et al., 2017). However, an exact mechanism of
elevated autophagy in cachectic skeletal muscle has yet to be fully elucidated however,
some researchers have suggested an association between cancer induced inflammation
and AMPK (Pettersen et al., 2017). In the current study we report the novel findings that
wheel running prior to fasting was sufficient to suppress the fasting induction of AMPK
in Min mice and suppress downstream degradation targets FOXO3a and ULK-1 thus,
alleviating the activation of E3 ligases and autophagy. Additionally, we report that wheel
running was also sufficient to restore mitochondrial quality control proteins PGC-1,
MFN-1 and DRP-1 while also inducing COX enzyme activity in Min mice. Collectively
these results demonstrate that 4 weeks of voluntary wheel running prior to fasting is
sufficient to attenuate aberrant AMPK mediated degradation signaling. Furthermore, 4
weeks of wheel activity also restored indices of mitochondrial quality control and
improves cachectic skeletal muscles response to a short term fast.
Increased physical activity as a treatment modality has become an important area
of interest in cancer cachexia (Argiles et al., 2012; Carson et al., 2015; Grande et al.,
2015; Solheim et al., 2018). Numerous studies have investigated the association between
physical activity, developing cancer, and skeletal muscle protein turnover (Antoun &
Raynard, 2018; Booth, Roberts, & Laye, 2012; Hardee, Counts, & Carson, 2019).
Studies and clinical trials have also suggested that prognosis is improved in physically
active cancer patients due to exercise performed after the cancer diagnosis (Alves, da
Cunha, da Paixao, & Brum, 2015; Argiles et al., 2012; Belloum, Rannou-Bekono, &
Favier, 2017; Gould et al., 2013; Grande et al., 2015). Additionally, similar results have
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been reported in pre-clinical models of cancer cachexia as well, wheel running activity in
C26 cancer mice blocked the induction of AMPK mediated degradation pathways in
gastrocnemius muscle (Pigna et al., 2016b). Additionally, our laboratory and others have
demonstrated the ability of muscle contraction to attenuate some of these markers of
degradation in cachectic muscle, further establishing the regulatory power of activity and
contraction (Hardee et al., 2016; Pigna et al., 2016b; Puppa, Murphy, et al., 2014). We
add to these findings by demonstrating that FOXO3a phosphorylation by AMPK,
Atrogin-1, and MuRF-1 were all suppressed with 4 weeks of wheel running prior to
fasting in both B6 and Min mice. Interestingly, ULK-1 phosphorylation, P62, and LC3B
(II/I) were actually induced by wheel running prior to fasting in B6 mice which
corroborates previous studies by our laboratory and others in healthy adult skeletal
muscle (Fix et al., 2018; Yan et al., 2012). However, wheel running activity prior to
fasting suppressed ULK-1 phosphorylation and its downstream targets P62 and LC3B
(II/I) in Min mice, demonstrating the therapeutic effect of physical activity in the caner
environment. Despite the robust changes in protein degradation markers we report that
wheel running prior to fasting had little to no effect on the phosphorylation of TSC2 and
Raptor. Interestingly, TSC2 phosphorylation was actually further induced in Min mice
while Raptor was actually suppressed in B6 mice when compared to fasting alone.
Previous research in non-muscle cells has suggested that Raptor phosphorylation is
actually required for the suppression of mTORC1 in response to fasting (Gwinn et al.,
2008). Despite these slight changes in TSC2 and Raptor we report that 4 week of wheel
running did not alter skeletal muscle puromycin incorporation in B6 and Min mice which
is indicative of protein synthesis. Collectively, these results demonstrate that the
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suppression of AMPK in Min mice was not reflected downstream in regard to mTORC1
signaling and skeletal muscle protein synthesis. However, these results suggest that the
attenuation in muscle mass loss is most likely attributed to a suppression of degradation
rather than protein synthesis.
In addition to regulating skeletal muscle mass, AMPK also exerts control over
muscle metabolism and mitochondrial quality control (Canto et al., 2010; Laker et al.,
2017; Mishra & Chan, 2016; Zong et al., 2002). In healthy human skeletal muscle,
exercise training has been demonstrated to improve the response to fasting when
compared to untrained muscle (Dethlefsen et al., 2018; McConell et al., 2005).
Furthermore, AMPK has emerged as a critical regulator of muscle mitochondrial health
via its regulation of mitochondrial biogenesis (PGC-1 ) and fission (DRP-1) (Z. Chen et
al., 2019; Jager et al., 2007). These processes are critical for the maintenance of skeletal
muscle during periods of energy deficiency such as fasting and acute exercise. However,
numerous disease models including cancer cachexia report that skeletal muscle AMPK is
chronically activated suggesting a state of constant energy stress or deficiency (Brown,
Rosa-Caldwell, Lee, Blackwell, et al., 2017; Bujak et al., 2015; Hall et al., 2018; Puppa,
Gao, et al., 2014; Rohm et al., 2016; White, Puppa, Gao, et al., 2013). Our laboratory has
previously reported that AMPK is robustly activated in severe cancer cachexia in both the
Lewis Lung Carcinoma (LLC) and ApcMin/+ mouse models of cancer cachexia while
PGC-1 is actually suppressed (Puppa, Gao, et al., 2014; Puppa et al., 2012; White,
Puppa, Gao, et al., 2013). In the current study PGC-1 was only induced by wheel
running in Min mice prior to fasting. Interestingly, this induction occurred despite a
suppression of AMPK phosphorylation upstream. The disconnect of AMPK and PGC-
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1 in cachexia has been previously reported by our laboratory (Puppa, Gao, et al., 2014;
Puppa et al., 2012; White, Puppa, Gao, et al., 2013).

Furthermore, results from the

current study further corroborate the ability of increased physical activity and exercise to
attenuate chronically activated AMPK in cachexia and restore the activation of PGC-1.
In addition to the increase in PGC-1, wheel running prior to fasting also induced
mitochondrial remodeling by inducing both MFN-1 and DRP-1 in both B6 and Min mice
which are critical regulators of mitochondrial health. In Min mice the induction of these
proteins coinciding with the restoration of PGC-1 is suggest of improved mitochondrial
quality control and remodeling. It is interesting to speculate how exactly the activation of
PGC-1 is occurring, previous studies have demonstrated that AMPK phosphorylation
may not always accurately reflect kinase activity. The decrease in phosphorylation of
AMPK in the current study may be occurring outside of kinase activity which may still
serve to induce PGC-1.

Furthermore, these results may also suggest a role for the

sirtuins, especially SIRT-1 which has been demonstrated to be a critical co-factor for
PGC-1 activation and reflective of AMPK kinase activity. Collectively, these results
suggest that 4 weeks of voluntary wheel running is sufficient to restore aberrant AMPK
signaling and induce mitochondrial remodeling in fasted Min mice.
In conclusion we demonstrate a role for increased physical activity through wheel
running to attenuate aberrant AMPK activation in fasted cachectic skeletal muscle. We
provide evidence that the suppression of AMPK by wheel running prior to fasting
attenuates protein degradation through suppressing E3 ligase and autophagy activation.
These results demonstrate that the sparing of muscle mass is occurring due to changes in
degradation rather than AMPK mediated mTORC1 signaling. Furthermore, the current
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study demonstrates that wheel running activity is sufficient to restore skeletal muscle
mitochondrial quality control through PGC-1, MFN-1, and DRP-1.

These results

suggest that the improvements in mitochondrial quality control may improve the ability
of cachectic skeletal muscle to handle a short term fast.
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Table 4.1. Animal Characteristics of Fast and Wheel+Fast Mice
WT

AMPK KO

Min

Min KO

Sex
Age (weeks)
N

Male
16.1
6

Male
15.9 ± 0.1
10

Male
21.2 ± 1.0
10

Male
19.0 ± 1.3
6

Peak BW (g)
BW (g)
Pre Fast BW (g)
BW @ Sac (g)

23.5 ± 0.5
23.3 ± 0.6
23.2 ± 0.5
22.5 ± 0.5

23.1 ± 0.7
23.3 ± 0.6
23.2 ± 0.5
22.3 ± 0.6

23.9 ± 0.4
23.2 ± 0.4
23.1 ± 0.4
21.2 ± 0.8

23.9 ± 0.6
22.9 ± 0.6
22.8 ± 0.6
22.2 ± 0.8

BW Change % (BW-Peak BW/Peak BW)
Fasting BW Change % (Pre Fast BW-BW @ Sac/Pre Fast BW)
Sac Glucose (mg/dL)
Food (g/day)
IL-6 (pg/ML)
Total Polyps
Gastrocnemius (mg)

1.0 ± 1.0
3.0 ± 1.0
140.7 ± 7.3
3.4 ± 0.2
0.0 ± 0.0
0.0 ± 0.1
120.2 ± 3.0

2.0 ± 0.3
4.0 ± 0.1
125.7 ± 7.1
3.2 ± 0.1
0.0 ± 0.0
0.0 ± 0.1
118.8 ± 2.1

3.7 ± 0.01
9.8 ± 0.2
112.7 ± 5.3
2.9 ± 0.3
15.6 ± 4.6
36.3 ± 6.7
99.9 ± 6.9

4.0 ± 1.0
3.0 ± 1.0*
132.8 ± 10.7 *
3.1 ± 0.2
17.7 ± 3.8
36.9 ± 10.2
119.8 ± 3.6 *

Stomach (mg)
Liver (mg)
Spleen (mg)
Sem Vesicles (mg)
Testes (mg)
Epdidymal Fat (mg
Tibia Length

250.7 ± 22.7
1007 ± 40.7
60.7 ± 2.2
176.4 ± 11.6
165.8 ± 10.5
237.3 ± 30.3
16.9 ± 0.1

257.6 ± 9.8
970.5 ± 26.9
83.9 ± 16.9
155.0 ± 14.4
168.9± 1.9
237.0 ± 22.3
17.1 ± 0.1

423.9 ± 38.1
1287.3 ± 56.7
344 ± 39.2
131.3 ± 24.0
168.7 ± 11.4
99.1 ± 39.3
16.8 ± 0.1

283.3 ± 21.7*
1039.7 ± 104.9 *
150.7 ± 29.8 *
166.0 ± 18.5
170.5 ± 3.1
202.3 ± 15.0 *
16.9 ± 0.1

B6 Fast and Min Fast groups are the same mice from specific aim 2. Values are means ±
SEM. Age given in weeks (wks). Body weights given in grams BW Change is
determined from BW-Peak BW/Peak BW, Fasting BW Change determined from Pre-Fast
BW-BW @ Sac/Pre-Fast BW. All tissue weights expressed in milligrams (mg). IL-6
values expressed as picograms per milliliter (pg/ml). Fast denotes 12-hour fast during the
12-hour light cycle. Wheel+Fast denotes 4 weeks of wheel access prior to 12-hour fast
during the light cycle.
Min denotes ApcMin/+ mice . B6 denotes C57BL/6 mice
*Significantly different from Fed state within genotype. p<0.05 (students pre-planned ttest within genotype).
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Figure 4.1 Experimental Design and Wheel Running Distance. A) Experimental design
figure depicting 12 hour light cycle fasting protocol and wheel running protocol. B)
Kilometers per week (Km/Week) in B6 and Min mice. C) Average distance (Km/Day) in
B6 wheel and Min wheel mice. * denotes different to B6 wheel. Significance was set at
p<0.05. Students pre-planned t-test.
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Figure 4.2 AMPK Activation in Fasted and Wheel+Fasted Mice. A) Representative
western blots of p-AMPK (T172), p-ACC (S79), ACC, and quantification of blots in B6
Fasted and Wheel+Fasted gastrocnemius muscle. B) Representative western blots of pAMPK (T172), p-ACC (S79), ACC, and quantification of blots in Min Fasted and
Wheel+Fasted gastrocnemius muscle. * denotes different to Fed state. Significance was
set at p<0.05. Students pre-planned t-test.
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Figure 4.3. AMPK Downstream Signaling in Fasted and Wheel+Fasted Cachectic
Skeletal Muscle. A) Representative western blots of p-Raptor (S792), Raptor, p-TSC2
(S1387), TSC2, p-FOXO3a (S413), FOXO3a, p-ULK-1 (S555), ULK-1, and
quantification of blots in B6 Fasted and Wheel+Fasted gastrocnemius muscle. C)
Representative western blots of p-Raptor (S792), Raptor, p-TSC2 (S1387), TSC2, pFOXO3a (S413), FOXO3a, p-ULK-1 (S555), ULK-1, and quantification of blots in Min
Fasted and Wheel+Fasted gastrocnemius muscle. * denotes different to Fed state.
Significance was set at p<0.05. Students pre-planned t-test.
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Figure 4.4. Protein Turnover in Fasted and Wheel+Fasted Cachectic Skeletal Muscle. A)
Representative western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, Puromycin, and
quantification of blots in B6 Fasted and Wheel+Fasted gastrocnemius muscle. C)
Representative western blots of MuRF-1, Atrogin-1, P62, LC3 I/II, Puromycin, and
quantification of blots in Min Fasted and Wheel+Fasted gastrocnemius muscle. * denotes
different to Fed state. Significance was set at p<0.05. Students pre-planned t-test.
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Figure 4.5. Mitochondrial Quality Control in Fasted and Wheel+Fasted Cachectic
Skeletal Muscle. A) Representative western blots of PGC-1, MFN-1, DRP-1, and
quantification of blots in B6 Fasted and Wheel+Fasted gastrocnemius muscle. B) COX
enzyme activity in B6 Fasted and Wheel+Fasted gastrocnemius muscle. C)
Representative western blots of PGC-1, MFN-1, DRP-1, and quantification of blots in
Min Fasted and Wheel+Fasted gastrocnemius muscle. D) COX enzyme activity and
correlation of COX activity to Distance (Km/Day). * denotes different to Fed state.
Significance was set at p<0.05. Students pre-planned t-test. Pearson Correlation where
appropriate.
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CHAPTER 5
OVERALL DISCUSSION

The overall purpose of the current dissertation was to determine if cachexia
associated aberrant AMPK signaling is responsive to fasting, feeding, and increased
wheel running activity to regulate skeletal muscle proteostasis. Our central hypothesis
was that cancer cachexia induces the disruption of AMPK signaling by fasting and
feeding through dysfunctional mitochondrial quality control leading to muscle mass loss.
We also further hypothesized that increased physical activity would improve
mitochondrial quality control and thus improve the regulation of AMPK to fasting and
feeding improving protein turnover and attenuating wasting. Utilizing manipulations of
AMPK signaling in each aim we sought to test our question and hypothesis and
determine the role of AMPK in skeletal muscle protein turnover. Key findings from this
dissertation experiments demonstrated that (1) AMPK is required for the cachexia
suppression of skeletal muscle protein synthesis through TSC2 and Raptor during a short
term fast, however we also demonstrate that AMPK is required for the cachexia induction
of degradation through E3 ligases and autophagy during fasting, and we identify that
AMPK is required for the cachexia disruption of mitochondrial dynamics. (2) Cancer
cachexia accelerates the skeletal muscle physiological fasting response through AMPK, a
short term fast accelerates skeletal muscle protein degradation, suppresses protein
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synthesis, and induces mitochondrial fission protein DRP-1. (3) Refeeding following a
short term fast suppresses AMPK and downstream signaling suggesting that cachectic
skeletal muscle is not anabolic resistant but rather hyper-sensitive to periods of fasting.
(4) 4 weeks of voluntary wheel activity inhibits the fasting induction of AMPK, restores
mitochondrial quality control, and attenuates muscle mass loss in cachectic skeletal
muscle.
5.1 AMPK and Cachexia: Imbalanced Protein Turnover
A negative energy balance, resulting from both reduced production of ATP and
increased energy expenditure is commonplace in cancer patients (Jager et al., 2007;
Kemp et al., 2007; Kjobsted et al., 2018; Koh et al., 2008). The increase of energy
expenditure in cachexia is prevalent in human and pre-clinical cachexia (Brown, RosaCaldwell, Lee, Blackwell, et al., 2017; Sandri, 2016; Tsoli et al., 2014; White, Baynes, et
al., 2011b). The energy sensing molecule adenosine monophosphate protein kinase
AMPK regulates energy metabolism and homeostasis in response to metabolic stressors
such as fasting and exercise (Bujak et al., 2015; Friedrichsen et al., 2013; Kjobsted et al.,
2018).

AMPK is known for facilitating a host of metabolic processes and couples

cellular energy status to protein synthesis.

AMPK activity is disrupted during the

progression of cancer cachexia (Hardee et al., 2017; Sanchez, Csibi, et al., 2012; Sandri,
2016). Multiple pre-clinical models of cachexia demonstrate an elevation of AMPK
activity during the later stages of cachexia (Brown, Rosa-Caldwell, Lee, Blackwell, et al.,
2017; Puppa et al., 2012; Rohm et al., 2016; White, Baynes, et al., 2011a). Often
coinciding with the elevation of AMPK in cachectic muscle is the suppression of protein
synthesis (mTORC1) and acceleration of degradation (E3 ligases and autophagy)
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pathways (Brown, Rosa-Caldwell, Lee, Blackwell, et al., 2017; Puppa et al., 2012; Rohm
et al., 2016; White, Baynes, et al., 2011a). While this induction of AMPK activity has
been established, very little has been done to mechanistically examine the role of AMPK
in the regulation of protein turnover. Our laboratory has previously suggested that
AMPK inhibition in cultured myotubes incubated with IL-6 and LLC media is capable of
restoring mTORC1 and protein synthesis (White, Baynes, et al., 2011b; White, Puppa,
Gao, et al., 2013). However, recent evidence has suggested that the timing of AMPK
activation may contribute to cachexia induced muscle mass loss (Rohm et al., 2016).
Activation of AMPK via AICAR immediately following C26 tumor implantation
attenuated tumor growth and cachexia induce muscle mass loss (Rohm et al., 2016).
Taken together these results although ambivalent, definitively demonstrate a role for
AMPK in the regulation of muscle mass during cancer cachexia. The current dissertation
is the first study to mechanistically examine the cellular processes AMPK regulates in
response to fasting, feeding, and activity during cancer cachexia.
AMPK Regulation of TSC2 and Raptor: Fasting, Feeding, and Activity in Cachexia
An intriguing question among researchers is whether cachectic muscle retains
anabolic plasticity (Hardee et al., 2017). This could prove beneficial for clinicians
looking to provide treatment and improve muscle mass and function in cachectic cancer
patients. While circadian fluctuations in protein turnover are the established norm in
muscle mass regulation, it has become evident that protein synthesis is highly responsive
to environmental stimuli (Chang et al., 2017; Lefta, Wolff, & Esser, 2011). Fasting,
feeding, and activity are extremely potent regulators of skeletal muscle protein synthesis
in basal healthy conditions; however, numerous wasting conditions have demonstrated
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perturbed sensitivity to these anabolic signals (Argiles, Lopez-Soriano, et al., 2015;
Bodine, 2013; Bowen et al., 2015). Short term fasting is a normal physiological process
that often occurs during sleep and contributes to the diurnal variation of protein turnover
(Lefta et al., 2011). Research has demonstrated that short term fasting in normal healthy
skeletal muscle does not activate the AMPK signaling pathway is well tolerated (Bujak et
al., 2015; Canto et al., 2010; Galic et al., 2018). However, our laboratory was one of the
first to suggest that the chronic activation of AMPK may be responsible for the cachexia
disruption of protein synthesis after an acute 5 hour fast (White, Baynes, et al., 2011a).
The current studies demonstrate that the fasting induction TSC2 and Raptor require
AMPK in cachectic skeletal muscle. Furthermore, we demonstrate that cancer cachexia
accelerates the skeletal muscle physiological response to fasting by robustly inducing
AMPK after a mere 12-hour fast during the light cycle.

Min mice that were fasted for

12-hours during the light cycle exhibited a robust activation of both TSC2 and Raptor
phosphorylation by AMPK which were not present in their fed counterparts. The AMPK
phosphorylation of TSC2 and Raptor are believed to serve as a metabolic checkpoint that
shuts off mTORC1 activity (Gwinn et al., 2008).

However, recent evidence has

suggested that the phosphorylation of Raptor and not TSC2 is critical in this process
(Gwinn et al., 2008).
Since cancer cachexia cannot be reversed by conventional nutritional
supplementation, it is also necessary to further our understanding of anabolic resistance
(Bruggeman et al., 2016; Dillon et al., 2012; Hardee et al., 2017). Growing evidence is
supporting the disruption of protein synthesis during cancer cachexia; however, very few
studies have examined if nutrients or feeding can stimulate anabolic signaling (Evans et
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al., 2008; A. M. H. Horstman et al., 2016; Kitagawa, Haji, & Amagai, 2017). We
provide evidence in the current studies that 1-hour of refeeding following a 12-hour short
term fast suppresses AMPK and its phosphorylation of downstream targets TSC2 and
Raptor.

Interestingly, this suppression of AMPK signaling was not reflected in

downstream puromycin incorporation which is indicative of protein synthesis.

The

disparity between the two may be an issue of timing as the refeeding paradigm was only
1 hour. However, it is interesting to speculate how long the suppression of AMPK occurs
for post feeding, the decrease in phosphorylation may only be an acute transient
suppression.

Furthermore, the composition of the food may contribute to protein

synthesis as well, cancer patients are still capable of inducing protein synthesis in
response to protein ingestion however, the degree of activation appears to be severely
impaired (Dillon et al., 2012). A newer approach using specially formulated medical
food that is high in protein and leucine has shown promise in cancer patients with
involuntary weight loss and may be applicable to the current data presented (Deutz et al.,
2011).
Physical activity and exercise have been deemed critical regulators of skeletal
muscle AMPK (Canto & Auwerx, 2009; Z. P. Chen et al., 2000; Friedrichsen et al., 2013;
Laker et al., 2017). Acute exercise has been extensively investigated to induce skeletal
muscle AMPK to compensate for the energy stress (Friedrichsen et al., 2013; Jorgensen
et al., 2005).

Increased physical activity as a treatment modality has become an

important area of interest in cancer cachexia (Alves et al., 2015; Argiles et al., 2012;
Grande et al., 2014).

Numerous studies have investigated the association between

physical activity, developing cancer, and skeletal muscle protein turnover (Ali & Garcia,
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2014; Alves et al., 2015; Argiles et al., 2012; Aversa et al., 2017; Grande et al., 2015;
Hardee et al., 2016; Hardee et al., 2017; Khamoui et al., 2016). Studies and clinical trials
have also suggested that prognosis is improved in physically active cancer patients due to
exercise performed after the cancer diagnosis (Gould et al., 2013; Grande et al., 2015).
Additionally, similar results have been reported in pre-clinical models of cancer cachexia
as well, wheel running activity in C26 cancer mice blocked the induction of AMPK
mediated degradation pathways in gastrocnemius muscle (Pigna et al., 2016b). In the
current study we provide evidence that 4 weeks of voluntary wheel activity prior to
fasting is sufficient to inhibit AMPK phosphorylation and activation of Raptor. These
results also demonstrated that wheel activity blocked the fasting suppression of protein
synthesis. Our laboratory has previously demonstrated that two models of contraction are
capable of suppressing AMPK and inducing protein synthesis in cachectic skeletal
muscle (Puppa, Gao, et al., 2014; White, Baynes, et al., 2011a). Seven bouts of high
frequency electrical stimulation as well as an acute bout of low frequency stimulation
were able to suppress AMPK, restore mitochondrial biogenesis, and induce protein
synthesis in Min and LLC mice (Hardee et al., 2016; Puppa, Murphy, et al., 2014).
AMPK Mediated Protein Degradation in Cachexia
It remains mostly unclear how tumors initiate the signal to stimulate muscle
protein degradation and cachexia.

The often anatomically distant location between

tumors and the wasting muscles are suggestive of tumor derived factors such as cytokines
into circulation to initiate signaling processes that cause muscle wasting (Baracos, 2006a;
Bowen et al., 2015; Johns et al., 2012). A hallmark feature of cancer cachexia is the net
loss of skeletal muscle protein through selective degradation pathways (Penna et al.,
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2014; Pettersen et al., 2017; Tisdale, 2009). A consistent finding that translates from preclinical models to the clinic is the elevation of muscle protein degradation while synthesis
is suppressed (Penna, Ballaro, Beltra, De Lucia, & Costelli, 2018).

While cancer

cachexia may be a multifactorial condition, clear evidence suggest that the ubiquitin
proteasome system and autophagy lysosomal system are major contributors to muscle
mass regulation (Penna, Costamagna, et al., 2013; Sandri, 2016; Yuan et al., 2015).
AMPK is a critical regulator of both the ubiquitin proteasome system through
FOXO3a and the autophagy lysosomal system through ULK-1 (Ju et al., 2016; K.
Nakashima & Yakabe, 2007; Sandri, 2016). Phosphorylation of these two downstream
targets induces both E3 ligases and autophagy indices (Ju et al., 2016; K. Nakashima &
Yakabe, 2007; Sanchez, Csibi, et al., 2012; Sandri, 2010, 2016). Activation of these two
degradation pathways has been studied extensively in catabolic conditions such as fasting
and cachexia and are believed to be key mediators of muscle mass loss (Ju et al., 2016; K.
Nakashima & Yakabe, 2007; Pettersen et al., 2017; Pigna et al., 2016b; Sandri, 2016).
AMPK regulation of FOXO3a and ULK-1 has been demonstrated through loss and gain
of function studies (Sandri et al., 2004). Treatment of mice with AICAR infusion has
demonstrated a robust activation of FOXO3a and E3 ligases Atrogin-1 and MuRF-1
(Sanchez, Csibi, et al., 2012). Multiple pre-clinical models and human cancer patients
have reported elevated E3 ligase expression (Bodine & Baehr, 2014; Bowen et al., 2017;
Mueller et al., 2016b). In addition to E3 ligase expression, the process of autophagy has
recently become a target of interest in cachexia (Penna et al., 2014). Both human cancer
patients and pre-clinical models of cachexia have demonstrated inductions of the
autophagy lysosomal system (Penna, Costamagna, et al., 2013).
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In the current

dissertation we demonstrate that a short term 12-hour fast induces FOXO3a and ULK-1
phosphorylation in Min mice and this induction requires AMPK. The phosphorylation of
these proteins leads to the induction of Atrogin-1, MuRF-1, and LC3B (II/I).
Interestingly, in line with our protein synthesis data described above, re-feeding
following a 12-hour fast suppressed the induction of these proteolytic systems. The
suppression of these signaling processes by re-feeding suggest that despite the failure to
induce protein synthesis, lowering AMPK via re-feeding may alleviate the elevation of
muscle protein degradation acutely. While the fasting induction of these proteins is not a
new concept the current dissertation is the first to report these findings in cachexia and
that acute re-feeding is capable of suppressing that fasting activation. AMPK mediated
protein degradation during a fast in healthy skeletal muscle is typically not activated until
24-48 hours of fasting is achieved (Galic et al., 2018). We demonstrate that cachectic
skeletal muscle induces these pathways after only 12-hours.
Many cancer patients suffer from chronic fatigue, either from the disease itself or
its treatment, which is often a confounder that limits regular exercise practice (Grande et
al., 2015). This lack of physical activity or exercise has been demonstrated to occur in
both the clinic and pre-clinical models (Grande et al., 2015; Roberts et al., 2013). While
the targeting of aberrant protein degradation processes has been suggested as a potential
treatment for cachexia, it is entirely plausible that inhibiting protein degradation could
prove detrimental to systemic metabolism and muscle function (Cohen, Nathan, &
Goldberg, 2015). Furthermore, damaged proteins induced by exercise must be removed
for successful regeneration and muscle function. Muscle protein degradation is stimulated
by both acute endurance and resistance exercise (Vainshtein, Tryon, Pauly, & Hood,
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2015; Wolfe, 2006). In contrast, exercise training can decrease indices of protein
breakdown in muscle, which may be related to improved protein quality in previously
cachectic muscle (Vainshtein et al., 2015). Indeed, voluntary wheel running decreased
muscle E3 ligase mRNA expression and autophagy protein expression in tumor bearing
mice (Pigna et al., 2016b) . In the current studies we demonstrate that 4 weeks of
voluntary wheel activity suppressed the fasting induction of Atrogin-1,MuRF-1, P62 and
LC3B. These results are in line with previous reports demonstrating treadmill exercise
prior to tumor inoculation decreased muscle protein breakdown in rats (Salomao, Toneto,
Silva, & Gomes-Marcondes, 2010). While exercise-induced improvements have not been
observed in all preclinical studies, this could be related to variables such as tumor type or
exercise intensity (Khamoui et al., 2016).
5.2 Mitochondrial Quality Control and AMPK
Mitochondrial respiration and ATP synthesis are intimately linked to cellular
energy utilization (Wai & Langer, 2016).

Protein synthesis is an energy demanding

process and is responsible for approximately 20-30% of ATP consumption (Hardee et al.,
2017). Many non-ribosomal energy-consuming enzymes and kinases are required for the
synthesis, assembly, and maintenance of ribosomes (Kressler et al., 2010a). Collectively,
the energetic cost of protein synthesis implicates mitochondrial function and quality are
important in protein turnover (Carson et al., 2015; Hardee et al., 2017).

AMPK tightly

couples energy consumption to oxidative phosphorylation and protein synthesis
(Kjobsted et al., 2018; Suliman & Piantadosi, 2016). The process of mitochondrial
quality control involves the processes of biogenesis, fission and fusion (dynamics), and
the selective turnover of mitochondria (mitophagy) (Kjobsted et al., 2018; Suliman &
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Piantadosi, 2016; Vitorino et al., 2015; Wai & Langer, 2016). Mitochondrial quality
control has recently become an intriguing therapeutic target of cancer cachexia (Vitorino
et al., 2015). Recent evidence suggest a role for the disruption of these processes in the
regulation of metabolic homeostasis.
Dysfunctional mitochondrial quality control and oxidative metabolism are found
in many diseases and pathological conditions (Argiles, Lopez-Soriano, et al., 2015;
Brown, Rosa-Caldwell, Lee, Blackwell, et al., 2017; Marzetti et al., 2017; Vitorino et al.,
2015; White et al., 2012).

Accelerated protein degradation and suppressed synthesis in

wasting muscle has recently been linked to dysfunctional mitochondrial quality control
and AMPK may be the link between these cellular processes (B. N. VanderVeen, Fix, et
al., 2017). Increased activity and exercise have been well studied as potent stimulators of
mitochondrial quality control and has been studied as a therapeutic for cancer (Alves et
al., 2015; Argiles et al., 2012; Aversa et al., 2017). Endurance training is associated with
increased mitochondrial density and metabolic enzymes in skeletal muscle (Egan &
Zierath, 2013; Forbes et al., 2012; Hood et al., 2015). Exercise improves mitochondrial
function and has the capacity to increase remodeling of the mitochondrial network
through improving dynamics (Fix et al., 2018; Yan et al., 2012). We have previously
reported that activity decreases before bodyweight loss suggesting that a lack of activity
contributes to a disuse type loss of mitochondrial capacity and function in cachexia
(Baltgalvis et al., 2010). These findings suggest a role for increased activity and exercise
as a potential therapy or countermeasure to the cachexia induced muscle mass loss.
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AMPK and PGC-1 in Cachexia: Disconnected?
AMPK is activated during energy stress and will induce mitochondrial biogenesis
and remodeling to meet the demand for ATP (Hood, 2009; Hood et al., 2015; Jorgensen
et al., 2005; Koh et al., 2008).

Mitochondrial biogenesis is modulated by AMPK

through its activation of PGC-1 and is actually required for the induction of the PGC-1
promoter (Penna et al., 2018). Most genes involved in mitochondrial metabolism seem to
be under the control of PGC-1 family of transcription factors (Penna et al., 2018).
Studies utilizing AMPK knockout models have demonstrated a blunted response to
exercise and decreased mitochondrial content (Viollet et al., 2009). Despite the
chronically elevated activation of AMPK in cachectic skeletal muscle PGC-1 is actually
suppressed demonstrating a disconnect between these two signaling molecules (Brown,
Rosa-Caldwell, Lee, Blackwell, et al., 2017; Puppa, Gao, et al., 2014; Puppa et al., 2012;
White, Baltgalvis, et al., 2011). Furthermore, our laboratory has previously reported that
cachectic skeletal muscle has depleted mitochondrial number and citrate synthase activity
(Puppa et al., 2012; White, Baltgalvis, et al., 2011). The loss of mitochondria and lack of
biogenesis in cachectic skeletal muscle has recently been determined to occur prior to
bodyweight loss in LLC tumor bearing mice (Brown, Rosa-Caldwell, Lee, Blackwell, et
al., 2017).

The use of contraction models using electrical stimulation have been

employed by our laboratory previously and have proven effective at inducing PGC-1
protein expression as well as cytochrome C oxidase (COX) activity (Hardee et al., 2016;
Puppa, Murphy, et al., 2014).

In the current dissertation we demonstrate that the
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cachexia suppression of PGC-1 does not require AMPK. These results are not unexpected given that there appears to be a disconnect between AMPK activation and PGC1 in cachectic skeletal muscle.

However, we also demonstrate that 4 weeks of

voluntary wheel running activity is able to restore AMPK phosphorylation to basal levels
following a fast and induce PGC-1 protein expression and COX activity in Min mice.
The induction of mitochondrial biogenesis and content in cachectic skeletal muscle may
serve to alleviate the energy stress induced by fasting and alleviate AMPK activation
restoring protein synthesis and attenuating degradation. Collectively these results in
context with previous literature in the field suggest that increased wheel running activity
improves mitochondrial quality control, thus alleviating the activation of AMPK during a
short term fast and attenuating dysfunctional protein turnover in cachectic skeletal
muscle.
AMPK and Mitochondrial Dynamics
Different mitochondrial morphologies have been proposed to modulate oxidative
metabolism (Wai & Langer, 2016). Elongated mitochondria have been proposed to
sustain ATP production during stress whereas fragmented mitochondria are believed to
facilitate mitophagy and turnover of damaged mitochondria (Trewin, Berry, &
Wojtovich, 2018). Recent evidence has come to light highlighting AMPK as a potential
regulator of these processes (especially fission) (Z. Chen et al., 2019). Studies suggest
that the process of mitochondrial fission induced atrophy is modulated through AMPK
mediated FOXO3a signaling (Romanello et al., 2010). Myofibers transfected with a
dominant negative AMPK inhibited the fasting induction of fission proteins DRP-1 and
FIS-1 and spared muscle mass (Romanello et al., 2010). Coinciding with the activation
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of AMPK in cachectic skeletal muscle is the induction of fission and suppression of
fusion proteins (White et al., 2012). Our laboratory has previously demonstrated that
suppressing the cachexia activation of AMPK through inhibiting IL-6 attenuated the
induction of mitochondrial fission and restored fusion to basal levels in-vivo and in-vitro
(White et al., 2012). While recent studies have shown a direct link to mitochondrial
fission and AMPK in catabolic conditions such as fasting, disuse, and cachexia very little
has actually examined mitochondrial fusion (Iqbal, Ostojic, Singh, Joseph, & Hood,
2013; Jheng et al., 2012; White et al., 2012). One recent study suggests a role for MFN-2
in the regulation of muscle mass in cachectic cancer patients and mice (Xi et al., 2016).
There are conflicting reports of AMPK regulating mitochondrial fusion proteins, some
suggest a potential link however, a phosphoproteomic study demonstrated that AMPK
did not interact with any known mitochondrial fusion protein but was responsible for
fission in fasting conditions (Z. Chen et al., 2019; Toyama et al., 2016). However, in
non-muscle cells a recent study suggest that AMPK activation of fusion prevented drug
induced mitochondrial damage (Kang et al., 2016). The activation of mitochondrial
fission by AMPK under energy stress classically serves to induce autophagy/mitophagy
processes and activate biogenesis to replace the damaged mitochondria (Z. Chen et al.,
2019; Toyama et al., 2016).

In cachectic skeletal muscle biogenesis is suppressed

suggesting a net loss of mitochondria and a constant energetic stress that may explain
why AMPK and fission are chronically elevated. In the current studies we provide
evidence that the cachexia suppression of MFN-1 and induction of DRP-1 require AMPK
following a short term physiological fast. Unexpectedly, we also report that MFN-1 is
induced 8 fold by re-feeding following a short term fast in both B6 and Min mice. The
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induction of MFN-1 in Min mice by re-feeding occurred simultaneously with a
suppression of AMPK suggesting MFN-1 is a target of AMPK however, whether this is
direct or in-direct requires further investigation. Interestingly, DRP-1 was not altered by
re-feeding in Min mice despite the AMPK suppression. In accordance with previously
reported literature we also demonstrate that 4 weeks of wheel activity prior to fasting
induced mitochondrial fission and fusion in B6 and Min mice. These changes coincided
with a suppression of AMPK activation when compared to fasted Min mice alone and
suggest that the restoration of mitochondrial quality control proteins improves the
cachectic skeletal muscles ability to cope with a short term fast and as mentioned
previously above restore protein turnover.
5.3 Overall Summary
Cachexia is a multifactorial syndrome that is associated with multiple systemic
disruptions such as chronic inflammation, anemia, and insulin resistance that can impact
muscle mass and metabolism (Argiles, Busquets, Stemmler, & Lopez-Soriano, 2014;
Baracos et al., 2018). AMPK is often deemed as a cellular fuel gauge that modulates
metabolism and protein turnover (Koh et al., 2008).

AMPK is supposed to stimulate

ATP synthesis while concurrently suppressing ATP consumption (Kjobsted et al., 2018).
Thus, AMPK has been implicated in the regulation of mTORC1, E3 ligases, and
autophagy/mitophagy (Carson et al., 2015; Hardee et al., 2017). Dysfunctional AMPK
signaling is a common hallmark of cancer cachexia and is indicative of energetic stress
(Brown, Rosa-Caldwell, Lee, Blackwell, et al., 2017; Puppa et al., 2012; Rohm et al.,
2016; Sandri, 2016; White, Baynes, et al., 2011b). Often coinciding with the elevation of
AMPK in cachexia is the suppression of muscle protein synthesis and induction of
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degradation (White, Baynes, et al., 2011b; White, Puppa, Gao, et al., 2013). These
processes make up muscle proteostasis and are important for the regulation of skeletal
muscle mass (Sanchez, Candau, et al., 2012; Sandri, 2016). The purpose of the current
dissertation was to investigate if cachexia associated aberrant AMPK signaling is
responsive to fasting, feeding, and increased wheel running activity to regulate skeletal
muscle proteostasis.
Healthy mitochondria are essential for metabolism and what is commonly referred
to as substrate flexibility. The concept of substrate flexibility is the ability of a tissue to
freely switch substrates in order to generate ATP and restore metabolic homeostasis.
Failure to do this results in energy stress and deficiency that can lead to disrupted
metabolism and the activation of proteolytic pathways. Catabolic conditions such as
fasting have been long studied as a classical activator of AMPK and its induction of
protein degradation however, very little has been done to investigate fasting in cachexia
(Bagherniya et al., 2018; Canto et al., 2010). Classically, under metabolic stress such as
exercise or fasting where carbohydrates are depleted, metabolism will switch to utilizing
lipids as fuel to generate ATP. This process is controlled by AMPK and its activation of
ACC which then signals to initiate lipolysis and subsequently beta oxidation in the
mitochondria. It is reasonable to suggest that in tumor bearing mice where mitochondrial
quality control is disrupted that an acute fast could exacerbate the lack of substrate
flexibility and lead to metabolic disruption. In the current study we provide evidence that
AMPK activation during an acute fast in Min mice may be due to a lack of substrate
flexibility. The activation of AMPK in Min mice by an acute fast is coupled with
disrupted fusion, fission, and biogenesis.

Fasting has recently been suggested as a
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method to improve the response to chemotherapeutics in non-cachectic cancer patients
however, our current results demonstrate that cachectic skeletal is hyper-sensitive to
periods of short fasting (Brandhorst & Longo, 2016). In the current series of studies, we
identify that cancer accelerates the fasting activation of AMPK signaling and induces
muscle protein degradation. Furthermore, we identify that AMPK is required for the
fasting induction of protein degradation in tumor bearing mouse skeletal muscle.
An important question that has come to the forefront of cachexia is whether
skeletal muscle retains its anabolic plasticity to respond to nutrients and activity/exercise.
Studies in cachectic cancer patients have demonstrated that the response to nutrients and
exercise are often blunted and require a potent stimulus to override the block of protein
synthesis (A. M. H. Horstman et al., 2016; K. Nakashima et al., 2006; Rennie et al.,
1982). Furthermore, the use of increased physical activity as a therapeutic to improve
mitochondrial quality control and protein synthesis has recently been suggested (Hardee
et al., 2017; B. N. VanderVeen, Hardee, et al., 2017).

We provide evidence that

cachectic skeletal muscle responds to re-feeding following a fast by suppressing AMPK
mediated degradation but fails to induce protein synthesis. These results suggest that an
acute fast sensitizes skeletal muscle AMPK signaling to re-feeding and the influx of
nutrients.

Additionally, we also provide evidence that increased activity via wheel

running suppresses the fasting induction of AMPK in cachectic skeletal muscle restoring
mitochondrial quality control, protein turnover, and attenuating muscle mass loss. These
results suggest that modulating AMPK through increased physical activity alleviates the
fasting disruption of mitochondrial quality control and muscle protein turnover and in
cachectic skeletal muscle.
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Taken collectively the current series of studies provides evidence that AMPK is a
critical modulator of skeletal muscle protein turnover and metabolism in cachectic
skeletal muscle. Previous reports from our laboratory have suggested the disruption of
AMPK during cachexia however, the current dissertation mechanistically examines
AMPK’s regulation of protein turnover and mitochondrial quality. The use of our muscle
specific knockout model identified targets of regulation by AMPK in cachexia and
fasting and spared gastrocnemius muscle mass.

Additionally, we provide evidence that

cachectic skeletal muscle has altered sensitivity to fasting and feeding and their roles in
regulating protein turnover through the AMPK signaling pathway.

Finally, we

demonstrate that increased physical activity in cachectic mice alleviates aberrant AMPK
signaling and restores mitochondrial quality control. The restoration of mitochondrial
quality control may serve to improve the physiological response to short term fasting and
attenuate disrupted proteostasis attenuating muscle mass loss . Overall, we identify
AMPK as a potential therapeutic target for cancer cachexia and the regulation of
proteostasis.

Modu

lating AMPK activity through interventions such as increased

physical activity and exercise training could prove beneficial in the preservation of
muscle mass through restoring mitochondrial quality control.
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APPENDIX A
DETAILED PROTOCOLS
Tissue Homogenization
1. Materials and Reagents
a. Mueller Buffer

Mueller Buffer
HEPES
Triton-X100
EGTA (pH 8.0)
EDTA (pH 8.0)
Na4P2O7
β-glycerophosphate
NaF
NaVO4
dH2O
Protease Inhibitor
b. Mueller Diluent:

Mueller Diluent
Glycerol
Na4P2O7
EGTA (pH 8.0)
β-mercaptoethanol
Protease Inhibitor

Stock
Desired
Volume of stock
Solution Concentration
needed(ul)
500mM
100%
500mM
500mM
100mM
2M
500mM
1M
-

50mM
0.10%
4mM
10mM
15mM
100mM
25mM
5mM
-

600
6
48
120
900
300
300
50
3585
60

Stock
Desired
Volume of stock
Solution Concentration
needed (ul)
100%
50%
1500
100mM
50mM
1500
500mM
2.5mM
15
500mM
1mM
6
30

2. Procedure
a. Weigh out the samples to be used and place weighted portion into an
Eppendorf tube labeled with the sample and M.
b. Add 10ul/mg tissue of Mueller buffer to the homogenization tube and add
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sample.
c. Homogenize in glass on glass tissue homogenizer keeping the sample in
ice while homogenizing. (homogenize ~30s check sample repeat if
needed)
d. Wash glass tissue homogenizer 3 times by dH2O between two samples.
e. Transfer tissue homogenate back to Eppendorf tube.
f. Spin samples at 13,000rpm for 10min at 4°C.
g. Transfer supernatant to clean Eppendorf tube labeled with sample and
D, discard the pellet.
h. Add 5ul/mg tissue of Diluent buffer to the D tube and vortex.
i. Run protein assay (Bradford).
j. Dilute samples down to a working concentration in a new tube labeled
with the sample and the working concentration. Keep both D tube and
diluted samples in -80°C.

Protein Assay (Bradford)
1. Materials and Reagents
a. Bradford Reagent (Bio-Rad, Catalog #: 5000006)
b. Make a stock of 1mg/ml BSA in PBS, store aliquot in -20°C.
c. Costar 96 well plate
2. Procedure
a. In a clear flat bottom 96 well plate create a standard curve with the
1ug/ul BSA solution from 0-14ug in duplicate or triplicate
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b. Dilute samples 1:5 in a new tube with water (5ul sample: 20ul dH20)
c. Add 5ul of the diluted samples to the wells of the plate being sure to run
them in duplicate or triplicate
d. Make a 1:5 dilution of Bradford reagent. You will need enough for
300ul/well. Be sure to clean the glassware well before you use it with
soap and water.
e. Add 300ul of diluted Bradford reagent to each well.
f. Let sit in dark drawer for 15 minutes
g. Read in plate reader at 595nm
h. Calculate protein concentration based on standard curve
i. Create curve being sure to subtract out the zero value from both curve and
samples.
j. Calculate protein concentration using y=mx+b equation (sample =
con*slope + intercept -> con=(sample-intercept)/slope)

SDS-PAGE/Western Blot
1. Materials and Reagents
a. Acrylamide Solution (38.5% Acrylamide + 1% Bis-Acrylamide) 1.5M
Tris-HCL, pH 8.8
b. 1.0M Tris-HCL, pH 6.8
c. 10% SDS
d. 10% APS
e. TEMED
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f. 4×SDS Loading Buffer: 200 mM Tris-Cl (pH 6.8), 400 mM DTT, 8%
SDS, 0.4% bromophenol blue, 40% glycerol
g. SDS Running Buffer: 25mM Tris, 200mM Glycine, 0.1% SDS Protein
Ladder (Bio-Rad, Catalog #: 1610373)
h. Transfer Buffer: 25mM Tris, 200mM Glycine, 20% Methanol 1×TBST:
50 mM Tris-Cl, 150 mM NaCl, 0.1% Tween-20 5% milk (solved in
1×TBST)
i. ECL plus (Thermo Scientific, Catalog #: 1610373)
2. Procedure – SDS-PAGE
a. Make gel. Base the % off of what molecular weight the protein of interest
is.
b. Prepare samples
c. Pipette desired amount of protein into Eppendorf tube
d. Add correct volume of 4 × SDS loading dye
e. Vortex and do a quick spin
f. Heat in heat block at 100°C or in boiling water for 5 minutes
g. Quick spin
h. Load 4ul of protein ladder to the 1st lane in the gel
i. Load all of sample on gel
j. Run gel at 200V for ~1h or until samples have run
through the gel
3. Procedure – Transfer
a. Prepare 750ml of transfer buffer

205

b. Prepare membrane by placing in a small amount of methanol for 1 minute
c. Pour methanol into the transfer buffer and wash membranes with the
transfer buffer
d. Set up the transfer with the black side of the holder facing down, sponge,
blotting paper, gel, membrane (be sure there are absolutely no bubbles
between the gel and the membrane), blotting paper, sponge, white/clear
side.
e. Carefully close the sandwich and place in the transfer box black side to
black side and clear side facing the red side of the transfer box.
f. Place ice pack in the box and pour remaining transfer buffer into the box.
g. Transfer either overnight at 70mA or for 200min at 200mA making sure
to pack well with ice.
4. Procedure – Probing
a. Prepare 5% milk in 1×TBST solution
b. Remove membrane from transfer and place in ponceau solution for 3-5
minute
c. Rinse off excess ponceau with dH2O and place membrane in plastic sheet
and scan into computer
d. Wash off ponceau with 1×TBST
e. Block the membrane for 1h in 5% TBST milk solution (made in step 13)
f. Incubate in primary antibody in milk solution
g. Wash membranes 3× with 1×TBST for 5 minutes each
h. Incubate in secondary antibody in milk solution for 1 hour
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i. Wash membranes 3× with 1×TBST for 5 minutes each
j. Develop with ECL or ECL quantum.
Cytochrome C Oxidase Activity
1. Materials and Reagents
a. 20 mM KCN; MW= 65.12, 13.02 mg/10 ml dH2O
b. 100 mM KPO4 Buffer (pH 7)
1. 0.1 M KH2PO4 (pH 5)
2. 0.1 M K2HPO4.3H2O (pH 8)
c. 10 mM K-Phosphate Buffer
d. Extraction Buffer (100 mM Na-K-Phosphate, 2 mM EDTA; pH 7.2)
1. 500 ml 0.1 M Na2HPO4. 2H2O;
1. 8.9 g sodium phosphate with 0.372 g EDTA up to 500 ml
2. 200 ml 0.1 M KH2PO4
1. 2.7 g potassium phosphate with 0.149 g EDTA up to 200
ml.
3. combine both solutions and pH to 7.2
e. Test Solution (reduced cytochrome c, 2 mg/ml), for 10 ml (enough for 36
microplate wells);
1. 20 mg of horse heart cytochrome c (Sigma, C-2506) in a
scintillation vial
2. add 1 ml of 10 mM KPO4 buffer and dissolve cytochrome c
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3. make up a small volume of 10 mg/ml sodium dithionite-10 mM
KPO4 stock solution (make fresh each experiment and use within
twenty minutes)
4. add 40 μl of the dithionite stock solution to the test solution and
observe red-orange colour change
5. add 8 ml of ddH2O
6. add 1 ml of 100 mM KPO4 buffer.
2. Procedure
a. Place powdered muscle samples in liquid N2.
b. Add 50 μl of extraction Buffer to 1.5 ml Eppendorf tubes in the aluminium
block on ice. (One Eppendorf per sample).
c. Add 5-7.5 mg tissue to each tube, recording exact tissue mass. Mix by
tapping.
d. Add the volume of Extraction Buffer required to obtain a 20-fold dilution.
e. Add a stir bar and mix for 15 min. Make up Test Solution during this time
and wrap in foil.
f. Sonicate each tube 3 x 3 seconds, cleaning the probe between samples.
g. Pipette some of 20-fold sample extract into new Eppendorf tube and add
volume of Extraction Buffer required to obtain an 80-fold dilution. (eg. 50
μl of 20-fold extract + 150 μl Ext. Buffer = 200 μl of 80-fold sample
extract).

Keep 80-fold sample extract tube on ice for duration of

experiment
h. Add 270 μl of Test Solution into 4-8 wells of 96-well microplate and
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incubate at 30°C for 10 minutes to stabilize the temperature and
absorbance.
i. Open KC4 plate reader program (on Triton). Select CONTROL icon, then
PRE-HEATING tab, enter 30°C and select ON. (Do not run assay until
KC4 temperature has reached 30°C.)
j. Select WIZARD icon, then READING PARAMETERS icon.
1. Select Kinetic for Reading Type.
2. Select Absorbance for Reader and 550 nm for wavelength (dropdown menu).
3. Select Sweep for Read Mode.
4. Select 96 Well Plate (default) for Plate Type.
5. Enter first and last well to be read (eg. A1 and A4 if reading 4
samples simultaneously).
6. Select Yes and Pre-heating and enter 30 for Temperature
Control.
7. For Shaking enter 0 for both intensity and duration (shaking is
not necessary, and it will delay the first reading).
8. Do not select either of the two options for Pre-reading.
9. Click on the KINETIC… rectangular tile to open the Kinetic
window.
10. Enter run time (1 minute is recommended) and select
MINIMUM for Interval time (under these conditions the
minimum Interval time should be 3 seconds).
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11. Select Allow Well Zoom During Read to see data in real time
(optional).
12. Under Scales, checkmarks should appear for both Auto check
boxes. Do not select Individual Well Auto Scaling.
13. Press OK to return to Reading Parameters window. Press OK to
return to Wizard window. Press OK. Do not save the protocols
k. Set the multipipette to 250 μl and secure 4-8 yellow tips on the white
projections (make sure they are on tight and all at the same height).
l. In a second, clean 96 well plate, pipette samples into 4-8 empty wells
(start with A1). Recommended volumes: 30 μl of 80-fold extract for
Mixed Gastroc, 10 μl for Heart. Adjust volumes according to oxidative
capacity of the tissue. (eg. 25 μl for Red Gastrocnemius and 35 μl for
White Gastrocnemius).
m. Remove microplate with Test Solution in 4-8 wells from the incubator (as
long as it has been incubating for 10 minutes). Place this plate beside the
plate with the sample extracts in it.
n. On KC4 program, select the READ icon and press the START READING
icon, then press the READ PLATE button. A box will appear that says,
“Insert plate and start reading”. Do not press OK yet but move the mouse
so that the cursor hovers over the OK button.
o. Using the multipipette (set to 250 μl) carefully draw up the Test Solution.
Make sure the volume is equal in all the pipette tips, and that no
significant air bubbles have entered any of the tips.
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p. Pipette the Test Solution into the wells with the sample extracts (the
second plate). As soon as all the Test Solution has been expelled from the
tips (do not wait for the second push from the multipipette), place the plate
onto the tray of the plate reader and with the other hand on the mouse,
press the OK button. (Speed at this point is paramount, as there is an
unavoidable latency period between the time of pressing the OK button
and the time of the first reading.)
q. If desired, add 5 μl KCN to one of the wells to measure any absorbance
changes in the presence of the CYTOX inhibitor.
r. Once reading is complete, hold the CTRL key on the keyboard, and use
the mouse to click once on each of the squares corresponding to a well that
had sample in it. Once all the desired wells have been highlighted by a
black square (up to a maximum of 8 wells), let go of the CTRL key and a
large graph will appear with lines on it representing each sample.
s. To obtain the rate of change of absorbance over different time periods,
select Options and enter the amount of time for which you would like a
rate of change of absorbance to be calculated. The graph, along with one
rate (at whichever time interval is selected) for each sample can be printed
on a single sheet of paper, and the results can be saved.
t. The delta absorbance will appear in units of mOD/min and the number
given will be negative. Convert this to OD/min by dividing by 1000 and
omit the negative sign in the calculation.
mOD/mn, then use 0.395 OD/min
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(eg. if Mean V: -394.8
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2.1 Specific Aims
Cancer Cachexia
Cancer-induced cachexia is a wasting syndrome that occurs in approximately 80%
of all cancer patients and results in 30% of deaths (Argiles et al., 2010; Narsale &
Carson, 2014; Puppa et al., 2012). Cancer-induced cachexia is a debilitating disease that
diminishes quality of life due to severe loss of skeletal muscle mass and function
(Baracos, 2011, 2013; Baracos et al., 2018). There are currently no approved therapeutic
approaches for cancer-induced cachexia, therefore it is necessary to elucidate key
underlying factors and processes as potential therapeutic targets. Skeletal muscle wasting
during cancer cachexia occurs through altered protein turnover (suppressed anabolic
signaling/increased degradation) (Aversa, Pin, Lucia, Penna, Verzaro, Fazi, Colasante,
Tirone, Fanelli, et al., 2016; Baracos, 2000). Our laboratory and others have
demonstrated suppressed anabolic signaling through mechanistic target of rapamycin
(mTORC1) and the induction of muscle protein degradation in pre-clinical models of
cancer cachexia (White, Puppa, Gao, et al., 2013). Coinciding with the suppression of
mTORC1 signaling is the chronic activation of the adenosine monophosphate protein
kinase (AMPK) (White, Puppa, Gao, et al., 2013). AMPK has been deemed a critical
regulator of skeletal muscle degradation through the regulation E3 ligases and the process
of autophagy, defined as the removal of organelles and protein aggregates through the
lysosomal proteasome system (Lira et al., 2013). While altered protein turnover has been
well characterized in the cachectic skeletal muscle of tumor bearing mice, less is
understood about the role of AMPK in this process.
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AMPK – The Checkpoint of Protein Metabolism
Skeletal muscle proteostasis fluctuates diurnally depending on different fasting
and feeding durations as well as in response to activity and exercise stimuli. Adequate
nutrient availability is key in the net loss and gain of skeletal muscle protein. AMPK is a
nutrient sensitive energy sensor and is essential for skeletal muscle metabolic
homeostasis (Romanello et al., 2010; Romanello & Sandri, 2015).

AMPK may be

capable of being activated by many different stimuli as well as diseases such as cancer
cachexia. During severe cancer cachexia, skeletal muscle AMPK is dysregulated and
chronically activated which could have dire consequences regarding muscle proteostasis.
The most widely investigated activators of skeletal muscle AMPK is the process of
prolonged energy deficiency (fasting).

While fasting has been proposed to have

beneficial effects in regard to aging and some cancers, less is understood about its role in
cancer cachexia and the regulation of muscle proteostasis. Exercise or increased physical
activity has been demonstrated to induce AMPK in a dose/intensity dependent manner
and stimulate mitochondrial biogenesis and glucose uptake by skeletal muscle. However,
less is understood about the role of exercise training or chronic increased activity in the
regulation of AMPK, especially in diseased states such as cancer cachexia.

Our

laboratory has previously demonstrated that both treadmill exercise training and electrical
stimulation (contraction) actually attenuate the chronic cachexia activation of AMPK and
improve indices of mitochondrial quality control.
AMPK has long been established as a critical regulator of both protein synthesis
and protein degradation. AMPK exerts its regulation the process of muscle protein
synthesis through two inhibitory phosphorylation events. When activated, AMPK will
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phosphorylate tuberous sclerosis protein 2 (TSC2) and raptor which inhibit mTORC1
activity. Inhibition of mTORC1 activates 4EBP1 and inhibits P70S6K, thus inhibiting
the initiation of translation and ribosomal proteins.

In addition to suppressing protein

synthesis AMPK also controls degradation through the activation of its direct
downstream targets ULK-1 and FOXO3a.

Activation of these targets through

phosphorylation induces both the ATP-independent autophagy lysosomal proteasome and
the ATP-dependent ubiquitin proteasome respectively (FOXO3a is capable of regulating
both degradation systems). The degradation of proteins through the ubiquitin proteasome
is a highly coordinated process and in skeletal muscle utilizes the muscle specific E3
ligases Atrogin-1 and MuRF-1 which are controlled upstream by FOXO3a and were
discovered initially through the studies examining starvation and fasting conditions.
These E3 ligases allow for targeted proteins to be recognized by the 26S proteasome and
ensure specificity of the UPS and additional adaptor proteins(Murton et al., 2008). The
process of autophagy is induced through the AMPK activation of ULK-1 and has been
extensively investigated with numerous catabolic conditions including fasting (Yan et al.,
2012). Autophagy is a highly conserved cellular degradation pathway that can be initiated
selectively and non-selectively by sequestering cytosolic substrates within a phagophore
which is then conjugated with ubiquitination-linked proteins and degraded by a lysosome
(Sanchez, Csibi, et al., 2012; Vainshtein & Hood, 2015).
Conversely, a common suppressor of AMPK is nutrient stimulation through the
consumption of glucose, a mixed meal (feeding), or amino acids (Koh et al., 2008; Long
& Zierath, 2006). Feeding has been widely investigated as a regulator of mTORC1 and
AMPK. The consumption of glucose or a mixed meal will induce a glucose and insulin
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response activating the IGF-1/AKT signaling cascade(Sengupta et al., 2010). AKT will
then phosphorylate TSC2 releasing its inhibition of mTORC1(Sengupta et al., 2010).
Both AMPK and mTORC1 are energy sensing kinases and regulate one another through
pathway cross talk. AMPK and mTORC1 negatively regulate one another, for example
during energy demand AMPK is activated thereby suppressing energy consuming
pathways (mTORC1) (Koh et al., 2008; Long & Zierath, 2006; Sanchez, Csibi, et al.,
2012). Muscle mTORC1 signaling is activated with both exercise and feeding and will
phosphorylate ULK-1 at Ser 757 and inhibit the ULK-1 activation of downstream
autophagy signaling (Laker et al., 2017; Sanchez, Csibi, et al., 2012). To date, our lab and
others have demonstrated that the cachectic environment elevates skeletal muscle AMPK
following a 5 hour fast, showing that a very short period of fasting is capable of inducing
AMPK in the cancer environment, suggestive of metabolic dysregulation (Penna et al.,
2010; White, Baynes, et al., 2011a; White, Puppa, Gao, et al., 2013). Concomitant with
the induction of AMPK, our laboratory has demonstrated mTORC1 suppression during
cancer cachexia, signifying a role for AMPK in the suppression of anabolic signaling
(Hardee et al., 2018; Hardee et al., 2016; White, Puppa, Gao, et al., 2013). Furthermore,
preliminary data from our laboratory suggests that the cachexia-related metabolic
dysfunction sensitizes skeletal muscle response to fasting. While the chronic activation of
AMPK and its potential role in anabolic suppression has been examined in detail, the role
of this signaling axis in the regulation of protein turnover (synthesis and degradation
through UPS and autophagy) is poorly understood in the skeletal muscle of cachectic
mice. Moreover, given the sensitivity of this pathway to nutrient availability, further
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investigation is warranted to elucidate if the feeding regulation of autophagy is disrupted
in the cancer environment.
Purpose and Hypothesis
The long-term goal of this research proposal is to establish AMPK’s role in the
regulation of skeletal muscle mass during cancer cachexia. The purpose of the current
proposal is to determine if cachexia associated aberrant AMPK signaling is responsive to
fasting, feeding, and increased wheel running activity to regulate skeletal muscle
proteostasis. Our central hypothesis is that the cachexia activation of AMPK alters the
skeletal muscle response to fasting, feeding, and voluntary wheel activity in a phenotype
specific way through the acceleration protein degradation while suppressing synthesis.
Specific Aims
Using preclinical models of cancer cachexia and manipulations of the AMPK signaling
pathway, we plant to test our hypothesis using the following 3 specific aims:
Specific Aim 1: Determine if downstream AMPK signaling is necessary for muscle
protein turnover in cachectic skeletal muscle.
Specific Aim 2: Determine if cancer cachexia disrupts the physiological regulation of
AMPK signaling by fasting/feeding in skeletal muscle.
Specific Aim 3: Determine if 4 weeks of voluntary wheel running activity regulates
aberrant AMPK signaling in response to physiological fasting during cancer
cachexia.
While the suppression of anabolic signaling and the activation of AMPK has been
established in cachectic skeletal muscle, less is known about how AMPK mechanistically
regulates total protein turnover during cancer cachexia and if these effects are dependent
on muscle phenotype. Significant gaps remain in our understanding of the cachexia
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induced activation of AMPK, whether AMPK is necessary for the attenuation of muscle
mass loss remains to be elucidated.

The results from these studies will provide

mechanistic insight into the AMPK regulation of muscle during cancer cachexia and
provide new potential mechanisms and therapeutic targets to further the cachexia field.
Specific Aim 1: Determine if downstream AMPK signaling is necessary for muscle
protein turnover in oxidative and glycolytic cachectic skeletal muscle.
Aim 1.1: Determine the role of AMPK in the cancer cachexia regulation of TSC2
and raptor mediated skeletal muscle protein synthesis.
Aim1.2: Determine the role of AMPK in the cancer cachexia regulation of ULK-1
and FOXO3 mediated skeletal muscle degradation through autophagy and E3
ligase expression.
Aim 1.3: Determine the role AMPK in the cancer cachexia regulation of skeletal
muscle mitochondrial quality control processes of biogenesis, fission, and fusion.
Specific Aim 2: Determine if cancer cachexia disrupts the physiological regulation of
AMPK signaling by fasting/feeding in oxidative and glycolytic skeletal muscle.
Aim 2.1: Determine the effect of fasting and re-feeding on the cachexia regulation
of protein synthesis via AMPK signaling and downstream targets TSC2 and
raptor.
Aim 2.2: Determine the effect of fasting and re-feeding on the cachexia regulation
of AMPK degradation targets ULK-1 and FOXO3 and their downstream
processes of autophagy and E3 ligase expression.
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Aim 2.3:

Determine the effect of fasting and re-feeding on the cachexia

regulation of AMPK mediated mitochondrial quality control processes biogenesis,
fission, and fusion.
Specific Aim 3: Determine if in oxidative and glycolytic cachectic skeletal muscle, 4
weeks of voluntary wheel running activity regulates aberrant AMPK signaling in
response to physiological fasting.
Aim 3.1: Determine if 4 weeks of voluntary wheel running activity regulates the
cachexia disruption of AMPK signaling and downstream targets TSC2, raptor,
and muscle protein synthesis in response to a physiological fast.
Aim 3.3: Determine if 4 weeks of voluntary wheel running activity regulates the
cachexia disruption of AMPK downstream degradation targets ULK-1, FOXO3 in
response to a physiological fast.
Aim 3.4: Determine if 4 weeks of voluntary wheel running activity regulates the
cachexia disruption of AMPK mediated mitochondrial quality control processes
biogenesis, fission, and fusion in response to a physiological fast
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Proposed Working Model

Figure B.1. Proposed working model of AMPK regulation of proteostasis during cancer
cachexia. The overall purpose of the study is to determine the role of AMPK in the
disruption of protein turnover during cancer cachexia. Our central hypothesis is that the
cachexia activation of AMPK alters the skeletal muscle response to fasting, feeding, and
voluntary wheel activity in a phenotype specific way through the acceleration protein
degradation while suppressing synthesis. Specific aim 1 will determine if downstream
AMPK signaling is necessary for muscle protein turnover in oxidative and glycolytic
cachectic skeletal muscle. Specific aim 2 will determine if cancer cachexia disrupts the
physiological regulation of AMPK signaling by fasting/feeding in oxidative and
glycolytic skeletal muscle.. Specific aim 3 will determine if in oxidative and glycolytic
cachectic skeletal muscle, 4 weeks of voluntary wheel running activity regulates aberrant
AMPK signaling in response to physiological fasting..
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2.2 Preliminary Data
AMPK Regulation of Anabolic Signaling in ApcMin/+ Mice
Our laboratory has published extensively utilizing the ApcMin/+ mouse model of
cancer cachexia(Puppa et al., 2012; White, Baynes, et al., 2011a). The cachexia induced
activation of AMPK has been demonstrated by our laboratory to occur during chronic
inflammation and the progression of cancer cachexia. While our laboratories initial
studies demonstrated a role for AMPK in the regulation muscle protein turnover, there
has not been any further mechanistic examination of this signaling process.

The

activation of AMPK during cachexia suppresses basal muscle protein synthesis through
inhibition of mTORC1 signaling. Our research group has demonstrated that this chronic
activation of AMPK can be attenuated utilizing an IL-6 receptor antibody and an acute
injection of glucose (nutrients) (White, Baynes, et al., 2011a). However, these studies
did not detect a change in total muscle protein synthesis. The cancer cachexia field has
continually measured AMPK in many pre-clinical models but has yet to establish its true
regulatory role in skeletal muscle protein turnover.
In many models that have impaired anabolic signaling such as cancer cachexia,
there is often an induction of AMPK activation (Brown, Rosa-Caldwell, Lee, Blackwell,
et al., 2017; Puppa, Gao, et al., 2014; White, Puppa, Gao, et al., 2013). These results
suggest that mTORC1 is an essential part of normal ATP production and its disruption
induces energetic stress and AMPK activity (Brown, Rosa-Caldwell, Lee, Blackwell, et
al., 2017). The suppression of AMPK in P70S6 kinase deficient myotubes has been
demonstrated to rescue myotube size and protein synthesis signaling further
demonstrating a role for AMPK in the regulation of anabolic dependent signaling
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processes (White, Puppa, Gao, et al., 2013). Studies have also demonstrated that the
constant infusion of AICAR suppresses P70S6 kinase activation leading to suppressed
synthesis rates (Suwa et al., 2003). This suppression is directly correlated to the chronic
activation of AMPK (Suwa et al., 2003). Conversely, activation of mTORC1 in AMPK
deficient myotubes has been demonstrated to robustly induce synthesis rate and lead to a
1.5 fold increase in myotube size (White, Puppa, Gao, et al., 2013).

Recent cachexia

research suggests that stimulating AMPK using AICAR is sufficient to attenuate
inflammation during cancer cachexia and improve loss of mass (Hall et al., 2018).
However, our key preliminary data suggest that the loss of AMPK during cancer cachexia
is sufficient to induce skeletal muscle anabolic signaling proteins ribosomal protein S6
(rpS6) and 4-eukaryotic binding protein 1 (4EBP-1) when compared to control ApcMin/+
mice (Figures B.2A, 2B, and 2C).
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Figure B.2. AMPK Regulation of Skeletal Muscle Anabolic Signaling During Cancer
Cachexia. A) Total protein expression of AMPK1 and AMPK2 in the gastrocnemius of
ApcMin/+ (Min) and AMPK12 ApcMin/+ (Min KO) mice. B) Upper: Immunoblot of prpS6S240/244 and rpS6 in the gastrocnemius muscle of Min and Min KO mice. Lower:
Quantification of above immunoblot. C) Upper: Immunoblot of p-4EBP-1T37/46 and
4EBP-1 in the gastrocnemius muscle of Min and Min KO mice. Lower: Quantification
of above immunoblot. N=6-10 mice per treatment group. Data presented as means ±
standard error. Students pre-planned t-test. Statistical significance was set at p<0.05. All
values normalized to Min. * denotes statistically significant from Min.
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Cachexia, AMPK, Fasting, and Autophagy
AMPK has been very well characterized for its roles in exercise and metabolism
(K. Nakashima & Yakabe, 2007; Sanchez, Csibi, et al., 2012) . However, only a few
researchers have examined AMPK’s role in cancer induced muscle wasting. These
studies have provided putative mechanisms of action and provided the initial evidence
that place AMPK at the center of muscle wasting. Few studies have mechanistically tried
to investigate the role it plays in regulating autophagy and protein synthesis during the
progression of the disease (Hall et al., 2018; Rohm et al., 2016; White, Puppa, Gao, et al.,
2013). AMPK as described above is a master energy sensor and regulator of skeletal
muscle metabolism and is capable of being activated by numerous stimuli. Downstream it
regulates a host of signaling processes related to lipid metabolism, glucose metabolism,
protein synthesis, degradation, autophagy, and mitochondrial biogenesis which are all
disrupted in cancer cachexia (Argiles, Busquets, et al., 2015; Carson et al., 2016; Sandri,
2016).
To date, our lab and others have demonstrated that the cachectic environment
elevates skeletal muscle AMPK and indices of autophagy following a 5 hour fast,
showing that a very short period of fasting is capable of inducing AMPK in the cancer
environment, suggestive of metabolic dysregulation (Penna et al., 2010; White, Baynes,
et al., 2011a; White, Puppa, Gao, et al., 2013). However, we now have key preliminary
data demonstrating that AMPK signaling is induced during the fed (ad libitum access to
food) state during cancer cachexia when compared to B6 mice (Figure B.3A, B, and C).
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Figure B.3. AMPK Signaling in the Fed State During Cancer Cachexia. A) % bodyweight
loss from peak in B6 and Min mice. B) Gastrocnemius mass in B6 and Min mice. C)
Left: Representative immunoblots of p-AMPKT172, AMPK, p-ULK-1S555, and ULK-1 in
the gastrocnemius of Fed B6 and Min mice. Right: Quantification of immunoblots. D)
Left: Representative immunoblots and quantification of P62 and LC3B II/I in the
gastrocnemius of Fed B6 and Min mice. Values are means ± SEM. Significance was set
at p<0.05. * Signifies different from B6. N=8-9 per group. Students pre-planned t-test
used for all analysis.
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AMPK has long been known to be a key regulator of autophagy (Kjobsted et al.,
2018).

While some initial studies reported conflicting results on AMPK’s role in

autophagy, it was later determined that these results were dependent on cell type and
conditions used.

Under normal basal conditions both mTORC1 and AMPK are

associated with ULK-1(J. Kim et al., 2011). Classically, a fast or nutrient deprivation
will lead to AMPK activation and suppress mTORC1 which promotes autophagy through
the direct phosphorylation of ULK-1(Bagherniya et al., 2018). Cancer cachexia and
skeletal muscle autophagy has become a very intriguing area of investigation (Penna et
al., 2014). Numerous mouse models of cancer cachexia have demonstrated elevations in
LC3 as well as p62 (Penna, Costamagna, et al., 2013; Tessitore et al., 1994; Tessitore et
al., 1993). The gastrocnemius muscle of C26 and LLC tumor bearing mice exhibited
robust inductions of Beclin-1, LC3 II, and p62 at 11 and 14 days which coincided with a
reduction in cathepsin activity(Pettersen et al., 2017; Talbert et al., 2014; White,
Baltgalvis, et al., 2011). Our laboratory has also demonstrated that LC3 II and Beclin-1
are also induced in the Min mouse model of cancer cachexia (White, Baynes, et al.,
2011a).
Interestingly, some researchers argue that the elevation in LC3 and p62 is
indicative of dysfunctional clearance of the autophagosome by the lysosome.

The

induction of skeletal muscle autophagy in tumor bearing animals is typically
demonstrated by increased LC3 II levels, which are further induced in the presence of a
lysosomal inhibitor such as colchicine (a recently employed technique to determine true
autophagy flux(Ju et al., 2010). The common link in pre-clinical models of cachexia
appears to be LC3 II and p62, which are often reported as accumulated in cachectic mice
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(Pigna et al., 2016b). Moreover, preliminary data from our laboratory suggests that the
cachectic environment sensitizes skeletal muscle to a 12-hour fast through the hyperactivation of AMPK and induction of autophagy when compared to B6 mice (Figures
B.4A, B, C, D, and E). We also have preliminary data demonstrating that AMPK is
necessary for the 12-fast induction of autophagy in ApcMin/+ Mice (Figures B.5 A and B).
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Figure B.4. Skeletal Muscle AMPK and Autophagy Response to a 12-hour Fast. A)
Experimental design figure depicting when 12-hour fast and ad-libitum access occurred.
B) Left: Representative immunoblots of p-AMPK (T172), AMPK, p-ULK-1(S555), and
ULK-1 protein expression in gastrocnemius of B6 fed and 12-hour fasted mice. Right:
Quantified results of immunoblots. C) Left: Representative immunoblots of P62 and LC3
II/I protein expression in gastrocnemius of B6 fed and 12-hour fasted mice. Right:
Quantified results of immunoblots D) Left: Immunoblot of p-AMPKT172, AMPK, p-ULK1S555, and ULK-1 protein expression in gastrocnemius of Min fed and 12-hour fasted
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used for all analysis.

228

Min Light Cycle 12hr Fast

Min KO Light Cycle 12hr Fast
Min KO Light Cycle 12hr Fast

Min Light Cycle 12hr Fast

A.

Protein Expression
(Normalized to Min 12hr Fast)

T172
P-AMPK
1.5

P-AMPKT172

MinFast
KO Light Cycle 12hr Fast
Min Light Cycle
12hr
Fast Cycle 12hr
Min
KO Light
12
hr. Fast
Min Light Cycle 12hr Fast
Min

Min KO

AMPK

p-AMPKT172

p-ULK-1S555

ULK-1

1.0

S555
P-ULK-1
AMPK

AMPKP-ULK-1S555

*

0.5

P-ULK-1*S555

P-ULK-1S555

ULK-1

12 hr. Fast
Min
Min KO
P62

LC3 I
LC3 II

Protein Expression
(Normalized to Min 12hr Fast)

ULK-1

B.

Min KO 12hr Fast

AMPK
T172
P-AMPK

P-AMPKT172

ULK-1

0.0

Min 12hr Fast

ULK-1

p-AMPK

p-ULK-1/ULK-1

Min 12hr Fast

1.5

Min KO 12hr Fast
1.0

*
0.5

*
0.0

P62

LC3B (II/I)

Figure B.5. AMPK Regulation of Fasting Induced Autophagy in ApcMin/+ Mice. A) Left:
Representative immunoblots of p-AMPKT172, AMPK, p-ULK-1S555, and ULK-1 in the
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was set at p<0.05. * Signifies different from Min. N=7-10 per group. Students preplanned t-test used for all analysis.

229

Cachexia and the Response to Feeding
Of recent interest in cancer cachexia and protein synthesis is the new concept of
anabolic resistance (A. M. H. Horstman et al., 2016). Many cancer patients experience
weight loss at the time of diagnosis and as mentioned previously, muscle loss is
indicative of poor prognosis in many cancers(Baracos, 2006a, 2011; Baracos et al., 2018;
Romanello & Sandri, 2015).

An intriguing question among researchers is whether

cachectic muscle retains anabolic plasticity. This could prove beneficial for clinicians
looking to provide treatment and improve muscle mass and function. While circadian
fluctuations in protein turnover are the established norm in muscle mass regulation, it has
become evident that protein synthesis is highly responsive to environmental stimuli.
Nutrients or feeding and exercise are extremely potent stimulators of skeletal muscle
protein synthesis in basal healthy conditions; however, numerous wasting conditions
have demonstrated reduced sensitivity to these anabolic signals(Argiles, Lopez-Soriano,
et al., 2015; Bodine, 2013; Bowen et al., 2015). Even the smallest decrement in daily
protein synthesis could significantly impact muscle maintenance in wasting conditions, it
is logical to suggest that anabolic resistance could also contribute to muscle loss during
cancer cachexia (Cuthbertson et al., 2005). Surprisingly, the cancer cachexia field is
actually lacking in the study of pre-clinical model studies examining anabolic resistance.
However, our laboratory has demonstrated blunted mTORC1 activation in response to
glucose administration in cachectic skeletal muscle (White, Puppa, Gao, et al., 2013). We
have key preliminary data demonstrating that free ad-libitum access to a food pellet
following a 12-hour fast is sufficient to induce blood glucose and phosphorylation of
AKT (T308) in ApcMin/+ mice (Figure B.6A and B).
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Figure B.6. 1-hour Re-FeedULK-1
Induces Blood Glucose and AKT. A) Blood glucose of 1hour Re-Feed mice pre and post food access. B) Left: Representative immunoblots of pAKTT308 and AKT in the gastrocnemius of 12-hour fast and 1-hour Re-Feed and Min
mice. Right: Quantification of immunoblot. Values are means ± SEM. Significance was
set at p<0.05. * Signifies different from Min 12-hour fast. N=8-10 per group. Students
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2.3 Research Design and Methods
Specific Aim 1: Determine if downstream AMPK signaling is necessary for muscle
protein turnover in oxidative and glycolytic cachectic skeletal muscle.
Aim 1.1: Determine the role of AMPK in the cancer cachexia regulation of TSC2 and
raptor mediated skeletal muscle protein synthesis.
Aim1.2: Determine the role of AMPK in the cancer cachexia regulation of ULK-1 and
FOXO3 mediated skeletal muscle degradation through autophagy and E3 ligase
expression.
Aim 1.3: Determine the role AMPK in the cancer cachexia regulation of skeletal muscle
mitochondrial quality control processes of biogenesis, fission, and fusion.
Premise
The loss of muscle mass during cancer cachexia is detrimental to quality of life
and is indicative to poor prognosis (Baracos, 2000). Additionally, muscle mass loss is
often an indicator of poor response to cancer treatment and therapeutics such as
chemotherapy (Barreto et al., 2016). The induction of muscle mass loss during cancer
cachexia has often coincided with the induction inflammation and AMPK. AMPK
heterotrimeric complex expression has also been previously reported to be regulated by
muscle phenotype. However, the consequences and mechanisms of this differential
expression has not yet been determined. As previously mentioned, AMPK is capable of
suppressing anabolic signaling through mTORC1 and inhibiting protein synthesis (Koh et
al., 2008). AMPK has also been established as a key modulator of mitochondrial quality
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control, having direct regulation of mitochondrial biogenesis and fission. Furthermore,
AMPK is capable of regulating multiple downstream signaling pathways contributing to
skeletal muscle degradation such as the ubiquitin proteasome and autophagy lysosome
system (Kjobsted et al., 2018).
Aim 1.1 Experimental Design
The purpose of Aim 1.1 is to determine the role of AMPK in the cancer cachexia
regulation of TSC2 and raptor mediated skeletal muscle protein synthesis. We
hypothesize that loss of skeletal muscle AMPK will alleviate the cachexia-induced
inhibitory AMPK phosphorylation of TSC2 at (Ser1387) and raptor at (Ser792). We also
hypothesize that the loss of AMPK will increase protein synthesis in glycolytic but not
oxidative muscle.

We will measure phosphorylated TSC2 Ser1387 and raptor Ser792

using western blotting. We will measure skeletal muscle protein synthesis using
puromycin incorporation (SUnSET technique). Briefly, at approximately 12 weeks of
age both control floxed ApcMin/+ (non HSA containing) and Min KO mice received 5
daily injections of tamoxifen to induce HSA Cre recombinase deletion of AMPK1 and
AMPK2 in skeletal muscle. A one week washout period following tamoxifen treatment
will be completed to avoid any acute effects of the treatment. At 14 weeks of age mice
initiated the study and will be tracked weekly for bodyweight and activity until sacrifice
at ~20 weeks of age. At sacrifice tissues will be dissected, weighed and snap frozen in
liquid nitrogen. The gastrocnemius and soleus muscle will be utilized in all analysis for
Aim 1.
Aim 1.1 Primary Outcomes
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Indices of Cachexia:
The progression of cachexia in the male ApcMin/+ mouse has been well described
(Baltgalvis et al., 2010). Body weight will be measured weekly throughout the early and
mid-stages of adulthood of the mice to determine the relative loss of body weight in
individual mice. The muscle and tissue weights of each mouse will be determined at
sacrifice. Intestines will be collected and analyzed for total tumor burden. Blood will be
collected immediately prior to sacrifice and plasma IL-6 levels will be examined using an
ELISA.
Analysis of Skeletal Muscle AMPK, TSC2, raptor, and Puromycin:
Phosphorylated AMPK (T172) and total AMPK, will be measured using will be
measured in the gastrocnemius and soleus using western blotting techniques (Fix et al.,
2018). To truly assess AMPK activation phosphorylated ACC (S79) and total ACC will
also be measured. Phosphorylated and total TSC1/2, and raptor will be measured using
will be measured in the gastrocnemius and soleus using western blotting techniques (Fix
et al., 2018). Protein synthesis will be determined using the SUnSET technique as
previously described (Hardee et al., 2018). Briefly, 30 minutes prior to sacrifice mice
will receive an intraperitoneal injection of puromycin at a concentration of 0.040 μmol/g
body weight in warm sterile PBS. Protein homogenates are then fractionated on gels
using western blotting technique as previously described.

Blots are incubated in

puromycin antibody at a dilution of 1:2000 for a duration of 4-6 hours. Total puromycin
incorporation will be expressed relative to Min. The phosphorylated and total ratios of
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these proteins will be quantified using Image J software and graphed statistically using
Prism GraphPad 7.
Aim 1.1 Secondary Outcomes
Skeletal Muscle AKT:
Phosphorylated and total protein expression of AKT T308 and total AKT

will be

measured in the gastrocnemius using western blotting techniques(Fix et al., 2018). The
phosphorylated and total ratio of this protein will be quantified using Image J software
and graphed statistically using Prism GraphPad 7.
Aim 1.1 Statistical Analysis
Determining Statistical Significance:
The purpose of this experiment is to determine the role of AMPK on the regulation of
skeletal muscle anabolic signaling during cancer cachexia. Mice will be divided into two
groups consisting of Min and Min KO. A pre-planned students t-test will be employed to
conduct analysis and significance set at p<.05. All statistical analysis will be performed
using GraphPad Prism 7 software. Values will be presented as means ± the standard
error of the mean.
Power analysis:
A power analysis was performed using a similar experimental design to determine the
sample size needed to detect a significant difference. Power (1-β) was set to 0.8 and error
of probability (α) was set at 0.05. Based on previous cancer cachexia analysis of anabolic
signaling proteins and preliminary data from our laboratory, to achieve significance for
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an estimated 20 ± 5% difference between groups, a minimum sample size of 6 is needed
for each group.
Aim 1.2 Experimental Design
The purpose of Aim 1.2 is to determine the role of AMPK in the cancer cachexia
regulation of ULK-1 and FOXO3 mediated skeletal muscle degradation through
autophagy and E3 ligase expression. We hypothesize that loss of skeletal muscle AMPK
will inhibit the cachexia activation of ULK-1 and FOXO3 in both oxidative and
glycolytic skeletal muscle.
Aim 1.2.

The same experimental groups as Aim 1.1 will be used in

At approximately 12 weeks of age both control floxed mins (non HSA

containing) and Min KO mice will receive 5 daily injections of tamoxifen to induce HSA
Cre recombinase deletion of AMPK1 and AMPK2 in skeletal muscle. A one week
washout period following tamoxifen treatment will be completed to avoid any acute
effects of the treatment. At 14 weeks of age mice will initiate the study and will be
tracked weekly for bodyweight and activity until sacrifice at ~20 weeks of age. Similar
muscle preparation of protein homogenates (gastrocnemius and soleus) will be performed
as in aim 1.1, however protein expression for skeletal muscle degradation markers will be
analyzed.
Aim 1.2 Primary Outcome
ULK-1and FOXO3a:
Phosphorylated ULK-1 S555 and total ULK-1 Phosphorylated and total protein
expression will be measured by Western blot as previously described in both the
gastrocnemius and soleus muscle (Fix et al., 2018). FOXO3a activation will be
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determined by S253 phosphorylation. Proteins will be expressed relative to Min or
Control.
E3 Ligases Atrogin-1 and MuRF-1:
Total protein expression will be measured by Western blot as previously described (Fix et
al., 2018) for E3 ligases Atrogin-1 and MuRF-1. Proteins will be expressed relative to
Min or Control.
Autophagy Signaling, P62, and LC3II/I:
total P62, and LC3II/I will be examined via western blot as previously described.
Proteins will be expressed relative to Min or Control.
Aim 1.2 Secondary Outcome
Protein ubiquitination:
Total ubiquitination of muscle proteins will be determined by Western blot as previously
described (Fix et al., 2018) . Total ubiquitination will be expressed relative to Min or
Control.
Aim 1.2 Statistical Analysis
Determining Statistical Significance: See Aim 1.1
Power Analysis: See Aim 1.1
Aim 1.3 Experimental Design
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The purpose of Aim 1.3 is to determine the role AMPK in the cancer cachexia regulation
of skeletal muscle mitochondrial quality control processes of biogenesis, fission, and
fusion. We hypothesize that loss of muscle AMPK during cachexia suppresses
mitochondrial biogenesis and fission while inducing fusion. The same experimental
groups as Aim 1.1 will be used in Aim 1.2. At approximately 12 weeks of age both
control floxed mins (non HSA containing) and Min KO mice will receive 5 daily
injections of tamoxifen to induce HSA Cre recombinase deletion of AMPK1 and
AMPK2 in skeletal muscle. A one week washout period following tamoxifen treatment
will be completed to avoid any acute effects of the treatment. At 14 weeks of age mice
will initiate the study and will be tracked weekly for bodyweight and activity until
sacrifice at ~20 weeks of age. Similar muscle preparation of protein homogenates will be
performed as in aim 1.1, however protein expression for mitochondrial quality control
will be measured and analyzed.
Aim 1.3 Primary Outcomes
Mitochondrial Quality Control: To assess AMPK regulation of mitochondrial quality
control during cancer cachexia. Total protein expression for Pgc-1, MFN-1, and DRP-1
will analyzed via western blot as previously described.
Aim 1.3 Statistical Analysis
Determining Statistical Significance:
See Aim 1.1
Power Analysis See Aim 1.1
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Aim 1 Overall Interpretation and Potential Pitfalls
This set of experiments will establish the role of AMPK in the regulation of
skeletal muscle protein turnover during cancer cachexia. Aim 1 will establish of AMPK
is necessary for muscle protein turnover in oxidative and glycolytic cachectic skeletal
muscle . I have strong preliminary data demonstrating that the loss of skeletal muscle
AMPK12 increases indices of the mTORC1 pathway that control anabolic signaling and
protein synthesis in the gastrocnemius (glycolytic) of ApcMin/+ mice. Furthermore, this
aim will also establish if cachexia-induced changes in mitochondrial quality occur
through AMPK. Additionally, this aim will establish if cachexia mediated changes in
muscle mass are related to increased skeletal muscle protein synthesis or a suppression
degradation through utilization of the muscle specific AMPK knockout.

Valuable

information can be gained if any of my hypothesis are rejected, and loss of skeletal
muscle AMPK in ApcMin/+mice does not improve any of these processes.
Aim 1 Methods
Animals
The ApcMin/+ mouse is a genetic model of colorectal cancer and cachexia
(Baltgalvis et al., 2010). These mice harbor a heterozygous mutation in the adenomas
polyposis coli (APC) gene, which promotes the development of intestinal tumors
beginning as early as 4 weeks of age (Shoemaker, Luongo, Moser, Marton, & Dove,
1997). Mice develop an IL-6-dependent cancer cachexia phenotype between 3 and 6
months of age (Baltgalvis et al., 2010). Due to the slow onset and progression of body
weight loss this model is advantageous as treatments can be started after the initiation of
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cancer cachexia. Male ApcMin/+ mice on a C57BL/6 background were originally
purchased from Jackson Laboratories (Bar Harbor, ME, USA) and bred at the University
of South Carolina’s Animal Resource Facility. All mice used in the current study were
obtained from the investigators breeding colony within the Center for Colon Cancer
Research Mouse Core. At 3-wk of age mice were genotyped as previously described
(Baltgalvis et al., 2009). Mice were individually housed, kept on a 12:12-h light-dark
cycle, and had access to standard rodent chow (#8604 Rodent Diet; Harlan Teklad,
Madison, WI) and water ad libitum. 12 hours prior to sacrifice all mice had food removed
from cage. Body weight measurements were taken weekly and the percentage body
weight loss from peak body weight (~12-20 weeks of age) was calculated. Mice lacking
the ApcMin/+ mutation (C57BL/6) served as controls for all experiments. The University of
South Carolina’s Institutional Animal Care and Use Committee approved all animal
experimentation in this study.
Skeletal Muscle Deletion of AMPK12
To generate a skeletal muscle specific knockout of AMPK12, mice that
contained individually floxed alleles for AMPK1 and AMPK2 were a kind gift from Dr.
Hoh-Jin Koh at the University of South Carolina. These mice were then crossed together
to generate a double floxed AMPK12 mouse. The AMPK12 was then crossed with
ApcMin/+ mice to generate an AMPK12 ApcMin/+ mouse. Tamoxifen inducible Mer Cre
Mer driven by a Human Skeletal Actin promoter (HSA) mice were purchased from
Jackson Laboratories (Bar Harbor, ME, USA)(McCarthy, Srikuea, Kirby, Peterson, &
Esser, 2012). These mice were then crossed with our AMPK12 to generate AMPK12
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HSA Cre mice. Finally, the AMPK12 HSA Cre mice were crossed with AMPK12
ApcMin/+ mice giving a 50% chance of the offspring producing an AMPK12 ApcMin/+
HSA Cre mouse. Tamoxifen injection via intraperitoneal cavity deletes skeletal muscle
AMPK12 in the ApcMin/+ mouse (Min KO).
Tissue Collection
Mice

were

anesthetized

via

a

subcutaneous

injection

of

ketamine/xylazine/acepromazine cocktail (1.4 ml/kg body weight) prior to sacrifice. Hind
limb muscles were rapidly excised, cleared of excess connective tissue, rinsed in PBS,
weighed, and snap frozen in liquid nitrogen. The gastrocnemius muscle was cut at the
mid-belly, and the proximal portion was split laterally and medially for protein. The left
and right soleus muscles were weighed and processed for protein analysis. Blood was
collected prior to muscle collection via retro-orbital eye bleed with heparinized capillary
tubes, placed on ice, and centrifuged (10,000 x g for 10 min at 4°C). The supernatant was
removed and stored for plasma IL-6 analysis. Plasma and tissue samples were stored at 80°C until further analysis.
Western Blotting
Western blot analysis was performed as previously described (Fix et al., 2018).
Frozen gastrocnemius muscle was homogenized in ice-cold Mueller buffer and protein
concentration was determined by the Bradford method. Crude muscle homogenates were
fractionated on 6 – 15% SDS-polyacrylamide gels and transferred to PVDF membranes
overnight. Membranes were stained with Ponceau red to verify equal loading and transfer
for each gel. Membranes were blocked at room temperature for 1 – 2 hrs. in 5% Tris-
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buffered saline with 0.1% Tween-20 (TBST) milk. Primary antibodies for p-AKT (T308),
AKT, puromycin, p-FOXO3(S253), FOXO3, p-ULK-1 (S555), ULK-1, P62, LC3II/I,
MuRF-1, Atrogin-1 (ECM Biosciences), p-AMPK (T172), AMPK, p-ACC (S79) , ACC,
p-TSC2 (S1387), TSC2, p-raptor (S792), raptor, DRP-1, FIS-1, MFN-1 (Abcam), PGC1 (Abcam), and GAPDH will be diluted 1:5000 – 1:2000 in 5% TBST-milk followed by
a 4-8-hr incubation with membranes at 4 degrees. Anti-rabbit or anti-mouse IgG
horseradish-peroxidase conjugated secondary antibody was incubated with the
membranes at 1:2000 dilutions for 1 hour in 5% TBST-milk at room temperature.
Enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was
used to visualize the antibody-antigen interactions. Images were digitally scanned and
quantified by densitometry using imaging software (Image J; NIH). All antibodies were
from Cell Signaling unless otherwise stated.
Plasma IL-6 concentrations
Plasma IL-6 concentrations were determined as previously described (B. N.
VanderVeen, Hardee, Fix, & Carson, 2018). A commercially available IL-6 enzymelinked immunosorbent assay kit was obtained from BD Biosciences (San Diego, CA,
USA) and the manufacturer’s protocol was followed. Briefly, a Costar clear 96-well plate
(Corning, NY, USA) was coated with IL-6 capture antibody and allowed to incubate
overnight. The next morning, the plate was blocked with assay diluent buffer, washed,
and IL-6 standards and plasma samples were added in duplicate to the plate. The plate
was again washed and sAV-HRP reagent was added to each well. After several washes,
TMB substrate was added and the reaction was developed for 20 minutes. The reaction
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was stopped with sulfuric acid and absorbance was read in a BioRad iMark plate reader
(Hercules, CA, USA) at 450 nm.
Statistical Analysis
Results are reported as the means ± standard error. An unpaired student’s preplanned t-test or One-way ANOVA was employed when appropriate. Post-hoc analyses
were performed with Student-Newman-Keuls methods when appropriate. The accepted
level of significance was set at p<0.05 for all analysis. Statistical analysis was performed
using Prism GraphPad 7 (GraphPad Software Inc., La Jolla, CA).
Specific Aim 2: Determine if cancer cachexia disrupts the physiological regulation of
AMPK signaling by fasting/re-feeding in oxidative and glycolytic skeletal muscle.
Aim 2.1: Determine the effect of fasting and re-feeding on the cachexia regulation of
protein synthesis via AMPK signaling and downstream targets TSC2 and raptor.
Aim 2.2: Determine the effect of fasting and re-feeding on the cachexia regulation of
AMPK degradation targets ULK-1 and FOXO3 and their downstream processes of
autophagy and E3 ligase expression.
Aim 2.3: Determine the effect of fasting and re-feeding on the cachexia regulation of
AMPK mediated mitochondrial quality control processes biogenesis, fission, and fusion.
Premise
Nutrient availability or energy status is a critical regulator of AMPK. Skeletal
muscle proteostasis fluctuates diurnally depending on different fasting and feeding
durations as well as in response to activity and exercise stimuli. Adequate nutrient
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availability is key in the net loss and gain of skeletal muscle protein. AMPK is a nutrient
sensitive energy sensor and is essential for skeletal muscle metabolic homeostasis
(Romanello et al., 2010; Romanello & Sandri, 2015). A lack of available energy (ATP)
results in the activation of AMPK in order to activate energy generating pathways
(degradation) while suppressing energy consuming pathways (protein synthesis). AMPK
is capable of being activated by many different stimuli as well as diseases such as cancer
cachexia. During severe cancer cachexia, skeletal muscle AMPK is dysregulated and
chronically activated which could have dire consequences regarding muscle proteostasis.
The most widely investigated activators of skeletal muscle AMPK is the process of
prolonged energy deficiency (fasting). Our laboratory has previously reported elevated
AMPK following an acute 5 hour fast (Cannavino, Brocca, Sandri, Bottinelli, &
Pellegrino, 2014). This activation is not present in non-tumor bearing mice and suggest
that cachectic skeletal muscle may be hyper-sensitive to fasting conditions exacerbating
the AMPK response. While fasting has been proposed to have beneficial effects in
regard to aging and some cancers, less is understood about its role in cancer cachexia and
the regulation of muscle proteostasis.
Conversely the abundance of nutrients following the ingestion of glucose or a
mixed meal (feeding) has been previously demonstrated to suppress AMPK. Feeding
induces the IGF-1/AKT signaling pathway which will control skeletal muscle protein
synthesis (K. Nakashima et al., 2006). The capacity cellular energy status or feeding to
induce mTORC1 and suppress AMPK has been characterized extensively in normal
physiological conditions (Bagherniya et al., 2018; Galic et al., 2018; K. Nakashima et al.,
2006; Russo et al., 2018). Some even argue that mTORC1 may actually be a homeostatic
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ATP energy sensor. Nutrient stimulation as well as insulin and certain cytokines will
induce the AKT phosphorylation of TSC2 releasing the block and allowing rheb to
induce mTORC1 and its activation of downstream targets.

We have previously

demonstrated an acute glucose injection was capable of attenuating AMPK and inducing
mTORC1 but was unable to induce protein synthesis.

In light of this, it is worth

mentioning the newly defined concept of anabolic resistance or the inability to respond to
nutrients has recently become an interesting and widely debated topic in cancer cachexia.
While circadian fluctuations in protein turnover are the established norm in muscle mass
regulation, it has become evident that protein synthesis is highly responsive to
environmental stimuli. Nutrients or feeding and exercise are extremely potent stimulators
of skeletal muscle protein synthesis in basal healthy conditions; however, numerous
wasting conditions have demonstrated reduced sensitivity to these anabolic signals
(Argiles, Lopez-Soriano, et al., 2015; Bodine, 2013; Bowen et al., 2015).
While the concept of fasting has been suggested to be therapeutic in some
diseases and even cancer less is understood about its role in cachexia. Therefore, we
hypothesize that the fasting induced changes in energy status will exacerbate the AMPK
mediated downstream process of degradation and suppress muscle protein synthesis.
Furthermore, we hypothesize that re-feeding following a fast will attenuate the fasting
induced activation of AMPK signaling. Additionally, we also believe that these events
will be differentially regulated by muscle phenotype.
Aim 2.1 Experimental Design
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The purpose of Aim 2.1 is to determine the effect of fasting and re-feeding on the
cachexia regulation of protein synthesis via AMPK signaling and downstream targets
TSC2 and raptor. We hypothesize that AMPK and downstream targets TSC2 and raptor
will be robustly activated in the glycolytic but not oxidative muscles of fasted ApcMin/+
(Min) mice when compared to ad libitum fed Mins and C57BL/6 (B6).

We also

hypothesize that a 1 hour re-feed following a fast will attenuate the AMPK
phosphorylation of TSC2 and raptor which will induce protein synthesis in both
glycolytic and oxidative cachectic muscle. To test this hypothesis male B6 and Min mice
~18-20 weeks of age will be stratified into either fed (ad-libitum food access during the
12 hour dark cycle) fasted (food removed from cages during the 12 hour light cycle) or
re-feed (fasted during the 12 hour light cycle and allowed access to a food pellet for 1
hour). Following completion of each groups fed or fasted treatment mice will be
sacrificed, and tissues collected for analysis similar to Aim 1.
Aim 2.1 Primary Outcomes
Indices of Cachexia: See Aim 1.1
Analysis of Skeletal Muscle AMPK, TSC2, raptor, and Puromycin: See Aim 1.1
Aim 2.1 Secondary Outcomes
Skeletal Muscle AKT: See Secondary Outcomes Aim 1.1
Aim 2.1 Statistical Analysis
Determining Statistical Significance: See Aim 1.1
Power Analysis:
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A power analysis was performed to determine the sample size needed to observe
statistical significance using a two-way ANOVA. Power (1-β) was set to 0.8 and error of
probability (α) was set at 0.05. Based on previously published results and our preliminary
data, to achieve significance difference between groups for an estimated 20 ± 5%
difference between groups, a minimum sample size of 7 is needed for each group.
Aim 2.2 Experimental Design
The purpose of Aim 2.2 is to determine the effect of fasting and re-feeding on the
cachexia regulation of AMPK degradation targets ULK-1 and FOXO3 and their
downstream processes of autophagy and E3 ligase expression. We hypothesize that
fasting exacerbates the activation of ULK-1 and FOXO3 in cachectic glycolytic but not
oxidative skeletal muscle. We also hypothesize that a 1 hour refeed will suppress the
induction of these proteins. Mice from Aim 2.1 will be utilized in this experiment.
Aim 2.2 Primary Outcomes
FOXO3a: See Aim 1.2
Atrogin-1 and MuRF-1: See Aim 1.2
Autophagy Signaling, P62, and LC3II/I: See Aim 1.2
Aim 2.2 Secondary Outcomes
Protein Ubiquitination: See Aim 1.2
Aim 2.2 Statistical Analysis
Determining Statistical Significance: See Aim 2.1
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Power: See Aim 2.1
Aim 2.3 Experimental Design
The purpose of Aim 2.3 is to determine the effect of fasting and re-feeding on the
cachexia regulation of AMPK mediated mitochondrial quality control processes
biogenesis, fission, and fusion. We hypothesize that fasting will exacerbate the chronic
cachexia activation of AMPK, suppressing mitochondrial biogenesis and fusion while
inducing fission in glycolytic but not oxidative muscle. We also hypothesize that 1 hour
of refeeding will be sufficient to suppress these signaling events.
Aim 2.3 Primary Outcomes
Mitochondrial Quality Control: See Aim 1.3
Aim 2.3 Statistical Analysis
Determining Statistical Significance: See Aim 1.1
Power: See Aim 2.1
Aim 2 Overall Interpretation and Potential Pitfalls:
Aim 2 will determine if cancer cachexia disrupts the physiological regulation of
AMPK signaling by fasting/re-feeding in oxidative and glycolytic skeletal muscle .
Furthermore, Aim 2 will elucidate if nutrients ingestion through re-feeding is sufficient to
suppress AMPK during cancer cachexia. Aim 2 will also demonstrate if these processes
are differentially regulated in oxidative and glycolytic muscle.

We will examine

immediate downstream AMPK targets that regulate muscle protein synthesis,
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mitochondrial quality control, and degradation through E3 ligases and the lysosomal
autophagy system.

I have strong preliminary data that AMPK mediated autophagy is

induced in Min mice during the fed state compared to B6 mice. Additionally, a fasting
exacerbates the activation of AMPK and downstream ULK-1 autophagy signaling in Min
mice when compared to the fed state. While there is strong rationale for the hyperactivation of AMPK and autophagy during fasting in cachectic skeletal muscle, less is
understood about the role of feeding AMPK and mTORC1 in this process. However, I
have strong preliminary data demonstrating that a 1-hour re-feed is capable of stimulating
mTORC1 in cachectic skeletal muscle. This should provide valuable information related
to the role of AMPK in the fasting and feeding regulation of skeletal muscle autophagy
during cancer cachexia.
Specific Aim 2 Methods
Animals
Male C57BL/6 (B6) and ApcMin/+ (Min) mice will be bred, housed, and monitored
as described in Aim 1. For experiment 2 B6 and Min mice will be allowed access to ad
libitum access to food, fasted 12-hours prior to sacrifice, or fasted 12-hours and allowed
ad libitum access to a food pellet for 1-hour. The University of South Carolina’s
Institutional Animal Care and Use Committee approved all animal experimentation
outline in this proposal.
Western Blotting
Western blot analysis was performed as previously described (Fix et al., 2018).
Frozen gastrocnemius muscle was homogenized in ice-cold Mueller buffer and protein
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concentration was determined by the Bradford method. Crude muscle homogenates were
fractionated on 6 – 15% SDS-polyacrylamide gels and transferred to PVDF membranes
overnight. Membranes were stained with Ponceau red to verify equal loading and transfer
for each gel. Membranes were blocked at room temperature for 1 – 2 hrs. in 5% Trisbuffered saline with 0.1% Tween-20 (TBST) milk. Primary antibodies for p-AKT (T308),
AKT, puromycin, p-FOXO3(S253), FOXO3, p-ULK-1 (S555), ULK-1, P62, LC3II/I,
MuRF-1, Atrogin-1 (ECM Biosciences), p-AMPK (T172), AMPK, p-ACC (S79) , ACC,
p-TSC2 (S1387), TSC2, p-raptor (S792), raptor, DRP-1, FIS-1, MFN-1 (Abcam), PGC1 (Abcam), and GAPDH will be diluted 1:5000 – 1:2000 in 5% TBST-milk followed by
a 4-8-hr incubation with membranes at 4 degrees. Anti-rabbit or anti-mouse IgG
horseradish-peroxidase conjugated secondary antibody was incubated with the
membranes at 1:2000 dilutions for 1 hour in 5% TBST-milk at room temperature.
Enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was
used to visualize the antibody-antigen interactions. Images were digitally scanned and
quantified by densitometry using imaging software (Image J; NIH). All antibodies were
from Cell Signaling unless otherwise stated.
Plasma IL-6 concentrations
Plasma IL-6 concentrations were determined as previously described (Hardee et
al., 2016). A commercially available IL-6 enzyme-linked immunosorbent assay kit was
obtained from BD Biosciences (San Diego, CA, USA) and the manufacturer’s protocol
was followed. Briefly, a Costar clear 96-well plate (Corning, NY, USA) was coated with
IL-6 capture antibody and allowed to incubate overnight. The next morning, the plate was
blocked with assay diluent buffer, washed, and IL-6 standards and plasma samples were
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added in duplicate to the plate. The plate was again washed and sAV-HRP reagent was
added to each well. After several washes, TMB substrate was added and the reaction was
developed for 20 minutes. The reaction was stopped with sulfuric acid and absorbance
was read in a BioRad iMark plate reader (Hercules, CA, USA) at 450 nm.
Statistical Analysis
Results are reported as the means ± standard error. An unpaired student’s preplanned t-test or One-way ANOVA was employed when appropriate. Post-hoc analyses
were performed with Student-Newman-Keuls methods when appropriate. The accepted
level of significance was set at p<0.05 for all analysis. Statistical analysis was performed
using Prism GraphPad 7 (GraphPad Software Inc., La Jolla, CA).
Specific Aim 3: Determine if in oxidative and glycolytic cachectic skeletal muscle, 4
weeks of voluntary wheel running activity regulates aberrant AMPK signaling in
response to physiological fasting.
Aim 3.1: Determine if 4 weeks of voluntary wheel running activity regulates the cachexia
disruption of AMPK signaling and downstream targets TSC2, raptor, and muscle protein
synthesis in response to a physiological fast
Aim 3.2: Determine if 4 weeks of voluntary wheel running activity regulates the cachexia
disruption of AMPK degradation targets ULK-1, FOXO3, and protein degradation in
response to a physiological fast.
Aim 3.3:

Determine if 4 weeks of voluntary wheel running activity regulates the

cachexia disruption of AMPK mediated mitochondrial quality control processes of
biogenesis, fission, and fusion in response to a physiological fast.
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Premise
While it is well established that acute exercise activates AMPK our laboratory
demonstrated that increased cage activity via voluntary wheel running was able to
attenuate the cachexia induced chronic activation of this pathway and improve muscle
mass loss (Hardee et al., 2016; Puppa et al., 2012). These results suggest that increased
activity may improve mitochondrial quality control during cancer cachexia and alleviate
the chronic energy deficit (ATP generation) thus lowering AMPK’s activity. Similar
results were also demonstrated using high frequency electrical stimulation in cachectic
muscle(Hardee et al., 2016). Seven repeated bouts of high frequency stimulation were
able to lower AMPK phosphorylation in cachectic ApcMin/+ and stimulate muscle protein
synthesis 3 hours post the final treatment(Hardee et al., 2016). These results demonstrate
that exercise training in the cachectic state has the ability to improve skeletal muscle
AMPK signaling and alleviate the AMPK mediated inhibition of mTORC1.
While cytokine treatments and anti-inflammatory therapies have been
demonstrated to improve AMPK signaling during cancer cachexia, less is understood
about the role exercise training in the regulation of fasting and autophagy. As mentioned
previously, numerous models of cancer cachexia have reported both elevated AMPK and
indices of autophagy (Pigna et al., 2016a; White, Baltgalvis, et al., 2011). The use of
exercise training to attenuate or improve AMPK signaling during cancer cachexia has
been utilized by our laboratory previously, however, whether this effect improves the
protein synthesis, degradation, and downstream autophagy response to a 12-hour fast
remains to be determined.
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Aim 3.1 Experimental Design
The purpose of Aim 3.1 is to determine if 4 weeks of voluntary wheel running activity
regulates the cachexia disruption of AMPK signaling and downstream targets TSC2,
raptor, and muscle protein synthesis in response to a physiological fast. We hypothesize
that 4 weeks of voluntary wheel running will attenuate the fasting activation of AMPK,
TSC2, and raptor in ApcMin/+ mice when compared to non-activity fasted ApcMin/+ mice.
Furthermore, we also believe that wheel running activity will improve these signaling
processes more in glycolytic than oxidative muscle. To test this hypothesis C57BL/6
mice and ApcMin/+ mice will be given access to a standard mouse wheel beginning at 1415 weeks of age and monitored until sacrifice at 18-19 weeks of age. Mice will have the
wheel removed 48 hours prior to sacrifice to avoid any acute effects of exercise and will
be fasted for 12-hours (the same fasting paradigm as in Aim 2). Tissues will be collected
as described in Aim 1 and will be compared to 12-hour fasted untrained mice from Aim
2. All analysis will be expressed relative to 12-hour fast.
Aim 3.1 Primary Outcomes
Voluntary Wheel Activity:
Voluntary wheel running will be used as our exercise training stimulus. At 14-15 weeks
of age, all mice will be single housed and placed in cages with 9.5-in.-diameter stainless
steel activity wheels (MiniMitter, Bend, OR). Running activity will be monitored daily
from 14-15 to 18-19 weeks of age. Bicycle computers (Specialized, Morgan Hill, CA)
with magnetic sensors are able to measure average speed, distance, time, and maximum
speed, which will be recorded daily, however expressed as means within a week.
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Indices of Cachexia: See Aim 1.1
Analysis of Skeletal Muscle AMPK, TSC2, raptor, and Puromycin: See Aim 1.1
Aim 3.1 Secondary Outcome
Skeletal Muscle AKT: See Secondary Outcomes Aim 1.1
Aim 3.1 Statistical Analysis
Determining Statistical Significance:
An unpaired pre-planned students t-test will be employed to conduct analysis between
12-hour fasted and exercise trained 12-hour fasted within each genotype and significance
set at p<.05. All statistical analysis will be performed using GraphPad Prism 7 software.
Values will be presented as means ± the standard error of the mean.
Power Analysis:
A power analysis was performed to determine the sample size needed to observe
statistical
significance using a one-way ANOVA. Power (1-β) was set to 0.8 and error of
probability (α) was
set at 0.05. Based on previously published results utilizing wheels, to achieve
significance for an estimated 20 ± 5% difference between groups, a minimum sample size
of 8 is needed for each group.
Aim 3.2 Experimental Design
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The purpose of Aim 3.2 is to determine if 4 weeks of voluntary wheel running activity
regulates the cachexia disruption of AMPK degradation targets ULK-1, FOXO3, and
protein degradation in response to a physiological fast. We hypothesize that 4 weeks of
voluntary wheel running will attenuate the fasting activation of ULK-1 and FOXO3
signaling in glycolytic and oxidative skeletal muscle of ApcMin/+ mice. C57BL/6 and
ApcMin/+ Mice from Aim 3.1 will be utilized for this experiment.
Aim 3.2 Primary Outcomes
FOXO3a: See Aim 1.2
Atrogin-1 and MuRF-1: See Aim 1.2
Autophagy Signaling, P62, and LC3II/I: See Aim 1.2
Aim 3.2 Secondary Outcomes
Protein ubiquitination: See Aim 1.2
Aim 3.2 Statistical Analysis
Determining Statistical Significance: See Aim 3.1
Power Analysis: See Aim 3.1
Aim 3.3 Experimental Design
The purpose of Aim 3.3 is to determine if 4 weeks of voluntary wheel running
activity regulates the cachexia disruption of AMPK mediated mitochondrial quality
control processes of biogenesis, fission, and fusion in response to a physiological fast.
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We hypothesize that 4 weeks of voluntary wheel running will attenuate the cachexia
disruption of AMPK mediated mitochondrial quality control following a fast. We also
hypothesize that wheel running activity will improve mitochondrial quality control more
in glycolytic than in oxidative muscle. To test this hypothesis C57BL/6 and ApcMin/+ Mice
from Aim 3.1 will be utilized for this experiment.
Aim 3.3 Primary Outcomes
Mitochondrial Quality Control: See Aim 1.3
Aim 3.3 Secondary Outcomes
COX Enzyme Activity: Skeletal muscle cytochrome c oxidase activity (COX) will be
measured using methods as previously described (Fix et al., 2018). Briefly, a 5-7mg
piece

of

muscle

will

be

homogenized

in

extraction

buffer

and

analyzed

spectrophotometrically using a kit from Sigma Aldrich (CYTOCOX1). The absorption at
550nm over a 1 minute period will determine COX activity.
Aim 3.3 Statistical Analysis
Determining Statistical Significance: See Aim 3.1
Power Analysis: See Aim 3.1
Aim 3 Overall Interpretation and Potential Pitfalls:
This set of experiments will establish the therapeutic potential of exercise training to
improve cachectic the skeletal muscle autophagy response following a 12-hour fast.
Furthermore, data from these experiments will further elucidate if exercise training can
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attenuate the fasting induction of AMPK in cachectic skeletal muscle and improve
muscle protein synthesis. We will also explore if improved mitochondrial quality control
in response to exercise training coincides with the potential AMPK suppression. This
Aim will give valuable information that can provide rationale to further explore exercise
training and the regulation of AMPK mediated autophagy and protein synthesis.
Furthermore, data from these experiments can provide intriguing rationale to explore if
exercise training is capable of sensitizing skeletal muscle to feeding following a 12-hour
fast.
Specific Aim 3 Methods
Animals
The ApcMin/+ mouse is a genetic model of colorectal cancer and cachexia
(Baltgalvis, Berger, Pena, Davis, Muga, et al., 2008; Mehl et al., 2005). These mice
harbor a heterozygous mutation in the adenomas polyposis coli (APC) gene, which
promotes the development of intestinal tumors beginning as early as 4 weeks of age
(Moser et al., 1990). Mice develop an IL-6-dependent cancer cachexia phenotype
between 3 and 6 months of age (Baltgalvis, Berger, Pena, Davis, Muga, et al., 2008; Mehl
et al., 2005). Due to the slow onset and progression of body weight loss this model is
advantageous as treatments can be started after the initiation of cancer cachexia. Male
ApcMin/+ mice on a C57BL/6 background were originally purchased from Jackson
Laboratories (Bar Harbor, ME, USA) and bred at the University of South Carolina’s
Animal Resource Facility. All mice used in the current study were obtained from the
investigators breeding colony within the Center for Colon Cancer Research Mouse Core.
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At 3-wk of age mice were genotyped as previously described (Baltgalvis, Berger, Pena,
Davis, Muga, et al., 2008). Mice were individually housed, kept on a 12:12-h light-dark
cycle, and had access to standard rodent chow (#8604 Rodent Diet; Harlan Teklad,
Madison, WI) and water ad libitum. 12 hours prior to sacrifice all mice had food removed
from cage. Body weight measurements were taken weekly and the percentage body
weight loss from peak body weight (~10-15 weeks of age) was calculated. Mice lacking
the ApcMin/+ mutation (C57BL/6) served as controls for all experiments. The University of
South Carolina’s Institutional Animal Care and Use Committee approved all animal
experimentation in this study.
Voluntary Wheel Running
Voluntary wheel running was used as a marker of volitional physical activity and was
performed as previously described (26). At 5 wks. of age, wild-type and ApcMin/+ were
housed individually in cages with 9.5-in.-diameter stainless steel activity wheels
(MiniMitter, Bend, OR). Running activity was monitored daily from 14-15 weeks of age
to 18-20 weeks of age. Bicycle computers (Specialized, Morgan Hill, CA) with magnetic
sensors measured average speed, distance, time, and maximum speed, and the data were
recorded daily.
Western Blotting
Western blot analysis was performed as previously described (Fix et al., 2018).
Frozen gastrocnemius muscle was homogenized in ice-cold Mueller buffer and protein
concentration was determined by the Bradford method. Crude muscle homogenates were
fractionated on 6 – 15% SDS-polyacrylamide gels and transferred to PVDF membranes
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overnight. Membranes were stained with Ponceau red to verify equal loading and transfer
for each gel. Membranes were blocked at room temperature for 1 – 2 hrs. in 5% Trisbuffered saline with 0.1% Tween-20 (TBST) milk. Primary antibodies for p-AKT (T308),
AKT, puromycin, p-FOXO3(S253), FOXO3, p-ULK-1 (S555), ULK-1, P62, LC3II/I,
MuRF-1, Atrogin-1 (ECM Biosciences), p-AMPK (T172), AMPK, p-ACC (S79) , ACC,
p-TSC2 (S1387), TSC2, p-raptor (S792), raptor, DRP-1, FIS-1, MFN-1 (Abcam), PGC1 (Abcam), and GAPDH will be diluted 1:5000 – 1:2000 in 5% TBST-milk followed by
a 4-8-hr incubation with membranes at 4 degrees. Anti-rabbit or anti-mouse IgG
horseradish-peroxidase conjugated secondary antibody was incubated with the
membranes at 1:2000 dilutions for 1 hour in 5% TBST-milk at room temperature.
Enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences, Piscataway, NJ) was
used to visualize the antibody-antigen interactions. Images were digitally scanned and
quantified by densitometry using imaging software (Image J; NIH). All antibodies were
from Cell Signaling unless otherwise stated.
Plasma IL-6 concentrations
Plasma IL-6 concentrations were determined as previously described (Hardee et
al., 2016). A commercially available IL-6 enzyme-linked immunosorbent assay kit was
obtained from BD Biosciences (San Diego, CA, USA) and the manufacturer’s protocol
was followed. Briefly, a Costar clear 96-well plate (Corning, NY, USA) was coated with
IL-6 capture antibody and allowed to incubate overnight. The next morning, the plate was
blocked with assay diluent buffer, washed, and IL-6 standards and plasma samples were
added in duplicate to the plate. The plate was again washed and sAV-HRP reagent was
added to each well. After several washes, TMB substrate was added and the reaction was
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developed for 20 minutes. The reaction was stopped with sulfuric acid and absorbance
was read in a BioRad iMark plate reader (Hercules, CA, USA) at 450 nm.
Cytochrome C Oxidase Enzyme Assay
Cytochrome-c oxidase (COX) activity was assessed in isolated mitochondria and whole
muscle homogenates from the gastrocnemius muscle. For whole muscle analysis,
gastrocnemius tissues were homogenized in extraction buffer (0.1M KH2PO4/Na2HPO4
and 2 mM EDTA, pH 7.2). COX enzyme activity was determined by measuring the rate
of oxidation of fully reduced cytochrome c at 550 nm as previously described(Fix et al.,
2018).
Statistical Analysis
Results are reported as the means ± standard error. An unpaired student’s preplanned t-test. The accepted level of significance was set at p<0.05 for all analysis.
Statistical analysis was performed using Prism GraphPad 7 (GraphPad Software Inc., La
Jolla, CA).
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